

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
10 October 2002 (10.10.2002)

PCT

(10) International Publication Number
WO 02/078526 A2

(51) International Patent Classification⁷: **A61B**
(21) International Application Number: PCT/US02/09808
(22) International Filing Date: 29 March 2002 (29.03.2002)
(25) Filing Language: English
(26) Publication Language: English
(30) Priority Data:
60/280,718 30 March 2001 (30.03.2001) US
60/285,154 20 April 2001 (20.04.2001) US
60/327,432 5 October 2001 (05.10.2001) US
10/054,683 22 January 2002 (22.01.2002) US

[CH/US]; 605 Third Avenue, New York, NY 10158 (US). CORNELL RESEARCH FOUNDATION, INC [US/US]; Cornell Business & Technology Park, 20 Thornwood Drive, Suite 105, Ithaca, NY 14850 (US).

(72) Inventors; and
(75) Inventors/Applicants (*for US only*): OLD, Lloyd, J. [US/US]; 33rd Floor, 605 Third Avenue, New York, NY 10158 (US). SCANLAN, Matthew, J. [US/US]; 33rd Floor, 605 Third Avenue, New York, NY 10158 (US). CHEN, Yao-Tseng [—/US]; The New York Hospital-Cornell Med. Center, Dept. of Pathology, 525 East 68th Street, New York, NY 10021 (US).



(74) Agent: VAN AMSTERDAM, John, R.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).

(71) Applicants (*for all designated States except US*): LUDWIG INSTITUTE FOR CANCER RESEARCH

(81) Designated States (*national*): AU, CA, CN, JP, KR, US.

[Continued on next page]

(54) Title: CANCER-TESTIS ANTIGENS



(57) Abstract: Cancer-testis (CT) antigens have been identified by screening public databases for transcripts that are expressed in tumor tissues and a limited set of normal tissues, or by screening for genes that are expressed in cancer and testis tissues (but not other normal tissues). The invention relates to nucleic acids and encoded polypeptides which are CT antigens expressed in patients afflicted with cancer. The invention provides, *inter alia* isolated nucleic acid molecules, expression vectors containing those molecules and host cells transfected with those molecules. The invention also provides isolated proteins and peptides, antibodies to those proteins and peptides and cytotoxic T lymphocytes which recognize the proteins and peptides. Fragments of the foregoing including functional fragments and variants also are provided. Kits containing the foregoing molecules additionally are provided. The molecules provided by the invention can be used in the diagnosis, monitoring, research, or treatment of conditions characterized by the expression of one or more CT antigens.

BEST AVAILABLE COPY

WO 02/078526 A2



(84) **Designated States (regional):** European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

— *without international search report and to be republished upon receipt of that report*

- 1 -

CANCER-TESTIS ANTIGENS**Related Applications**

This application is a continuation-in-part of application serial number 10/054,683,
5 filed January 22, 2002, now pending, which claims priority under 35 U.S.C. § 119(e) from
U.S. provisional application serial number 60/280,718, filed March 30, 2001, from U.S.
provisional application serial number 60/285,154, filed April 20, 2001, and from U.S.
provisional application serial number 60/327,432, filed October 5, 2001.

Field of the Invention

10 The invention relates to nucleic acids and encoded polypeptides which are novel
cancer-testis antigens expressed in a variety of cancers. The invention also relates to agents
which bind the nucleic acids or polypeptides. The nucleic acid molecules, polypeptides
coded for by such molecules and peptides derived therefrom, as well as related antibodies and
15 cytolytic T lymphocytes, are useful, *inter alia*, in diagnostic and therapeutic contexts.

Background of the Invention

It is a little acknowledged fact that the discipline of tumor immunology has been the
source of many findings of critical importance in cancer-related as well as cancer-unrelated
20 fields. For example, it was the search for tumor antigens that led to the discovery of the CD8
T cell antigen (1) and the concept of differentiation antigens (2) (and the CD system for
classifying cell surface antigens), and to the discovery of p53 (3). The immunogenetic
analysis of resistance to viral leukemogenesis provided the first link between the MHC and
disease susceptibility (4), and interest in the basis for non-specific immunity to cancer gave
25 rise to the discovery of TNF (5).

Another area of tumor immunology that holds great promise is the category of
antigens referred to as cancer/testis (CT) antigens, first recognized as targets for CD8 T cell
recognition of autologous human melanoma cells (6, 7). The molecular definition of these
antigens was a culmination of prior efforts to establish systems and methodologies for the
30 unambiguous analysis of humoral (8) and cellular (9) immune reactions of patients to
autologous tumor cells (autologous typing), and this approach of autologous typing also led

- 2 -

to the development of SEREX (serological analysis of cDNA expression libraries) for defining the molecular structure of tumor antigens eliciting a humoral immune response (10).

Although the usefulness of the known CT antigens in the diagnosis and therapy of cancer is accepted, the expression of these antigens in tumors of various types and sources is not universal. Accordingly, there is a need to identify additional CT antigens to provide more targets for diagnosis and therapy of cancer, and for the development of pharmaceuticals useful in diagnostic and therapeutic applications.

Summary of the Invention

Bioinformatic analysis of sequence databases has been applied to identify sequences having expression characteristics that fit the profile of cancer/testis antigens. Several novel cancer/testis antigens and cancer associated antigens have been identified. The invention provides, *inter alia*, isolated nucleic acid molecules, expression vectors containing those molecules and host cells transfected with those molecules. The invention also provides isolated proteins and peptides, antibodies to those proteins and peptides and CTLs which recognize the proteins and peptides. Fragments and variants of the foregoing also are provided. Kits containing the foregoing molecules additionally are provided. The foregoing can be used in the diagnosis, monitoring, research, or treatment of conditions characterized by the expression of one or more cancer-testis and/or cancer associated antigens.

Prior to the present invention, only a handful of cancer/testis antigens had been identified in the past 20 years. The invention involves the surprising discovery of several sequence clusters (UniGene) in sequence databases that have expression patterns that fit the profile of cancer-testis antigens. Other sequence clusters fit the profile of cancer associated antigens. The knowledge that these sequence clusters have these certain expression patterns makes the sequences useful in the diagnosis, monitoring and therapy of a variety of cancers.

The invention involves the use of a single material, a plurality of different materials and even large panels and combinations of materials. For example, a single gene, a single protein encoded by a gene, a single functional fragment thereof, a single antibody thereto, etc. can be used in methods and products of the invention. Likewise, pairs, groups and even panels of these materials and optionally other CT antigen genes and/or gene products can be used for diagnosis, monitoring and therapy. The pairs, groups or panels can involve 2, 3, 4, 5 or more genes, gene products, fragments thereof or agents that recognize such materials. A

- 3 -

plurality of such materials are not only useful in monitoring, typing, characterizing and diagnosing cells abnormally expressing such genes, but a plurality of such materials can be used therapeutically. An example of the use of a plurality of such materials for the prevention, delay of onset, amelioration, etc. of cancer cells, which express or will express such genes prophylactically or acutely. Any and all combinations of the genes, gene products, and materials which recognize the genes and gene products can be tested and identified for use according to the invention. It would be far too lengthy to recite all such combinations; those skilled in the art, particularly in view of the teaching contained herein, will readily be able to determine which combinations are most appropriate for which circumstances.

As will be clear from the following discussion, the invention has *in vivo* and *in vitro* uses, including for therapeutic, diagnostic, monitoring and research purposes. One aspect of the invention is the ability to fingerprint a cell expressing a number of the genes identified according to the invention by, for example, quantifying the expression of such gene products. Such fingerprints will be characteristic, for example, of the stage of the cancer, the type of the cancer, or even the effect in subjects or animal models of a therapy on a cancer. Cells also can be screened to determine whether such cells abnormally express the genes identified according to the invention.

According to one aspect of the invention, methods of diagnosing a disorder are provided. The methods include contacting a non-testis biological sample isolated from a subject with an agent that specifically binds to a nucleic acid molecule, an expression product thereof, a fragment of the expression product thereof complexed with an HLA molecule, or an antibody that binds the expression product or fragment, wherein the nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs:18, 20, 22, 46 and 48, and determining the interaction between the agent and the nucleic acid molecule or the expression product to diagnose the cancer in the subject.

In certain embodiments, the agent is selected from the group consisting of (a) a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:18, 20, 22, 46 and 48 or a fragment thereof, (b) an antibody that binds to an expression product of a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:18, 20, 22, 46 and 48, (c) an agent that binds to a complex of an HLA molecule and a fragment of an expression product of a nucleic acid

- 4 -

molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:18, 20, 22, 46 and 48, and (d) a polypeptide that binds the antibody that binds the expression product or fragment.

In other embodiments, the cancer is characterized by expression of a plurality of human CT antigen precursors and wherein the agent is a plurality of agents, each of which is specific for a different human CT antigen precursor, and wherein said plurality of agents is at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, or at least 8, at least 9 or at least 10 such agents.

According to another aspect of the invention, methods of diagnosing a cancer are provided. The methods include contacting a non-testis, non-brain biological sample isolated from a subject with an agent that specifically binds to a nucleic acid molecule, an expression product thereof, or a fragment of an expression product thereof complexed with an HLA molecule, wherein the nucleic acid molecule comprises a nucleotide sequence set forth as SEQ ID NO:32, and determining the interaction between the agent and the nucleic acid molecule or the expression product to diagnose the cancer in the subject.

According to a further aspect of the invention, other methods of diagnosing a cancer are provided. The methods include contacting a non-testis, non-ovary, non-cervix, non-lung biological sample isolated from a subject with an agent that specifically binds to a nucleic acid molecule, an expression product thereof, or a fragment of an expression product thereof complexed with an HLA molecule, wherein the nucleic acid molecule comprises a nucleotide sequence set forth as SEQ ID NO:34, and determining the interaction between the agent and the nucleic acid molecule or the expression product to diagnose the cancer in the subject.

According to still another aspect of the invention, other methods of diagnosing a cancer are provided. These methods include contacting a non-testis, non-ovary, non-lung, non-breast, non-prostate, non-colon biological sample isolated from a subject with an agent that specifically binds to a nucleic acid molecule, an expression product thereof, or a fragment of an expression product thereof complexed with an HLA molecule, wherein the nucleic acid molecule comprises a nucleotide sequence set forth as SEQ ID NO:36, and determining the interaction between the agent and the nucleic acid molecule or the expression product to diagnose the cancer in the subject.

According to another aspect of the invention, other methods of diagnosing a cancer are provided. These methods include contacting a non-testis, non-placenta, non-lung, non-

- 5 -

breast, non-prostate biological sample isolated from a subject with an agent that specifically binds to a nucleic acid molecule, an expression product thereof, a fragment of the expression product thereof complexed with an HLA molecule, or an antibody that binds the expression product or fragment, wherein the nucleic acid molecule comprises a nucleotide sequence set forth as SEQ ID NO:38, and determining the interaction between the agent and the nucleic acid molecule or the expression product to diagnose the cancer in the subject.

According to yet another aspect of the invention, other methods of diagnosing a cancer are provided. These methods include contacting a non-testis, non-ovary, non-placenta, non-lung, non-prostate, non-cervix biological sample isolated from a subject with an agent that specifically binds to a nucleic acid molecule, an expression product thereof, a fragment of the expression product thereof complexed with an HLA molecule, or an antibody that binds the expression product or fragment, wherein the nucleic acid molecule comprises a nucleotide sequence set forth as SEQ ID NO:40, and determining the interaction between the agent and the nucleic acid molecule or the expression product to diagnose the cancer in the subject.

According to a further aspect of the invention, other methods of diagnosing a cancer are provided. These methods include contacting a non-testis, non-ovary, non-prostate biological sample isolated from a subject with an agent that specifically binds to a nucleic acid molecule, an expression product thereof, a fragment of the expression product thereof complexed with an HLA molecule, or an antibody that binds the expression product or fragment, wherein the nucleic acid molecule comprises a nucleotide sequence set forth as SEQ ID NO:51, and determining the interaction between the agent and the nucleic acid molecule or the expression product to diagnose the cancer in the subject.

In another aspect of the invention, methods for determining regression, progression or onset of a cancer characterized by expression of abnormal levels of a protein encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:18, 20, 22, 46 and 48 are provided. The methods include monitoring a plurality of non-testis samples obtained at different times from a subject who has or is suspected of having the cancer, for a parameter selected from the group consisting of (i) the protein, (ii) a peptide derived from the protein, (iii) an antibody which selectively binds the protein or peptide, (iv) cytolytic T cells specific for a complex of the peptide derived from the protein and an MHC molecule, and (v) a nucleic acid molecule comprising a nucleotide sequence

selected from the group consisting of SEQ ID NOs:18, 20, 22, 46 and 48. The methods also include comparing the parameters from the plurality of samples to determine regression, progression or onset of the cancer.

In some embodiments, the sample is a body fluid, a body effusion, cell or a tissue. In other embodiments, the step of monitoring comprises contacting the sample with a detectable agent selected from the group consisting of (a) an antibody which selectively binds the protein of (i) or the peptide of (ii), (b) a protein or peptide which binds the antibody of (iii), (c) a cell which presents the complex of the peptide and MHC molecule of (iv), and (d) at least one nucleic acid probe or primer that hybridizes to the nucleic acid molecule of (v) or its complement. Preferably the antibody, the protein, the peptide, the cell or the nucleic acid probe or primer is labeled with a radioactive label or an enzyme. In further embodiments, the protein is a plurality of proteins, the parameter is a plurality of parameters, each of the plurality of parameters being specific for a different of the plurality of proteins, at least one of which is a CT antigen protein encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:18, 20, 22, 46 and 48.

According to yet another aspect of the invention, pharmaceutical preparations for a human subject are provided. The pharmaceutical preparations include an agent which, when administered to the subject, enriches selectively the presence of complexes of an HLA molecule and a human CT antigen peptide, and a pharmaceutically acceptable carrier. The human CT antigen peptide is a fragment of a human CT antigen encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:18, 20, 22, 46 and 48.

In some embodiments, the foregoing pharmaceutical preparations includes a plurality of agents, each of which enriches selectively in the subject complexes of an HLA molecule and a different human CT antigen peptide, wherein at least one of the human CT antigens is encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:18, 20, 22, 46 and 48.

In other embodiments of the foregoing pharmaceutical preparations, the agent is selected from the group consisting of (1) an isolated polypeptide comprising the human CT antigen peptide, (2) an isolated nucleic acid operably linked to a promoter for expressing the isolated polypeptide, (3) a host cell expressing the isolated polypeptide, and (4) isolated complexes of the polypeptide and an HLA molecule.

- 7 -

In still other embodiments, the agent is a cell expressing an isolated polypeptide comprising the human CT antigen peptide, or a cell expressing an isolated polypeptide comprising the human CT antigen peptide, and an HLA molecule that binds the polypeptide. In certain of these embodiments, the cell expresses the polypeptide and/or the HLA molecule recombinantly. Preferably, the foregoing cells are nonproliferative.

The foregoing pharmaceutical preparations preferably also include an adjuvant.

According to another aspect of the invention, compositions are provided. The compositions include an isolated agent that binds selectively a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:21, 23, 25, 27, 29, 31, 35 and 37. Preferably, the agent is an antibody or an antigen-binding fragment thereof. More preferably, the antibody is a monoclonal antibody, a chimeric antibody or a humanized antibody. Also provided are compositions of matter include one or more conjugates of the foregoing agents and a therapeutic or diagnostic agent. Preferably the therapeutic or diagnostic agent is a toxin.

Pharmaceutical compositions are provided in another aspect of the invention. The compositions include an isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:18, 20, 22, 46 and 48, and a pharmaceutically acceptable carrier. In some embodiments, the isolated nucleic acid molecule comprises at least two isolated nucleic acid molecules coding for two different polypeptides, each polypeptide comprising a different human CT antigen. In other embodiments, the foregoing pharmaceutical compositions also include an expression vector with a promoter operably linked to the isolated nucleic acid molecule. In still other embodiments, the foregoing pharmaceutical compositions also include a host cell recombinantly expressing the isolated nucleic acid molecule.

In a further aspect of the invention, additional pharmaceutical compositions are provided. The compositions include an isolated polypeptide comprising a polypeptide encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:18, 20, 22, 46 and 48, and a pharmaceutically acceptable carrier. In certain embodiments, the isolated polypeptide includes at least two different polypeptides, each comprising a different human CT antigen. In still other embodiments, the foregoing pharmaceutical compositions also include an adjuvant.

- 8 -

According to yet another aspect of the invention, protein microarrays are provided. The protein microarrays include at least one polypeptide encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:18, 20, 22, 46 and 48, or an antigenic fragment of the at least one polypeptide. In preferred
5 embodiments, the at least one polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:19, 21, 23, 47, 49 and 50.

According to yet a further aspect of the invention, protein microarrays are provided. The protein microarrays include at least one polypeptide encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:24, 26,
10 28 and 30, or an antigenic fragment of the polypeptide. Preferably, the at least one polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:25, 27, 29 and 31.

Additional protein microarrays are provided according to another aspect of the invention. The microarrays include at least one polypeptide encoded by a nucleic acid
15 molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:32, 34, 36, 38, 40 and 51, or an antigenic fragment of the polypeptide. Preferably the at least one polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:33, 35, 37, 39, 41 and 52.

In another aspect of the invention, protein microarrays are provided that include a
20 plurality of antibodies or antigen-binding fragments thereof that specifically bind at least one polypeptide encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the groups consisting of (i) SEQ ID NOs:18, 20, 22, 46 and 48; (ii) SEQ ID NOs:24, 26, 28 and 30; or (iii) SEQ ID NOs:32, 34, 36, 38, 40 and 51; or antigenic fragments of the foregoing polypeptides. Preferably, the polypeptides include at least one amino acid
25 sequence selected from the groups consisting of (i) SEQ ID NOs:19, 21, 23, 47, 49 and 50; (ii) SEQ ID NOs:25, 27, 29 and 31; or (iii) SEQ ID NOs:33, 35, 37, 39, 41 and 52.

According to still another aspect of the invention, nucleic acid microarrays are provided that include at least one nucleic acid molecule comprising a nucleotide sequence selected from the groups consisting of (i) SEQ ID NOs:18, 20, 22, 46 and 48; (ii) SEQ ID
30 NOs:24, 26, 28 and 30; or (iii) SEQ ID NOs:32, 34, 36, 38, 40 and 51; or fragments thereof of at least 20 nucleotides that selectively hybridizes to its complement in a biological sample.

- 9 -

Also provided in accordance with a further aspect of the invention are isolated fragments of a human CT antigen which, or a portion of which, binds a HLA molecule or a human antibody. The foregoing CT antigens are encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:18, 20, 22, 46 and 48. In some embodiments, the fragment is part of a complex with the HLA molecule. Preferably the fragment is between 8 and 12 amino acids in length.

According to yet another aspect of the invention, kits for detecting the expression of two or more human CT antigens are provided. The kits include two or more pairs of isolated nucleic acid molecules, each of which consists essentially of a nucleic acid molecule selected from the group consisting of (a) a 12-32 nucleotide contiguous segment of the nucleotide sequence of any of SEQ ID NOs:18, 20, 22, 46 or 48, and (b) complements of (a), wherein the contiguous segments are nonoverlapping, and wherein the nucleic acid molecules in each of the pairs are specific for a human CT antigen. In certain embodiments, the pair of isolated nucleic acid molecules is constructed and arranged to selectively amplify at least a fragment of an isolated nucleic acid molecule selected from the group consisting of SEQ ID NOs:18, 20, 22, 46 and 48.

Also provided in an additional aspect of the invention are methods for treating a subject with a cancer characterized by expression of a human CT antigen. The methods include administering to the subject an amount of an agent, which enriches selectively in the subject the presence of complexes of a HLA molecule and a human CT antigen peptide, effective to ameliorate the disorder. The human CT antigen peptide is a fragment of a human CT antigen encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:18, 20, 22, 46 and 48. In certain embodiments, the cancer is characterized by expression of a plurality of human CT antigens and wherein the agent is a plurality of agents, each of which enriches selectively in the subject the presence of complexes of an HLA molecule and a different human CT antigen peptide, wherein at least one of the human CT antigens is encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:18, 20, 22, 46 and 48. In other embodiments, the agent is an isolated polypeptide encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:18, 20, 22, 46 and 48.

- 10 -

In a further aspect of the invention, methods for treating a subject having a cancer characterized by expression of a human CT antigen in cells of the subject are provided. The methods include (i) removing an immunoreactive cell containing sample from the subject, (ii) contacting the immunoreactive cell containing sample to the host cell under conditions favoring production of cytolytic T cells against a human CT antigen peptide that is a fragment of the human CT antigen, and (iii) introducing the cytolytic T cells to the subject in an amount effective to lyse cells which express the human CT antigen. In these methods, the host cell is transformed or transfected with an expression vector comprising an isolated nucleic acid molecule operably linked to a promoter, wherein the isolated nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs:18, 20, 22, 46 and 48. In different embodiments of the foregoing methods, the host cell recombinantly or endogenously expresses an HLA molecule which binds the human CT antigen peptide.

In still another aspect of the invention, methods for treating a subject having a cancer characterized by expression of a human CT antigen in cells of the subject are provided. The methods include (i) identifying a nucleic acid molecule expressed by the cells of the cancer, wherein the nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs:18, 20, 22, 46 and 48, or a fragment thereof; (ii) transfecting a host cell with a nucleic acid molecule selected from the group consisting of (a) the nucleic acid molecule identified, (b) a fragment of the nucleic acid identified which includes a segment coding for a human CT antigen, (c) degenerates of (a) or (b) (iii) culturing said transfected host cells to express the transfected nucleic acid molecule, and; (iv) introducing an amount of said host cells or an extract thereof to the subject effective to increase an immune response against the cells of the subject associated with the condition.

In certain embodiments, the foregoing methods also include identifying an MHC molecule which presents a portion of an expression product of the nucleic acid molecule, wherein the host cell expresses the same MHC molecule as identified and wherein the host cell presents an MHC binding portion of the expression product of the nucleic acid molecule. In other embodiments, the immune response comprises a B-cell response or a T cell response. Preferably the response is a T-cell response which comprises generation of cytolytic T-cells specific for the host cells presenting the portion of the expression product of the nucleic acid molecule or cells of the subject expressing the human CT antigen.

- 11 -

In some embodiments, the nucleic acid molecule is selected from the group consisting of SEQ ID NOs:18, 20, 22, 46 and 48. In still other embodiments, the methods also include treating the host cells to render them non-proliferative.

According to yet another aspect of the invention, methods for treating or diagnosing
5 or monitoring a subject having a cancer characterized by expression of a protein encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:18, 20, 22, 46 and 48, in cells or tissues other than testis are provided. The methods include administering to the subject an antibody which specifically binds to the protein or a peptide derived therefrom, the antibody being coupled to a therapeutically or
10 diagnostically useful agent, in an amount effective to treat, diagnose or monitor the condition.

In some embodiments, the antibody is a monoclonal antibody or an antigen-binding fragment thereof. Preferably the monoclonal antibody is a chimeric antibody or a humanized antibody.

In another aspect of the invention, methods are provided for treating a cancer
15 characterized by expression of a protein encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:18, 20, 22, 46 and 48, in cells or tissues other than testis. The methods include administering to a subject one or more of the foregoing pharmaceutical compositions in an amount effective to prevent, delay the onset of, or inhibit the condition in the subject. In some embodiments, the methods also
20 include first identifying that the subject expresses abnormal amounts of the protein in a non-testis tissue.

According to another aspect of the invention, methods for treating a subject having a cancer characterized by expression of a protein encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:18, 20,
25 22, 46 and 48, in cells or tissues other than testis are provided. The methods include (i) identifying cells from the subject which express abnormal amounts of the protein; (ii) isolating a sample of the cells; (iii) cultivating the cells, and (iv) introducing the cells to the subject in an amount effective to provoke an immune response against the cells. In certain embodiments, the methods also include rendering the cells non-proliferative, prior to
30 introducing them to the subject.

Methods for treating a pathological cell condition characterized by expression of a protein encoded by a nucleic acid molecule comprising a nucleotide sequence selected from

- 12 -

the group consisting of SEQ ID NOs:18, 20, 22, 46 and 48, in cells or tissues other than testis, are provided in accordance with another aspect of the invention. The methods include administering to a subject in need thereof an effective amount of an agent which inhibits the expression or activity of the protein. In some embodiments, the agent is an inhibiting
5 antibody which selectively binds to the protein and wherein the antibody is a monoclonal antibody, a chimeric antibody, a humanized antibody or an antibody fragment. In other embodiments, the agent is an antisense nucleic acid molecule which selectively binds to the nucleic acid molecule which encodes the protein.

Also provided in accordance with a further aspect of the invention are compositions
10 of matter useful in stimulating an immune response to a plurality of a proteins comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:19, 21, 23, 47, 49 and 50. The compositions include a plurality of peptides that are fragments of the proteins, wherein the peptides bind to one or more MHC molecules presented on the surface of non-testis cells. In certain embodiments of the compositions, at least a portion of the plurality of
15 peptides bind to MHC molecules and elicit a cytolytic response thereto. In other embodiments, at least one of the proteins is encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:18, 20, 22, 46 and 48. Preferably, the compositions also include an adjuvant. Preferred adjuvants include saponins, GM-CSF, interleukins, and immunostimulatory oligonucleotides.

20 In another aspect of the invention, isolated antibodies are provided which selectively binds to a complex of: (i) a peptide that is a fragment of a protein comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:19, 21, 23, 47, 49 and 50, and (ii) a MHC molecule to which binds the peptide to form the complex, wherein the isolated antibody does not bind to (i) or (ii) alone. Preferably the antibody is a monoclonal antibody,
25 a chimeric antibody, a humanized antibody, or an antigen-binding fragment thereof.

According to a further aspect of the invention, methods are provided for treating or diagnosing or monitoring a subject having a cancer characterized by expression of a protein encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:18, 20, 22, 46 and 48, in cells or tissues other than testis.
30 The methods include administering to the subject the foregoing antibodies, in an amount effective to treat, diagnose or monitor the condition. Preferably the antibodies are coupled to one or more therapeutically or diagnostically useful agents.

- 13 -

The invention also involves the use of the genes, gene products, fragments thereof, agents which bind thereto, and so on in the preparation of medicaments. Preferably the medicaments are for treating cancer.

These and other aspects of the invention will be described in further detail in connection with the detailed description of the invention.

Brief Description of the Drawings

Fig. 1 shows a digitized image of RT-PCR expression analysis of cancer/testis-associated Unigene clusters in normal adult tissues and cancer. Fig. 1A shows the expression of mRNA transcripts in normal adult tissue following 35 cycles of PCR. Lane 1, brain; 2, kidney; 3, liver; 4, pancreas; 5, placenta; 6, testis; 7, small intestine; 8, heart; 9, prostate; 10, adrenal gland; 11, spleen; 12, colon; 13, stomach; 14, lung; 15, bladder; 16, ovary; 17, mammary gland; 18, cervix; 19, skeletal muscle. The majority of transcripts are testis-specific, with the exceptions of Hs.183009, Hs.293317, Hs. 128836, and Hs.130926.

Expression of Hs.130926 was used as a positive control for cDNA template integrity of the various tissue samples. Fig. 1B shows RT-PCR analysis of CT15/Hs.177959 mRNA expression in renal cancer (RCC1, RCC6, RCC5), CT16/Hs245431 mRNA expression in melanoma (Mel-1 and Mel-11) and breast cancer; and CT17/Hs.178062 mRNA expression in breast cancer (BR-297), renal cancer (RCC5) and melanoma (Mel-1).

Detailed Description of the Invention

As a consequence of T cell epitope cloning and SEREX analysis, a growing number of cancer-testis (CT) antigens have now been defined. See Table 1 and references cited therein. There are now 14 genes or gene families identified that code for presumptive cancer-testis antigens.

Table 1: Cancer-testis (CT) antigens

CT*	System	# Genes	Chromosome Location	Detection System**	Refs.
1	MAGE	16	Xq28/Xp21	T, Ab	7, 10, 12, 13
2	BAGE	2	Unknown	T	14
3	GAGE	9	Xp11	T	15, 16
4	SSX	>5	Xp11	Ab	10, 17
5	NY-ESO-1	2	Xq28	Ab, T, RDA	18, 19

	LAGE-1				
6	SCP-1	3	1p12-p13	Ab	20
7	CT7/MAGE-C1	1	Xq26	Ab, RDA	21, 22
8	CT8	1	Unknown	Ab	23
9	CT9	1	1p	Ab	24
10	CT10/MAGE-C2	1	Xq27	RDA, Ab	25, 26
11	CT11p	1	Xq26- Xq27	***	27
12	SAGE	1	Xq28	RDA	28
13	cTAGE-1	1	18p11	Ab	29
14	OY-TES-1	2	12p12-p13	Ab	30

* Numbered according to the CT nomenclature proposed by Old & Chen (11).

** Ab=Antibody, T=CD8+ T cell, RDA=representational difference analysis.

*** Defined by differential mRNA expression in a parental vs. metastatic melanoma cell variant.

5

A thorough analysis of these gene reveals that they encode products with the following characteristics.

i) mRNA expression in normal tissues is restricted to testis, fetal ovary, and placenta, with little or no expression detected in adult ovary.

10

ii) mRNA expression in cancers of diverse origin is common - up to 30-40% of a number of different cancer types, e.g., melanoma, bladder cancer, sarcoma express one or more CT antigens.

iii) The X chromosome codes for the majority of CT antigens, but a number of more recently defined CT coding genes have a non-X chromosomal locus.

15

iv) In normal adult testis, expression of CT antigens is primarily restricted to immature germ cells -, e.g., spermatogonia (31). However, a recently defined CT antigen, OY-TES-1, is clearly involved in late stages of sperm maturation (see below). In fetal ovary, immature germ cells (oogonia/primary oocytes) express CT antigens, whereas oocytes in the resting primordial follicles do not (32). In fetal placenta, both cytotrophoblast and syncytiotrophoblast express CT antigens, but in term placenta, CT antigen expression is weak or absent (33).

20

v) A highly variable pattern of CT antigen expression is found in different cancers, from tumors showing only single positive cells or small cluster of positive cells to other tumors with a generally homogeneous expression pattern (31, 34).

25

vi) The function of most CT antigens is unknown, although some role in regulating gene expression appears likely. Two CT antigens, however, have known roles in gamete development - SCP-1, the synaptonemal complex protein, is involved in chromosomal

- 15 -

reduction during meiosis (35), and OY-TES-1 is a proacrosin binding protein sp32 precursor thought to be involved in packaging acrosin in the acrosome in the sperm head (36).

vii) There is increasing evidence that CT expression is correlated with tumor progression and with tumors of higher malignant potential. For instance, a higher frequency of MAGE mRNA expression is found in metastatic vs. primary melanoma (37) and in invasive vs. superficial bladder cancer (38), and NY-ESO-1 expression in bladder cancer is correlated with high nuclear grade (39).

viii) There appears to be considerable variation in the inherent immunogenicity of different CT antigens as indicated by specific CD8⁺ T cell and antibody responses in patients with antigen positive tumors. To date, NY-ESO-1 appears to have the strongest spontaneous immunogenicity of any of the CT antigens - e.g., up to 50% of patients with advanced NY-ESO-1⁺ tumors develop humoral and cellular immunity to NY-ESO-1 (40, 41).

These characteristics indicate the desirability of cancer-testis antigens for use in diagnostics and therapeutics. These characteristics also provide a basis for the identification of additional cancer-testis antigens.

While others have attempted to identify cancer related sequences in public databases by the use of bioinformatics techniques, (e.g., database mining plus rapid screening by fluorescent-PCR expression, Loging et al., *Genome Res* 10(9):1393-402, 2000), these techniques have not focused on the identification of nucleic acid sequences that the preferred cancer-testis antigen profile. In particular, the present invention includes the identification of cancer-testis sequences by more stringent criteria. The database analysis criteria for identifying cancer-testis antigen sequences include the requirement that the sequences are expressed in cancers from at least two different tissues, and preferably are expressed in cancers from at least three different tissues. In addition, the sequences preferably have normal tissue expression restricted to one or more tissue selected from the group consisting of testis, placenta and ovary (preferably only fetal ovary).

In the above summary and in the ensuing description, lists of sequences are provided. The lists are meant to embrace each single sequence separately, two or more sequences together where they form a part of the same gene, any combination of two or more sequences which relate to different genes, including and up to the total number on the list, as if each and every combination were separately and specifically enumerated. Likewise, when mentioning fragment size, it is intended that a range embrace the smallest fragment mentioned to the full-

- 16 -

length of the sequence (less one nucleotide or amino acid so that it is a fragment), each and every fragment length intended as if specifically enumerated. Thus, if a fragment could be between 10 and 15 in length, it is explicitly meant to mean 10, 11, 12, 13, 14, or 15 in length.

The summary and the claims mention antigen precursors and antigens. As used in the summary and in the claims, a precursor is substantially the full-length protein encoded by the coding region of the isolated nucleic acid and the antigen is a peptide which complexes with MHC, preferably HLA, and which participates in the immune response as part of that complex. Such antigens are typically 9 amino acids long, although this may vary slightly.

As used herein, a subject is a human, non-human primate, cow, horse, pig, sheep, goat, dog, cat or rodent. In all embodiments human cancer antigens and human subjects are preferred.

The present invention in one aspect involves involves the identification of human CT gene products by mining databases (e.g., Unigene) for transcripts expressed exclusively in cancer and normal testis. Subsequent mRNA expression analysis of candidate transcripts identified several gene products with highly restricted mRNA expression patterns, some of which are classified as CT antigens. The sequences representing CT antigen genes identified according to the methods described herein are presented in the attached Sequence Listing. In another aspect the invention involves the identification of human CT antigens using autologous antisera of subjects having cancer. The nature of the sequences as encoding CT antigens recognized by the immune systems of cancer patients is, of course, unexpected.

The invention thus involves in one aspect CT antigen polypeptides, genes encoding those polypeptides, functional modifications and variants of the foregoing, useful fragments of the foregoing, as well as diagnostics and therapeutics relating thereto.

Homologs and alleles of the CT antigen nucleic acids of the invention can be identified by conventional techniques, including those techniques used in the Examples. Thus, an aspect of the invention is those nucleic acid sequences which code for CT antigen precursors.

The term "high stringency hybridization conditions" as used herein refers to parameters with which the art is familiar. Nucleic acid hybridization parameters may be found in references which compile such methods, e.g. *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, or *Current Protocols in Molecular Biology*, F.M.

- 17 -

Ausubel, et al., eds., John Wiley & Sons, Inc., New York. More specifically, high stringency conditions, as used herein, refers, for example, to hybridization at 65°C in hybridization buffer (3.5 x SSC, 0.02% Ficoll, 0.02% polyvinyl pyrrolidone, 0.02% Bovine Serum Albumin, 2.5mM NaH₂PO₄(pH7), 0.5% SDS, 2mM EDTA). SSC is 0.15M sodium chloride/0.15M sodium citrate, pH7; SDS is sodium dodecyl sulphate; and EDTA is ethylenediaminetetracetic acid. After hybridization, the membrane upon which the DNA is transferred is washed, for example, in 2 x SSC at room temperature and then at 0.1 - 0.5 x SSC/0.1 x SDS at temperatures up to 68°C.

There are other conditions, reagents, and so forth which can be used, which result in a similar degree of stringency. The skilled artisan will be familiar with such conditions, and thus they are not given here. It will be understood, however, that the skilled artisan will be able to manipulate the conditions in a manner to permit the clear identification of homologs and alleles of CT antigen nucleic acids of the invention (e.g., by using lower stringency conditions). The skilled artisan also is familiar with the methodology for screening cells and libraries for expression of such molecules which then are routinely isolated, followed by isolation of the pertinent nucleic acid molecule and sequencing.

In general homologs and alleles typically will share at least about 75% nucleotide identity and/or at least about 90% amino acid identity to the sequences of CT antigen nucleic acid and polypeptides, respectively, in some instances will share at least about 90% nucleotide identity and/or at least about 95% amino acid identity, in still other instances will share at least about 95% nucleotide identity and/or at least about 99% amino acid identity, and in further instances will share at least about 98% nucleotide identity and/or at least about 99.5% amino acid identity. The homology can be calculated using various, publicly available software tools developed by NCBI (Bethesda, Maryland) that can be obtained through the internet (<ftp://ncbi.nlm.nih.gov/pub/>). Exemplary tools include the BLAST software available at <http://www.ncbi.nlm.nih.gov>, using default settings. Pairwise and ClustalW alignments (BLOSUM30 matrix setting) as well as Kyte-Doolittle hydropathic analysis can be obtained using the MacVector sequence analysis software (Oxford Molecular Group). Watson-Crick complements of the foregoing nucleic acids also are embraced by the invention.

In screening for CT antigen genes, a Southern blot may be performed using the foregoing conditions, together with a radioactive probe. After washing the membrane to which the DNA is finally transferred, the membrane can be placed against X-ray film to

- 18 -

detect the radioactive signal. In screening for the expression of CT antigen nucleic acids, Northern blot hybridizations using the foregoing can be performed on samples taken from cancer patients or subjects suspected of having a condition characterized by expression of CT antigen genes. Amplification protocols such as polymerase chain reaction using primers
5 which hybridize to the sequences presented also can be used for detection of the CT antigen genes or expression thereof.

The invention also includes degenerate nucleic acids which include alternative codons to those present in the native materials. For example, serine residues are encoded by the codons TCA, AGT, TCC, TCG, TCT and AGC. Each of the six codons is equivalent for the
10 purposes of encoding a serine residue. Thus, it will be apparent to one of ordinary skill in the art that any of the serine-encoding nucleotide triplets may be employed to direct the protein synthesis apparatus, *in vitro* or *in vivo*, to incorporate a serine residue into an elongating CT antigen polypeptide. Similarly, nucleotide sequence triplets which encode other amino acid residues include, but are not limited to: CCA, CCC, CCG and CCT (proline codons); CGA,
15 CGC, CGG, CGT, AGA and AGG (arginine codons); ACA, ACC, ACG and ACT (threonine codons); AAC and AAT (asparagine codons); and ATA, ATC and ATT (isoleucine codons). Other amino acid residues may be encoded similarly by multiple nucleotide sequences. Thus, the invention embraces degenerate nucleic acids that differ from the biologically isolated nucleic acids in codon sequence due to the degeneracy of the genetic code.

20 The invention also provides modified nucleic acid molecules which include additions, substitutions and deletions of one or more nucleotides. In preferred embodiments, these modified nucleic acid molecules and/or the polypeptides they encode retain at least one activity or function of the unmodified nucleic acid molecule and/or the polypeptides, such as antigenicity, enzymatic activity, receptor binding, formation of complexes by binding of
25 peptides by MHC class I and class II molecules, etc. In certain embodiments, the modified nucleic acid molecules encode modified polypeptides, preferably polypeptides having conservative amino acid substitutions as are described elsewhere herein. The modified nucleic acid molecules are structurally related to the unmodified nucleic acid molecules and in preferred embodiments are sufficiently structurally related to the unmodified nucleic acid
30 molecules so that the modified and unmodified nucleic acid molecules hybridize under stringent conditions known to one of skill in the art.

- 19 -

For example, modified nucleic acid molecules which encode polypeptides having single amino acid changes can be prepared. Each of these nucleic acid molecules can have one, two or three nucleotide substitutions exclusive of nucleotide changes corresponding to the degeneracy of the genetic code as described herein. Likewise, modified nucleic acid molecules which encode polypeptides having two amino acid changes can be prepared which have, e.g., 2-6 nucleotide changes. Numerous modified nucleic acid molecules like these will be readily envisioned by one of skill in the art, including for example, substitutions of nucleotides in codons encoding amino acids 2 and 3, 2 and 4, 2 and 5, 2 and 6, and so on. In the foregoing example, each combination of two amino acids is included in the set of modified nucleic acid molecules, as well as all nucleotide substitutions which code for the amino acid substitutions. Additional nucleic acid molecules that encode polypeptides having additional substitutions (i.e., 3 or more), additions or deletions (e.g., by introduction of a stop codon or a splice site(s)) also can be prepared and are embraced by the invention as readily envisioned by one of ordinary skill in the art. Any of the foregoing nucleic acids or polypeptides can be tested by routine experimentation for retention of structural relation or activity to the nucleic acids and/or polypeptides disclosed herein.

The invention also provides isolated fragments of CT antigen nucleic acid sequences or complements thereof, and in particular unique fragments. A unique fragment is one that is a 'signature' for the larger nucleic acid. It, for example, is long enough to assure that its precise sequence is not found in molecules within the human genome outside of the CT antigen nucleic acids defined above (and human alleles). Those of ordinary skill in the art may apply routine procedures to determine if a fragment is unique within the human genome, such as the use of publicly available sequence comparison software to selectively distinguish the sequence fragment of interest from other sequences in the human genome, although *in vitro* confirmatory hybridization and sequencing analysis may be performed.

Fragments can be used as probes in Southern and Northern blot assays to identify CT antigen nucleic acids, or can be used in amplification assays such as those employing PCR. As known to those skilled in the art, large probes such as 200, 250, 300 or more nucleotides are preferred for certain uses such as Southern and Northern blots, while smaller fragments will be preferred for uses such as PCR. Fragments also can be used to produce fusion proteins for generating antibodies or determining binding of the polypeptide fragments, or for generating immunoassay components. Likewise, fragments can be employed to produce

- 20 -

nonfused fragments of the CT antigen polypeptides, useful, for example, in the preparation of antibodies, and in immunoassays. Fragments further can be used as antisense molecules to inhibit the expression of CT antigen nucleic acids and polypeptides, particularly for therapeutic purposes as described in greater detail below.

5 As mentioned above, this disclosure intends to embrace each and every fragment of each sequence, beginning at the first nucleotide, the second nucleotide and so on, up to 8 nucleotides short of the end, and ending anywhere from nucleotide number 8, 9, 10 and so on for each sequence, up to the entire length of the disclosed sequence. Preferred fragments are those useful as amplification primers, e.g., typically between 12 and 32 nucleotides (e.g. 12,
10 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 and 32) in length.

Those skilled in the art are well versed in methods for selecting such sequences, typically on the basis of the ability of the fragment to selectively distinguish the sequence of interest from other sequences in the human genome of the fragment to those on known databases typically is all that is necessary, although *in vitro* confirmatory hybridization and
15 sequencing analysis may be performed.

Especially preferred fragment include nucleic acids encoding a series of epitopes, known as "polytopes". The epitopes can be arranged in sequential or overlapping fashion (see, e.g., Thomson et al., *Proc. Natl. Acad. Sci. USA* 92:5845-5849, 1995; Gilbert et al., *Nature Biotechnol.* 15:1280-1284, 1997), with or without the natural flanking sequences, and
20 can be separated by unrelated linker sequences if desired. The polytope is processed to generated individual epitopes which are recognized by the immune system for generation of immune responses.

Thus, for example, peptides derived from a polypeptide having an amino acid sequence encoded by one of the nucleic acid disclosed herein, and which are presented by
25 MHC molecules and recognized by CTL or T helper lymphocytes, can be combined with peptides from one or more other CT antigens (e.g. by preparation of hybrid nucleic acids or polypeptides) to form "polytopes". The two or more peptides (or nucleic acids encoding the peptides) can be selected from those described herein, or they can include one or more peptides of previously known CT antigens. Exemplary cancer associated peptide antigens
30 that can be administered to induce or enhance an immune response are derived from tumor associated genes and encoded proteins including MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A5, MAGE-A6, MAGE-A7, MAGE-A8, MAGE-A9, MAGE-A10,

MAGE-A11, MAGE-A12, GAGE-1, GAGE-2, GAGE-3, GAGE-4, GAGE-5, GAGE-6, GAGE-7, GAGE-8, GAGE-9, BAGE-1, RAGE-1, LB33/MUM-1, PRAME, NAG, MAGE-B2, MAGE-B3, MAGE-B4, tyrosinase, brain glycogen phosphorylase, Melan-A, MAGE-C1, MAGE-C2, MAGE-C3, MAGE-C4, MAGE-C5, NY-ESO-1, LAGE-1, SSX-1, SSX-2
5 (HOM-MEL-40), SSX-4, SSX-5, SCP-1 and CT-7. See, for example, PCT application publication no. WO96/10577. Other examples will be known to one of ordinary skill in the art and can be used in the invention in a like manner as those disclosed herein. Other examples of HLA class I and HLA class II binding peptides will be known to one of ordinary skill in the art. For example, see the following references: Coulie, *Stem Cells* 13:393-403,
10 1995; Traversari et al., *J. Exp. Med.* 176:1453-1457, 1992; Chaux et al., *J. Immunol.* 163:2928-2936, 1999; Fujie et al., *Int. J. Cancer* 80:169-172, 1999; Tanzarella et al., *Cancer Res.* 59:2668-2674, 1999; van der Bruggen et al., *Eur. J. Immunol.* 24:2134-2140, 1994; Chaux et al., *J. Exp. Med.* 189:767-778, 1999; Kawashima et al., *Hum. Immunol.* 59:1-14, 1998; Tahara et al., *Clin. Cancer Res.* 5:2236-2241, 1999; Gaugler et al., *J. Exp. Med.* 179:921-930, 1994; van der Bruggen et al., *Eur. J. Immunol.* 24:3038-3043, 1994; Tanaka et al., *Cancer Res.* 57:4465-4468, 1997; Oiso et al., *Int. J. Cancer* 81:387-394, 1999; Herman et al., *Immunogenetics* 43:377-383, 1996; Manici et al., *J. Exp. Med.* 189:871-876, 1999; Duffour et al., *Eur. J. Immunol.* 29:3329-3337, 1999; Zorn et al., *Eur. J. Immunol.* 29:602-607, 1999; Huang et al., *J. Immunol.* 162:6849-6854, 1999; Boël et al., *Immunity* 2:167-175,
20 1995; Van den Eynde et al., *J. Exp. Med.* 182:689-698, 1995; De Backer et al., *Cancer Res.* 59:3157-3165, 1999; Jäger et al., *J. Exp. Med.* 187:265-270, 1998; Wang et al., *J. Immunol.* 161:3596-3606, 1998; Aarnoudse et al., *Int. J. Cancer* 82:442-448, 1999; Guilloux et al., *J. Exp. Med.* 183:1173-1183, 1996; Lupetti et al., *J. Exp. Med.* 188:1005-1016, 1998; Wölfel et al., *Eur. J. Immunol.* 24:759-764, 1994; Skipper et al., *J. Exp. Med.* 183:527-534, 1996; Kang et al., *J. Immunol.* 155:1343-1348, 1995; Morel et al., *Int. J. Cancer* 83:755-759, 1999; Brichard et al., *Eur. J. Immunol.* 26:224-230, 1996; Kittlesen et al., *J. Immunol.* 160:2099-2106, 1998; Kawakami et al., *J. Immunol.* 161:6985-6992, 1998; Topalian et al., *J. Exp. Med.* 183:1965-1971, 1996; Kobayashi et al., *Cancer Research* 58:296-301, 1998; Kawakami et al., *J. Immunol.* 154:3961-3968, 1995; Tsai et al., *J. Immunol.* 158:1796-1802, 1997; Cox et al., *Science* 264:716-719, 1994; Kawakami et al., *Proc. Natl. Acad. Sci. USA* 91:6458-6462,
30 1994; Skipper et al., *J. Immunol.* 157:5027-5033, 1996; Robbins et al., *J. Immunol.* 159:303-308, 1997; Castelli et al., *J. Immunol.* 162:1739-1748, 1999; Kawakami et al., *J. Exp. Med.*

180:347-352, 1994; Castelli et al., *J. Exp. Med.* 181:363-368, 1995; Schneider et al., *Int. J. Cancer* 75:451-458, 1998; Wang et al., *J. Exp. Med.* 183:1131-1140, 1996; Wang et al., *J. Exp. Med.* 184:2207-2216, 1996; Parkhurst et al., *Cancer Research* 58:4895-4901, 1998; Tsang et al., *J. Natl Cancer Inst* 87:982-990, 1995; Correale et al., *J Natl Cancer Inst* 89:293-300, 1997; Coulie et al., *Proc. Natl. Acad. Sci. USA* 92:7976-7980, 1995; Wölfel et al., *Science* 269:1281-1284, 1995; Robbins et al., *J. Exp. Med.* 183:1185-1192, 1996; Brändle et al., *J. Exp. Med.* 183:2501-2508, 1996; ten Bosch et al., *Blood* 88:3522-3527, 1996; Mandruzzato et al., *J. Exp. Med.* 186:785-793, 1997; Guéguen et al., *J. Immunol.* 160:6188-6194, 1998; Gjertsen et al., *Int. J. Cancer* 72:784-790, 1997; Gaudin et al., *J. Immunol.* 162:1730-1738, 1999; Chiari et al., *Cancer Res.* 59:5785-5792, 1999; Hogan et al., *Cancer Res.* 58:5144-5150, 1998; Pieper et al., *J. Exp. Med.* 189:757-765, 1999; Wang et al., *Science* 284:1351-1354, 1999; Fisk et al., *J. Exp. Med.* 181:2109-2117, 1995; Brossart et al., *Cancer Res.* 58:732-736, 1998; Röpke et al., *Proc. Natl. Acad. Sci. USA* 93:14704-14707, 1996; Ikeda et al., *Immunity* 6:199-208, 1997; Ronsin et al., *J. Immunol.* 163:483-490, 1999; Vonderheide et al., *Immunity* 10:673-679, 1999.

One of ordinary skill in the art can prepare polypeptides comprising one or more CT antigen peptides and one or more of the foregoing cancer associated peptides, or nucleic acids encoding such polypeptides, according to standard procedures of molecular biology.

Thus polytopes are groups of two or more potentially immunogenic or immune response stimulating peptides which can be joined together in various arrangements (e.g. concatenated, overlapping). The polytope (or nucleic acid encoding the polytope) can be administered in a standard immunization protocol, e.g. to animals, to test the effectiveness of the polytope in stimulating, enhancing and/or provoking an immune response.

The peptides can be joined together directly or via the use of flanking sequences to form polytopes, and the use of polytopes as vaccines is well known in the art (see, e.g., Thomson et al., *Proc. Acad. Natl. Acad. Sci USA* 92(13):5845-5849, 1995; Gilbert et al., *Nature Biotechnol.* 15(12):1280-1284, 1997; Thomson et al., *J. Immunol.* 157(2):822-826, 1996; Tam et al., *J. Exp. Med.* 171(1):299-306, 1990). For example, Tam showed that polytopes consisting of both MHC class I and class II binding epitopes successfully generated antibody and protective immunity in a mouse model. Tam also demonstrated that polytopes comprising "strings" of epitopes are processed to yield individual epitopes which are presented by MHC molecules and recognized by CTLs. Thus polytopes containing various

- 23 -

numbers and combinations of epitopes can be prepared and tested for recognition by CTLs and for efficacy in increasing an immune response.

It is known that tumors express a set of tumor antigens, of which only certain subsets may be expressed in the tumor of any given patient. Polytopes can be prepared which correspond to the different combination of epitopes representing the subset of tumor rejection antigens expressed in a particular patient. Polytopes also can be prepared to reflect a broader spectrum of tumor rejection antigens known to be expressed by a tumor type. Polytopes can be introduced to a patient in need of such treatment as polypeptide structures, or via the use of nucleic acid delivery systems known in the art (see, e.g., Allsopp et al., *Eur. J. Immunol.* 26(8):1951-1959, 1996). Adenovirus, pox viruses, Ty-virus like particles, adeno-associated virus, alphaviruses, plasmids, bacteria, etc. can be used in such delivery. One can test the polytope delivery systems in mouse models to determine efficacy of the delivery system. The systems also can be tested in human clinical trials.

In instances in which a human HLA class I molecule presents tumor rejection antigens derived from CT antigens, the expression vector may also include a nucleic acid sequence coding for the HLA molecule that presents any particular tumor rejection antigen derived from these nucleic acids and polypeptides. Alternatively, the nucleic acid sequence coding for such a HLA molecule can be contained within a separate expression vector. In a situation where the vector contains both coding sequences, the single vector can be used to transfect a cell which does not normally express either one. Where the coding sequences for a CT antigen precursor and the HLA molecule which presents it are contained on separate expression vectors, the expression vectors can be cotransfected. The CT antigen precursor coding sequence may be used alone, when, e.g. the host cell already expresses a HLA molecule which presents a CT antigen derived from precursor molecules. Of course, there is no limit on the particular host cell which can be used. As the vectors which contain the two coding sequences may be used in any antigen-presenting cells if desired, and the gene for CT antigen precursor can be used in host cells which do not express a HLA molecule which presents a CT antigen. Further, cell-free transcription systems may be used in lieu of cells.

As mentioned above, the invention embraces antisense oligonucleotides that selectively bind to a nucleic acid molecule encoding a CT antigen polypeptide, to reduce the expression of CT antigens. This is desirable in virtually any medical condition wherein a reduction of expression of CT antigens is desirable, e.g., in the treatment of cancer. This is

- 24 -

also useful for *in vitro* or *in vivo* testing of the effects of a reduction of expression of one or more CT antigens.

As used herein, the term "antisense oligonucleotide" or "antisense" describes an oligonucleotide that is an oligoribonucleotide, oligodeoxyribonucleotide, modified oligoribonucleotide, or modified oligodeoxyribonucleotide which hybridizes under physiological conditions to DNA comprising a particular gene or to an mRNA transcript of that gene and, thereby, inhibits the transcription of that gene and/or the translation of that mRNA. The antisense molecules are designed so as to interfere with transcription or translation of a target gene upon hybridization with the target gene or transcript. Those skilled in the art will recognize that the exact length of the antisense oligonucleotide and its degree of complementarity with its target will depend upon the specific target selected, including the sequence of the target and the particular bases which comprise that sequence. It is preferred that the antisense oligonucleotide be constructed and arranged so as to bind selectively with the target under physiological conditions, i.e., to hybridize substantially more to the target sequence than to any other sequence in the target cell under physiological conditions. Based upon the sequences of nucleic acids encoding CT antigens, or upon allelic or homologous genomic and/or cDNA sequences, one of skill in the art can easily choose and synthesize any of a number of appropriate antisense molecules for use in accordance with the present invention.

In order to be sufficiently selective and potent for inhibition, such antisense oligonucleotides should comprise at least 10 and, more preferably, at least 15 consecutive bases which are complementary to the target, although in certain cases modified oligonucleotides as short as 7 bases in length have been used successfully as antisense oligonucleotides (Wagner et al., *Nature Biotechnol.* 14:840-844, 1996). Most preferably, the antisense oligonucleotides comprise a complementary sequence of 20-30 bases.

Although oligonucleotides may be chosen which are antisense to any region of the gene or mRNA transcripts, in preferred embodiments the antisense oligonucleotides correspond to N-terminal or 5' upstream sites such as translation initiation, transcription initiation or promoter sites. In addition, 3'-untranslated regions may be targeted. Targeting to mRNA splicing sites has also been used in the art but may be less preferred if alternative mRNA splicing occurs. In addition, the antisense is targeted, preferably, to sites in which mRNA secondary structure is not expected (see, e.g., Sainio et al., *Cell Mol. Neurobiol.*

- 25 -

14(5):439-457, 1994) and at which proteins are not expected to bind. Suitable antisense molecules can be identified by a "gene walk" experiment in which overlapping oligonucleotides corresponding to the CT antigen nucleic acid are synthesized and tested for the ability to inhibit expression, cause the degradation of sense transcripts, etc. Finally, although the listed sequences are cDNA sequences, one of ordinary skill in the art may easily derive the genomic DNA corresponding to the cDNA of a CT antigen. Thus, the present invention also provides for antisense oligonucleotides which are complementary to the genomic DNA corresponding to nucleic acids encoding CT antigens. Similarly, antisense to allelic or homologous cDNAs and genomic DNAs are enabled without undue experimentation.

In one set of embodiments, the antisense oligonucleotides of the invention may be composed of "natural" deoxyribonucleotides, ribonucleotides, or any combination thereof. That is, the 5' end of one native nucleotide and the 3' end of another native nucleotide may be covalently linked, as in natural systems, via a phosphodiester internucleoside linkage. These oligonucleotides may be prepared by art recognized methods which may be carried out manually or by an automated synthesizer. They also may be produced recombinantly by vectors.

In preferred embodiments, however, the antisense oligonucleotides of the invention also may include "modified" oligonucleotides. That is, the oligonucleotides may be modified in a number of ways which do not prevent them from hybridizing to their target but which enhance their stability or targeting or which otherwise enhance their therapeutic effectiveness.

The term "modified oligonucleotide" as used herein describes an oligonucleotide in which (1) at least two of its nucleotides are covalently linked via a synthetic internucleoside linkage (i.e., a linkage other than a phosphodiester linkage between the 5' end of one nucleotide and the 3' end of another nucleotide) and/or (2) a chemical group not normally associated with nucleic acids has been covalently attached to the oligonucleotide. Preferred synthetic internucleoside linkages are phosphorothioates, alkylphosphonates, phosphorodithioates, phosphate esters, alkylphosphonothioates, phosphoramidates, carbamates, carbonates, phosphate triesters, acetamides, carboxymethyl esters and peptides.

The term "modified oligonucleotide" also encompasses oligonucleotides with a covalently modified base and/or sugar. For example, modified oligonucleotides include

- 26 -

oligonucleotides having backbone sugars which are covalently attached to low molecular weight organic groups other than a hydroxyl group at the 3' position and other than a phosphate group at the 5' position. Thus modified oligonucleotides may include a 2'-O-alkylated ribose group. In addition, modified oligonucleotides may include sugars such as arabinose instead of ribose. Base analogs such as C-5 propyne modified bases also can be included (*Nature Biotechnol.* 14:840-844, 1996). The present invention, thus, contemplates pharmaceutical preparations containing modified antisense molecules that are complementary to and hybridizable with, under physiological conditions, nucleic acids encoding the CT antigen polypeptides, together with pharmaceutically acceptable carriers.

Antisense oligonucleotides may be administered as part of a pharmaceutical composition. Such a pharmaceutical composition may include the antisense oligonucleotides in combination with any standard physiologically and/or pharmaceutically acceptable carriers which are known in the art. The compositions should be sterile and contain a therapeutically effective amount of the antisense oligonucleotides in a unit of weight or volume suitable for administration to a patient. The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredients. The term "physiologically acceptable" refers to a non-toxic material that is compatible with a biological system such as a cell, cell culture, tissue, or organism. The characteristics of the carrier will depend on the route of administration. Physiologically and pharmaceutically acceptable carriers include diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials which are well known in the art, as further described below.

As used herein, a "vector" may be any of a number of nucleic acids into which a desired sequence may be inserted by restriction and ligation for transport between different genetic environments or for expression in a host cell. Vectors are typically composed of DNA although RNA vectors are also available. Vectors include, but are not limited to, plasmids, phagemids and virus genomes. A cloning vector is one which is able to replicate autonomously or integrated in the genome in a host cell, and which is further characterized by one or more endonuclease restriction sites at which the vector may be cut in a determinable fashion and into which a desired DNA sequence may be ligated such that the new recombinant vector retains its ability to replicate in the host cell. In the case of plasmids, replication of the desired sequence may occur many times as the plasmid increases in copy number within the host bacterium or just a single time per host before the host reproduces by

- 27 -

mitosis. In the case of phage, replication may occur actively during a lytic phase or passively during a lysogenic phase. An expression vector is one into which a desired DNA sequence may be inserted by restriction and ligation such that it is operably joined to regulatory sequences and may be expressed as an RNA transcript. Vectors may further contain one or more marker sequences suitable for use in the identification of cells which have or have not been transformed or transfected with the vector. Markers include, for example, genes encoding proteins which increase or decrease either resistance or sensitivity to antibiotics or other compounds, genes which encode enzymes whose activities are detectable by standard assays known in the art (e.g., β -galactosidase, luciferase or alkaline phosphatase), and genes which visibly affect the phenotype of transformed or transfected cells, hosts, colonies or plaques (e.g., green fluorescent protein). Preferred vectors are those capable of autonomous replication and expression of the structural gene products present in the DNA segments to which they are operably joined.

As used herein, a coding sequence and regulatory sequences are said to be "operably" joined when they are covalently linked in such a way as to place the expression or transcription of the coding sequence under the influence or control of the regulatory sequences. If it is desired that the coding sequences be translated into a functional protein, two DNA sequences are said to be operably joined if induction of a promoter in the 5' regulatory sequences results in the transcription of the coding sequence and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the promoter region to direct the transcription of the coding sequences, or (3) interfere with the ability of the corresponding RNA transcript to be translated into a protein. Thus, a promoter region would be operably joined to a coding sequence if the promoter region were capable of effecting transcription of that DNA sequence such that the resulting transcript might be translated into the desired protein or polypeptide.

The precise nature of the regulatory sequences needed for gene expression may vary between species or cell types, but shall in general include, as necessary, 5' non-transcribed and 5' non-translated sequences involved with the initiation of transcription and translation respectively, such as a TATA box, capping sequence, CAAT sequence, and the like. Especially, such 5' non-transcribed regulatory sequences will include a promoter region which includes a promoter sequence for transcriptional control of the operably joined gene.

- 28 -

Regulatory sequences may also include enhancer sequences or upstream activator sequences as desired. The vectors of the invention may optionally include 5' leader or signal sequences. The choice and design of an appropriate vector is within the ability and discretion of one of ordinary skill in the art.

5 Expression vectors containing all the necessary elements for expression are commercially available and known to those skilled in the art. See, e.g., Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press, 1989. Cells are genetically engineered by the introduction into the cells of heterologous DNA (RNA) encoding a CT antigen polypeptide or fragment or variant thereof.
10 That heterologous DNA (RNA) is placed under operable control of transcriptional elements to permit the expression of the heterologous DNA in the host cell.

Preferred systems for mRNA expression in mammalian cells are those such as pRc/CMV or pcDNA3.1 (available from Invitrogen, Carlsbad, CA) that contain a selectable marker such as a gene that confers G418 resistance (which facilitates the selection of stably
15 transfected cell lines) and the human cytomegalovirus (CMV) enhancer-promoter sequences. Additionally, suitable for expression in primate or canine cell lines is the pCEP4 vector (Invitrogen), which contains an Epstein Barr Virus (EBV) origin of replication, facilitating the maintenance of plasmid as a multicopy extrachromosomal element. Another expression vector is the pEF-BOS plasmid containing the promoter of polypeptide Elongation Factor 1 α ,
20 which stimulates efficiently transcription *in vitro*. The plasmid is described by Mishizuma and Nagata (*Nuc. Acids Res.* 18:5322, 1990), and its use in transfection experiments is disclosed by, for example, Demoulin (*Mol. Cell. Biol.* 16:4710-4716, 1996). Still another preferred expression vector is an adenovirus, described by Stratford-Perricaudet, which is defective for E1 and E3 proteins (*J. Clin. Invest.* 90:626-630, 1992). The use of the
25 adenovirus as an Adeno.P1A recombinant for the expression of an antigen is disclosed by Warnier et al., in intradermal injection in mice for immunization against P1A (*Int. J. Cancer*, 67:303-310, 1996).

The invention also embraces so-called expression kits, which allow the artisan to prepare a desired expression vector or vectors. Such expression kits include at least separate
30 portions of a vector and one or more of the previously discussed CT antigen nucleic acid molecules. Other components may be added, as desired, as long as the previously mentioned nucleic acid molecules, which are required, are included. The invention also includes kits for

- 29 -

amplification of a CT antigen nucleic acid, including at least one pair of amplification primers which hybridize to a CT antigen nucleic acid. The primers preferably are 12-32 nucleotides in length and are non-overlapping to prevent formation of "primer-dimers". One of the primers will hybridize to one strand of the CT antigen nucleic acid and the second primer will hybridize to the complementary strand of the CT antigen nucleic acid, in an arrangement which permits amplification of the CT antigen nucleic acid. Selection of appropriate primer pairs is standard in the art. For example, the selection can be made with assistance of a computer program designed for such a purpose, optionally followed by testing the primers for amplification specificity and efficiency.

The invention also permits the construction of CT antigen gene "knock-outs" and "knock-ins" in cells and in animals, providing materials for studying certain aspects of cancer and immune system responses to cancer.

The invention also provides isolated polypeptides (including whole proteins and partial proteins) encoded by the foregoing CT antigen nucleic acids. Such polypeptides are useful, for example, alone or as fusion proteins to generate antibodies, as components of an immunoassay or diagnostic assay or as therapeutics. CT antigen polypeptides can be isolated from biological samples including tissue or cell homogenates, and can also be expressed recombinantly in a variety of prokaryotic and eukaryotic expression systems by constructing an expression vector appropriate to the expression system, introducing the expression vector into the expression system, and isolating the recombinantly expressed protein. Short polypeptides, including antigenic peptides (such as are presented by MHC molecules on the surface of a cell for immune recognition) also can be synthesized chemically using well-established methods of peptide synthesis.

A unique fragment of a CT antigen polypeptide, in general, has the features and characteristics of unique fragments as discussed above in connection with nucleic acids. As will be recognized by those skilled in the art, the size of the unique fragment will depend upon factors such as whether the fragment constitutes a portion of a conserved protein domain. Thus, some regions of CT antigens will require longer segments to be unique while others will require only short segments, typically between 5 and 12 amino acids (e.g. 5, 6, 7, 8, 9, 10, 11 or 12 or more amino acids including each integer up to the full length).

Fragments of a CT antigen polypeptide preferably are those fragments which retain a distinct functional capability of the polypeptide. Functional capabilities which can be

- 30 -

retained in a fragment of a polypeptide include interaction with antibodies, interaction with other polypeptides or fragments thereof, selective binding of nucleic acids or proteins, and enzymatic activity. One important activity is the ability to act as a signature for identifying the polypeptide. Another is the ability to complex with HLA and to provoke in a human an immune response. Those skilled in the art are well versed in methods for selecting unique amino acid sequences, typically on the basis of the ability of the fragment to selectively distinguish the sequence of interest from non-family members. A comparison of the sequence of the fragment to those on known databases typically is all that is necessary.

The invention embraces variants of the CT antigen polypeptides described above. As used herein, a "variant" of a CT antigen polypeptide is a polypeptide which contains one or more modifications to the primary amino acid sequence of a CT antigen polypeptide. Modifications which create a CT antigen variant can be made to a CT antigen polypeptide 1) to reduce or eliminate an activity of a CT antigen polypeptide; 2) to enhance a property of a CT antigen polypeptide, such as protein stability in an expression system or the stability of protein-protein binding; 3) to provide a novel activity or property to a CT antigen polypeptide, such as addition of an antigenic epitope or addition of a detectable moiety; or 4) to provide equivalent or better binding to an HLA molecule. Modifications to a CT antigen polypeptide are typically made to the nucleic acid which encodes the CT antigen polypeptide, and can include deletions, point mutations, truncations, amino acid substitutions and additions of amino acids or non-amino acid moieties. Alternatively, modifications can be made directly to the polypeptide, such as by cleavage, addition of a linker molecule, addition of a detectable moiety, such as biotin, addition of a fatty acid, and the like. Modifications also embrace fusion proteins comprising all or part of the CT antigen amino acid sequence. One of skill in the art will be familiar with methods for predicting the effect on protein conformation of a change in protein sequence, and can thus "design" a variant CT antigen polypeptide according to known methods. One example of such a method is described by Dahiyat and Mayo in *Science* 278:82-87, 1997, whereby proteins can be designed *de novo*. The method can be applied to a known protein to vary a only a portion of the polypeptide sequence. By applying the computational methods of Dahiyat and Mayo, specific variants of a CT antigen polypeptide can be proposed and tested to determine whether the variant retains a desired conformation.

- 31 -

In general, variants include CT antigen polypeptides which are modified specifically to alter a feature of the polypeptide unrelated to its desired physiological activity. For example, cysteine residues can be substituted or deleted to prevent unwanted disulfide linkages. Similarly, certain amino acids can be changed to enhance expression of a CT antigen polypeptide by eliminating proteolysis by proteases in an expression system (e.g.,
5 dibasic amino acid residues in yeast expression systems in which KEX2 protease activity is present).

Mutations of a nucleic acid which encode a CT antigen polypeptide preferably preserve the amino acid reading frame of the coding sequence, and preferably do not create
10 regions in the nucleic acid which are likely to hybridize to form secondary structures, such as hairpins or loops, which can be deleterious to expression of the variant polypeptide.

Mutations can be made by selecting an amino acid substitution, or by random mutagenesis of a selected site in a nucleic acid which encodes the polypeptide. Variant polypeptides are then expressed and tested for one or more activities to determine which
15 mutation provides a variant polypeptide with the desired properties. Further mutations can be made to variants (or to non-variant CT antigen polypeptides) which are silent as to the amino acid sequence of the polypeptide, but which provide preferred codons for translation in a particular host. The preferred codons for translation of a nucleic acid in, e.g., *E. coli*, are well known to those of ordinary skill in the art. Still other mutations can be made to the
20 noncoding sequences of a CT antigen gene or cDNA clone to enhance expression of the polypeptide. The activity of variants of CT antigen polypeptides can be tested by cloning the gene encoding the variant CT antigen polypeptide into a bacterial or mammalian expression vector, introducing the vector into an appropriate host cell, expressing the variant CT antigen polypeptide, and testing for a functional capability of the CT antigen polypeptides as
25 disclosed herein. For example, the variant CT antigen polypeptide can be tested for binding to antibodies or T cells. Preferred variants are those that compete for binding with the original polypeptide for binding to antibodies or T cells. Preparation of other variant polypeptides may favor testing of other activities, as will be known to one of ordinary skill in the art.

30 The skilled artisan will also realize that conservative amino acid substitutions may be made in CT antigen polypeptides to provide functionally equivalent variants of the foregoing polypeptides, i.e., the variants retain the functional capabilities of the CT antigen

- 32 -

polypeptides. As used herein, a "conservative amino acid substitution" refers to an amino acid substitution which does not alter the relative charge or size characteristics of the protein in which the amino acid substitution is made. Variants can be prepared according to methods for altering polypeptide sequence known to one of ordinary skill in the art such as are found in references which compile such methods, e.g. *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, or *Current Protocols in Molecular Biology*, F.M. Ausubel, et al., eds., John Wiley & Sons, Inc., New York. Exemplary functionally equivalent variants of the CT antigen polypeptides include conservative amino acid substitutions of in the amino acid sequences of proteins disclosed herein. Conservative substitutions of amino acids include substitutions made amongst amino acids within the following groups: (a) M, I, L, V; (b) F, Y, W; (c) K, R, H; (d) A, G; (e) S, T; (f) Q, N; and (g) E, D.

For example, upon determining that a peptide derived from a CT antigen polypeptide is presented by an MHC molecule and recognized by CTLs (e.g., as described in the Examples), one can make conservative amino acid substitutions to the amino acid sequence of the peptide, particularly at residues which are thought not to be direct contact points with the MHC molecule, i.e., the anchor residues that confer MHC binding. One of ordinary skill in the art will know these residues and will preferentially substitute other amino acid residues in the peptides in making variants. It is possible also to use other members of the consensus amino acids for a particular anchor residue. For example, consensus anchor residues for HLA-B35 are P in position 2 and Y, F, M, L or I in position 9. Therefore, if position 9 of a peptide was tyrosine (Y), one could substitute phenylalanine (F), methionine (M), leucine (L) or isoleucine (I) and maintain a consensus amino acid at the anchor residue positions of the peptide.

In general, it is preferred that fewer than all of the amino acids are changed when preparing variant polypeptides. Where particular amino acid residues are known to confer function, such amino acids will not be replaced, or alternatively, will be replaced by conservative amino acid substitutions. Preferably, 1, 2, 3, 4, 5, 6, 7, 8, and so on up to one fewer than the length of the peptide are changed when preparing variant polypeptides. It is generally preferred that the fewest number of substitutions is made. Thus, one method for generating variant polypeptides is to substitute all other amino acids for a particular single

- 33 -

amino acid, then assay activity of the variant, then repeat the process with one or more of the polypeptides having the best activity.

As another example, methods for identifying functional variants of HLA class II binding peptides are provided in a published PCT application of Strominger and
5 Wucherpennig (PCT/US96/03182). Peptides bearing one or more amino acid substitutions also can be tested for concordance with known HLA/MHC motifs prior to synthesis using, e.g. the computer program described by D'Amaro and Drijfhout (D'Amaro et al., *Human Immunol.* 43:13-18, 1995; Drijfhout et al., *Human Immunol.* 43:1-12, 1995). The substituted peptides can then be tested for binding to the MHC molecule and recognition by CTLs when
10 bound to MHC. These variants can be tested for improved stability and are useful, *inter alia*, in vaccine compositions.

Conservative amino-acid substitutions in the amino acid sequence of CT antigen polypeptides to produce functionally equivalent variants of CT antigen polypeptides typically are made by alteration of a nucleic acid encoding a CT antigen polypeptide. Such
15 substitutions can be made by a variety of methods known to one of ordinary skill in the art. For example, amino acid substitutions may be made by PCR-directed mutation, site-directed mutagenesis according to the method of Kunkel (Kunkel, *Proc. Nat. Acad. Sci. U.S.A.* 82: 488-492, 1985), or by chemical synthesis of a gene encoding a CT antigen polypeptide. Where amino acid substitutions are made to a small unique fragment of a CT antigen
20 polypeptide, such as an antigenic epitope recognized by autologous or allogeneic sera or cytolytic T lymphocytes, the substitutions can be made by directly synthesizing the peptide. The activity of functionally equivalent fragments of CT antigen polypeptides can be tested by cloning the gene encoding the altered CT antigen polypeptide into a bacterial or mammalian expression vector, introducing the vector into an appropriate host cell, expressing the altered
25 CT antigen polypeptide, and testing for a functional capability of the CT antigen polypeptides as disclosed herein. Peptides which are chemically synthesized can be tested directly for function, e.g., for binding to antisera recognizing associated antigens.

The invention also provides, in certain embodiments, "dominant negative" polypeptides derived from CT antigen polypeptides. A dominant negative polypeptide is an
30 inactive variant of a protein, which, by interacting with the cellular machinery, displaces an active protein from its interaction with the cellular machinery or competes with the active protein, thereby reducing the effect of the active protein. For example, a dominant negative

- 34 -

receptor which binds a ligand but does not transmit a signal in response to binding of the ligand can reduce the biological effect of expression of the ligand. Likewise, a dominant negative catalytically-inactive kinase which interacts normally with target proteins but does not phosphorylate the target proteins can reduce phosphorylation of the target proteins in response to a cellular signal. Similarly, a dominant negative transcription factor which binds to a promoter site in the control region of a gene but does not increase gene transcription can reduce the effect of a normal transcription factor by occupying promoter binding sites without increasing transcription.

The end result of the expression of a dominant negative polypeptide in a cell is a reduction in function of active proteins. One of ordinary skill in the art can assess the potential for a dominant negative variant of a protein, and using standard mutagenesis techniques to create one or more dominant negative variant polypeptides. For example, given the teachings contained herein of CT antigens, especially those which are similar to known proteins which have known activities, one of ordinary skill in the art can modify the sequence of the CT antigens by site-specific mutagenesis, scanning mutagenesis, partial gene deletion or truncation, and the like. See, e.g., U.S. Patent No. 5,580,723 and Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press, 1989. The skilled artisan then can test the population of mutagenized polypeptides for diminution in a selected and/or for retention of such an activity. Other similar methods for creating and testing dominant negative variants of a protein will be apparent to one of ordinary skill in the art.

The invention as described herein has a number of uses, some of which are described elsewhere herein. First, the invention permits isolation of the CT antigen protein molecules. A variety of methodologies well-known to the skilled practitioner can be utilized to obtain isolated CT antigen molecules. The polypeptide may be purified from cells which naturally produce the polypeptide by chromatographic means or immunological recognition. Alternatively, an expression vector may be introduced into cells to cause production of the polypeptide. In another method, mRNA transcripts may be microinjected or otherwise introduced into cells to cause production of the encoded polypeptide. Translation of mRNA in cell-free extracts such as the reticulocyte lysate system also may be used to produce polypeptide. Those skilled in the art also can readily follow known methods for isolating CT antigen polypeptides. These include, but are not limited to, immunochromatography, HPLC,

- 35 -

size-exclusion chromatography, ion-exchange chromatography and immune-affinity chromatography.

The invention also makes it possible isolate proteins which bind to CT antigens as disclosed herein, including antibodies and cellular binding partners of the CT antigens.

5 Additional uses are described further herein.

The isolation and identification of CT antigen genes also makes it possible for the artisan to diagnose a disorder characterized by expression of CT antigens. These methods involve determining expression of one or more CT antigen nucleic acids, and/or encoded CT antigen polypeptides and/or peptides derived therefrom. In the former situation, such
10 determinations can be carried out via any standard nucleic acid determination assay, including the polymerase chain reaction, or assaying with labeled hybridization probes. In the latter two situations, such determinations can be carried out by immunoassays including, for example, ELISAs for the CT antigens, immunohistochemistry on tissue samples, and screening patient antisera for recognition of the polypeptide.

15 The invention also includes methods to monitor the onset, progression, or regression of cancer in a subject by, for example, obtaining cell or tissue samples at sequential times from a subject and assaying such samples for the presence and/or level of expression of the cancer-associated polypeptides of the invention. A subject may be suspected of having cancer or may be believed not to have cancer and the sample can serve as a baseline level for
20 comparison with subsequent cell or tissue samples from the subject.

Onset of a condition is the initiation of the physiological changes or characteristics associated with the condition in a subject. Such changes may be evidenced by physiological symptoms, or may be clinically asymptomatic. For example, the onset of cancer may be followed by a period during which there may be cancer-associated physiological
25 characteristics in the subject, even though clinical symptoms may not be evident at that time. The progression of a condition follows onset and is the advancement of the physiological characteristics of the condition, which may or may not be marked by an increase in clinical symptoms. In contrast, the regression of a condition is a decrease in physiological characteristics of the condition, perhaps with a parallel reduction in symptoms, and may
30 result from a treatment or may be a natural reversal in the condition.

The presence of a cancer-associated nucleic acid or polypeptide in a cell or tissue sample from a subject that is determined to be at a level above the baseline level for that

- 36 -

nucleic acid or polypeptide, is a marker for cancer in the subject. For example, a marker for cancer may be the specific binding of a cancer-associated polypeptide with an antibody. The onset of a cancer condition may be indicated by the appearance of such a marker(s) in a subject's samples where there was no such marker(s) determined previously. For example, if
5 marker(s) for cancer are determined not to be present in a first sample from a subject, the determination that cancer marker(s) are present in a second or subsequent sample from the subject is an indication of the onset of cancer in the subject.

Progression and regression of a cancer condition are indicated by the increase or decrease, respectively, of marker(s) in a subject's samples over time. For example, if
10 marker(s) for cancer are determined to be present in a first sample from a subject and additional marker(s) or more of the initial marker(s) for cancer are determined to be present in a second or subsequent sample from the subject, it indicates the progression of cancer. Regression of cancer is indicated by finding that marker(s) determined to be present in a sample from a subject are not determined to be found, or found at lower amounts in a second
15 or subsequent sample from the subject.

The progression and regression of a cancer condition may also be indicated based on characteristics of the expression of the cancer-associated polypeptides determined in the subject. For example, some cancer-associated polypeptides may be abnormally expressed at specific stages of cancer (e.g. early-stage cancer-associated polypeptides; mid-stage cancer-associated polypeptides; and late-stage cancer-associated polypeptides). Another example,
20 although not intended to be limiting, is that cancer-associated polypeptides may be differentially expressed in primary tumors versus metastases, thereby allowing the stage and/or diagnostic level of the disease to be established, based on the identification of selected cancer-associated polypeptides in a subject sample.

Different types of cancer in a single tissue type may express different cancer-associated polypeptides and the encoding nucleic acid molecules thereof, or may have different spatial or temporal expression patterns. Such variations may allow cancer-specific diagnosis and subsequent treatment tailored to the patient's specific condition. These differences in expression, can enable a physician to diagnose the cancer on the basis of
25 differential expression of the cancer-associated polypeptides and the encoding nucleic acid molecules of the invention, or immune responses thereto (e.g., serum antibodies) and permits specific treatments to be selected and administered on the basis of the differential expression.
30

- 37 -

The isolation and identification of cancer-associated nucleic acids and polypeptides also permits the artisan to diagnose a disorder characterized by expression of cancer-associated polypeptides, and characterized preferably by an immune response against the cancer-associated polypeptides. As shown herein, the expression in of cancer-associated polypeptides in a subject with cancer can result in a measurable immune response to the cancer-associated polypeptides in the subject. The evaluation of this immune response is useful in the diagnosis of cancer in a subject expressing one or more of the cancer-associated polypeptides of the invention.

The methods of the invention related to cancer-associated polypeptide immune responses involve determining the immune response (antibody or cellular) against one or more cancer-associated polypeptides. The immune response can be assayed by any of the various immunoassay methodologies known to one of ordinary skill in the art. For example, the antigenic cancer-associated polypeptides can be used as a target to capture antibodies from a sample, such as a blood sample drawn from a patient, in an immunoassay, such as an ELISA assay. Thus, the invention involves in some aspects diagnosing or monitoring cancer in a subject by determining the presence of an immune response to one or more of the cancer-associated polypeptides described herein. In preferred embodiments, this determination is performed by assaying a bodily fluid obtained from the subject, for example blood or lymph node fluid, for the presence of antibodies against one or more cancer-associated polypeptides or the nucleic acid molecules that encode the cancer-associated polypeptides, or for the presence of antibodies against one of the cancer-associated polypeptides as described herein.

Measurement of the immune response against one or more of the cancer-associated polypeptides described herein in a subject over time by sequential determinations is useful to monitor the onset, progression, or regression of cancer including that resulting from a course of treatment. For example, a sample such as blood or lymph node fluid may be obtained from a subject and contacted with a cancer-associated polypeptide of the invention, and binding between an agent in the sample (e.g., an antibody) with one of the cancer-associated polypeptides, is an indication of an immune response to the cancer-associated polypeptide. At a second, subsequent time, another sample may be obtained from the subject and similarly tested. The results of the first and second tests (and/or subsequent tests) can be compared as a measure of the onset, regression, or progression of cancer, or, if cancer treatment was

- 38 -

undertaken during the interval between obtaining the samples, the effectiveness of the treatment may be evaluated by comparing the results of the two tests.

The stage of cancer in a subject may be determined based on variation in a subject's immune response to cancer-associated polypeptides of the invention. Variability in the immune response to the polypeptides may be used to indicate the stage of cancer in a subject. For example, some cancer-associated polypeptides may trigger an immune response at different stages of the cancer than that triggered by other cancer-associated polypeptides. The cancer-specific diagnoses described herein above may also be based on the variations in immune responses to the different cancer-associated polypeptides.

The invention includes kits for assaying the presence of cancer-associated polypeptides and/or antibodies that specifically bind to cancer-associated polypeptides. An example of a kit may include an antibody or antigen-binding fragment thereof, that binds specifically to a cancer-associated polypeptide. The antibody or antigen-binding fragment thereof, may be applied to a tissue or cell sample from a patient with cancer, suspected of having cancer, or believed to be free of cancer and the sample then processed to assess whether specific binding occurs between the antibody and a polypeptide or other component of the sample.

Another example of such a kit may include the above-mentioned polypeptides bound to a substrate, for example a dipstick, which is dipped into a blood or body fluid sample of a subject. The surface of the substrate may then be processed using procedures well known to those of skill in the art, to assess whether specific binding occurred between the polypeptides and agents (e.g. antibodies) in the subject's sample. For example, procedures may include, but are not limited to, contact with a secondary antibody, or other method that indicates the presence of specific binding.

In addition, the antibody or antigen-binding fragment thereof, may be applied to a body fluid sample, such as blood or lymph node fluid, from a subject, either suspected of having cancer, diagnosed with cancer, or believed to be free of cancer. As will be understood by one of skill in the art, such binding assays may also be performed with a sample or object contacted with an antibody and/or cancer-associated polypeptide that is in solution, for example in a 96-well plate or applied directly to an object surface.

Another example of a kit of the invention, is a kit that provides components necessary to determine the level of expression of one or more cancer-associated nucleic acid molecules

- 39 -

of the invention. Such components may include primers useful for amplification of one or more cancer-associated nucleic acid molecules and/or other chemicals for PCR amplification.

Another example of a kit of the invention, is a kit that provides components necessary to determine the level of expression of one or more cancer-associated nucleic acid molecules of the invention using a method of hybridization.

The foregoing kits can include instructions or other printed material on how to use the various components of the kits for diagnostic purposes.

The invention further includes nucleic acid or protein microarrays with CT antigens or nucleic acids encoding such polypeptides. In this aspect of the invention, standard techniques of microarray technology are utilized to assess expression of the CT antigens and/or identify biological constituents that bind such polypeptides. The constituents of biological samples include antibodies, lymphocytes (particularly T lymphocytes), and the like. Protein microarray technology, which is also known by other names including: protein chip technology and solid-phase protein array technology, is well known to those of ordinary skill in the art and is based on, but not limited to, obtaining an array of identified peptides or proteins on a fixed substrate, binding target molecules or biological constituents to the peptides, and evaluating such binding. See, e.g., G. MacBeath and S.L. Schreiber, "Printing Proteins as Microarrays for High-Throughput Function Determination," *Science* 289(5485):1760-1763, 2000. Nucleic acid arrays, particularly arrays that bind CT antigens, also can be used for diagnostic applications, such as for identifying subjects that have a condition characterized by CT antigen expression.

Microarray substrates include but are not limited to glass, silica, aluminosilicates, borosilicates, metal oxides such as alumina and nickel oxide, various clays, nitrocellulose, or nylon. The microarray substrates may be coated with a compound to enhance synthesis of a probe (peptide or nucleic acid) on the substrate. Coupling agents or groups on the substrate can be used to covalently link the first nucleotide or amino acid to the substrate. A variety of coupling agents or groups are known to those of skill in the art. Peptide or nucleic acid probes thus can be synthesized directly on the substrate in a predetermined grid.

Alternatively, peptide or nucleic acid probes can be spotted on the substrate, and in such cases the substrate may be coated with a compound to enhance binding of the probe to the substrate. In these embodiments, presynthesized probes are applied to the substrate in a precise, predetermined volume and grid pattern, preferably utilizing a computer-controlled

robot to apply probe to the substrate in a contact-printing manner or in a non-contact manner such as ink jet or piezo-electric delivery. Probes may be covalently linked to the substrate.

Targets are peptides or proteins and may be natural or synthetic. The tissue may be obtained from a subject or may be grown in culture (e.g. from a cell line).

5 In some embodiments of the invention one or more control peptide or protein molecules are attached to the substrate. Preferably, control peptide or protein molecules allow determination of factors such as peptide or protein quality and binding characteristics, reagent quality and effectiveness, hybridization success, and analysis thresholds and success.

10 In other embodiments, one or more control peptide or nucleic acid molecules are attached to the substrate. Preferably, control nucleic acid molecules allow determination of factors such as binding characteristics, reagent quality and effectiveness, hybridization success, and analysis thresholds and success.

Nucleic acid microarray technology, which is also known by other names including: DNA chip technology, gene chip technology, and solid-phase nucleic acid array technology, 15 is well known to those of ordinary skill in the art and is based on, but not limited to, obtaining an array of identified nucleic acid probes on a fixed substrate, labeling target molecules with reporter molecules (e.g., radioactive, chemiluminescent, or fluorescent tags such as fluorescein, Cy3-dUTP, or Cy5-dUTP), hybridizing target nucleic acids to the probes, and evaluating target-probe hybridization. A probe with a nucleic acid sequence that perfectly 20 matches the target sequence will, in general, result in detection of a stronger reporter-molecule signal than will probes with less perfect matches. Many components and techniques utilized in nucleic acid microarray technology are presented in *The Chipping Forecast*, Nature Genetics, Vol.21, Jan 1999, the entire contents of which is incorporated by reference herein.

25 According to the present invention, nucleic acid microarray substrates may include but are not limited to glass, silica, aluminosilicates, borosilicates, metal oxides such as alumina and nickel oxide, various clays, nitrocellulose, or nylon. In all embodiments a glass substrate is preferred. According to the invention, probes are selected from the group of nucleic acids including, but not limited to: DNA, genomic DNA, cDNA, and 30 oligonucleotides; and may be natural or synthetic. Oligonucleotide probes preferably are 20 to 25-mer oligonucleotides and DNA/cDNA probes preferably are 500 to 5000 bases in length, although other lengths may be used. Appropriate probe length may be determined by

- 41 -

one of ordinary skill in the art by following art-known procedures. In one embodiment, preferred probes are sets of two or more of the CT antigen nucleic acid molecules set forth herein. Probes may be purified to remove contaminants using standard methods known to those of ordinary skill in the art such as gel filtration or precipitation.

- 5 In one embodiment, the microarray substrate may be coated with a compound to enhance synthesis of the probe on the substrate. Such compounds include, but are not limited to, oligoethylene glycols. In another embodiment, coupling agents or groups on the substrate can be used to covalently link the first nucleotide or oligonucleotide to the substrate. These agents or groups may include, for example, amino, hydroxy, bromo, and carboxy groups.
- 10 These reactive groups are preferably attached to the substrate through a hydrocarbyl radical such as an alkylene or phenylene divalent radical, one valence position occupied by the chain bonding and the remaining attached to the reactive groups. These hydrocarbyl groups may contain up to about ten carbon atoms, preferably up to about six carbon atoms. Alkylene radicals are usually preferred containing two to four carbon atoms in the principal chain.
- 15 These and additional details of the process are disclosed, for example, in U.S. Patent 4,458,066, which is incorporated by reference in its entirety.

- In one embodiment, probes are synthesized directly on the substrate in a predetermined grid pattern using methods such as light-directed chemical synthesis, photochemical deprotection, or delivery of nucleotide precursors to the substrate and
- 20 subsequent probe production.

- In another embodiment, the substrate may be coated with a compound to enhance binding of the probe to the substrate. Such compounds include, but are not limited to: polylysine, amino silanes, amino-reactive silanes (Chipping Forecast, 1999) or chromium. In this embodiment, presynthesized probes are applied to the substrate in a precise,
- 25 predetermined volume and grid pattern, utilizing a computer-controlled robot to apply probe to the substrate in a contact-printing manner or in a non-contact manner such as ink jet or piezo-electric delivery. Probes may be covalently linked to the substrate with methods that include, but are not limited to, UV-irradiation. In another embodiment probes are linked to the substrate with heat.

- 30 Targets for microarrays are nucleic acids selected from the group, including but not limited to: DNA, genomic DNA, cDNA, RNA, mRNA and may be natural or synthetic. In

- 42 -

all embodiments, nucleic acid target molecules from human tissue are preferred. The tissue may be obtained from a subject or may be grown in culture (e.g. from a cell line).

In embodiments of the invention one or more control nucleic acid molecules are attached to the substrate. Preferably, control nucleic acid molecules allow determination of factors such as nucleic acid quality and binding characteristics, reagent quality and effectiveness, hybridization success, and analysis thresholds and success. Control nucleic acids may include but are not limited to expression products of genes such as housekeeping genes or fragments thereof.

In some embodiments, one or more control peptide or nucleic acid molecules are attached to the substrate. Preferably, control nucleic acid molecules allow determination of factors such as binding characteristics, reagent quality and effectiveness, hybridization success, and analysis thresholds and success.

Expression of CT antigen polypeptides can also be determined using protein measurement methods. Preferred methods of specifically and quantitatively measuring proteins include, but are not limited to: mass spectroscopy-based methods such as surface enhanced laser desorption ionization (SELDI; e.g., Ciphergen ProteinChip System, Ciphergen Biosystems, Fremont CA), non-mass spectroscopy-based methods, and immunohistochemistry-based methods such as two-dimensional gel electrophoresis.

SELDI methodology may, through procedures known to those of ordinary skill in the art, be used to vaporize microscopic amounts of tumor protein and to create a "fingerprint" of individual proteins, thereby allowing simultaneous measurement of the abundance of many proteins in a single sample. Preferably SELDI-based assays may be utilized to classify tumor samples with respect to the expression of a variety of CT antigens. Such assays preferably include, but are not limited to the following examples. Gene products discovered by RNA microarrays may be selectively measured by specific (antibody mediated) capture to the SELDI protein disc (e.g., selective SELDI). Gene products discovered by protein screening (e.g., with 2-D gels), may be resolved by "total protein SELDI" optimized to visualize those particular markers of interest from among CT antigens.

Tumors can be classified based on the measurement of multiple CT antigens. Classification based on CT antigen expression can be used to stage disease, monitor progression or regression of disease, and select treatment strategies for the cancer patients.

- 43 -

The invention also involves agents such as polypeptides which bind to CT antigen polypeptides. Such binding agents can be used, for example, in screening assays to detect the presence or absence of CT antigen polypeptides and complexes of CT antigen polypeptides and their binding partners and in purification protocols to isolated CT antigen polypeptides and complexes of CT antigen polypeptides and their binding partners. Such agents also can be used to inhibit the native activity of the CT antigen polypeptides, for example, by binding to such polypeptides.

The invention, therefore, embraces peptide binding agents which, for example, can be antibodies or fragments of antibodies having the ability to selectively bind to CT antigen polypeptides. Antibodies include polyclonal and monoclonal antibodies, prepared according to conventional methodology.

Significantly, as is well-known in the art, only a small portion of an antibody molecule, the paratope, is involved in the binding of the antibody to its epitope (see, in general, Clark, W.R. (1986) The Experimental Foundations of Modern Immunology Wiley & Sons, Inc., New York; Roitt, I. (1991) Essential Immunology, 7th Ed., Blackwell Scientific Publications, Oxford). The pFc' and Fc regions, for example, are effectors of the complement cascade but are not involved in antigen binding. An antibody from which the pFc' region has been enzymatically cleaved, or which has been produced without the pFc' region, designated an F(ab')₂ fragment, retains both of the antigen binding sites of an intact antibody. Similarly, an antibody from which the Fc region has been enzymatically cleaved, or which has been produced without the Fc region, designated an Fab fragment, retains one of the antigen binding sites of an intact antibody molecule. Proceeding further, Fab fragments consist of a covalently bound antibody light chain and a portion of the antibody heavy chain denoted Fd. The Fd fragments are the major determinant of antibody specificity (a single Fd fragment may be associated with up to ten different light chains without altering antibody specificity) and Fd fragments retain epitope-binding ability in isolation.

Within the antigen-binding portion of an antibody, as is well-known in the art, there are complementarity determining regions (CDRs), which directly interact with the epitope of the antigen, and framework regions (FRs), which maintain the tertiary structure of the paratope (see, in general, Clark, 1986; Roitt, 1991). In both the heavy chain Fd fragment and the light chain of IgG immunoglobulins, there are four framework regions (FR1 through FR4) separated respectively by three complementarity determining regions (CDR1 through CDR3).

- 44 -

The CDRs, and in particular the CDR3 regions, and more particularly the heavy chain CDR3, are largely responsible for antibody specificity.

It is now well-established in the art that the non-CDR regions of a mammalian antibody may be replaced with similar regions of conspecific or heterospecific antibodies while retaining the epitopic specificity of the original antibody. This is most clearly
5 manifested in the development and use of "humanized" antibodies in which non-human CDRs are covalently joined to human FR and/or Fc/pFc' regions to produce a functional antibody. See, e.g., U.S. patents 4,816,567, 5,225,539, 5,585,089, 5,693,762 and 5,859,205.

Fully human monoclonal antibodies also can be prepared by immunizing mice
10 transgenic for large portions of human immunoglobulin heavy and light chain loci. See, e.g., U.S. patents 5,545,806, 6,150,584, and references cited therein. Following immunization of these mice (e.g., XenoMouse (Abgenix), HuMAb mice (Medarex/GenPharm)), monoclonal antibodies can be prepared according to standard hybridoma technology. These monoclonal antibodies will have human immunoglobulin amino acid sequences and therefore will not
15 provoke human anti-mouse antibody (HAMA) responses when administered to humans.

Thus, as will be apparent to one of ordinary skill in the art, the present invention also provides for F(ab')₂, Fab, Fv and Fd fragments; chimeric antibodies in which the Fc and/or FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; chimeric F(ab')₂ fragment antibodies in which
20 the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; chimeric Fab fragment antibodies in which the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; and chimeric Fd fragment antibodies in which the FR and/or CDR1 and/or CDR2 regions have been replaced by homologous human or non-
25 human sequences. The present invention also includes so-called single chain antibodies.

Accordingly, the invention involves polypeptides of numerous size and type that bind specifically to CT antigen polypeptides, and complexes of both CT antigen polypeptides and their binding partners. These polypeptides may be derived also from sources other than antibody technology. For example, such polypeptide binding agents can be provided by
30 degenerate peptide libraries which can be readily prepared in solution, in immobilized form or as phage display libraries. Combinatorial libraries also can be synthesized of peptides

- 45 -

containing one or more amino acids. Libraries further can be synthesized of peptoids and non-peptide synthetic moieties.

Phage display can be particularly effective in identifying binding peptides useful according to the invention. Briefly, one prepares a phage library (using e.g. m13, fd, or
5 lambda phage), displaying inserts from 4 to about 80 amino acid residues using conventional procedures. The inserts may represent, for example, a completely degenerate or biased array. One then can select phage-bearing inserts which bind to the CT antigen polypeptide. This process can be repeated through several cycles of reselection of phage that bind to the CT antigen polypeptide. Repeated rounds lead to enrichment of phage bearing particular
10 sequences. DNA sequence analysis can be conducted to identify the sequences of the expressed polypeptides. The minimal linear portion of the sequence that binds to the CT antigen polypeptide can be determined. One can repeat the procedure using a biased library containing inserts containing part or all of the minimal linear portion plus one or more additional degenerate residues upstream or downstream thereof. Yeast two-hybrid screening
15 methods also may be used to identify polypeptides that bind to the CT antigen polypeptides. Thus, the CT antigen polypeptides of the invention, or a fragment thereof, can be used to screen peptide libraries, including phage display libraries, to identify and select peptide binding partners of the CT antigen polypeptides of the invention. Such molecules can be used, as described, for screening assays, for purification protocols, for interfering directly
20 with the functioning of CT antigen and for other purposes that will be apparent to those of ordinary skill in the art.

As detailed herein, the foregoing antibodies and other binding molecules may be used for example to identify tissues expressing protein or to purify protein. Antibodies also may be coupled to specific diagnostic labeling agents for imaging of cells and tissues that express
25 CT antigens or to therapeutically useful agents according to standard coupling procedures. Diagnostic agents include, but are not limited to, barium sulfate, iocetamic acid, iopanoic acid, ipodate calcium, diatrizoate sodium, diatrizoate meglumine, metrizamide, tyropanoate sodium and radiodiagnostics including positron emitters such as fluorine-18 and carbon-11, gamma emitters such as iodine-123, technitium-99m, iodine-131 and indium-111, nuclides
30 for nuclear magnetic resonance such as fluorine and gadolinium. Other diagnostic agents useful in the invention will be apparent to one of ordinary skill in the art.

- 46 -

As used herein, "therapeutically useful agents" include any therapeutic molecule which desirably is targeted selectively to a cell expressing one of the cancer antigens disclosed herein, including antineoplastic agents, radioiodinated compounds, toxins, other cytostatic or cytolytic drugs, and so forth. Antineoplastic therapeutics are well known and include: aminoglutethimide, azathioprine, bleomycin sulfate, busulfan, carmustine, chlorambucil, cisplatin, cyclophosphamide, cyclosporine, cytarabidine, dacarbazine, dactinomycin, daunorubicin, doxorubicin, taxol, etoposide, fluorouracil, interferon- α , lomustine, mercaptopurine, methotrexate, mitotane, procarbazine HCl, thioguanine, vinblastine sulfate and vincristine sulfate. Additional antineoplastic agents include those disclosed in Chapter 52, Antineoplastic Agents (Paul Calabresi and Bruce A. Chabner), and the introduction thereto, 1202-1263, of Goodman and Gilman's "The Pharmacological Basis of Therapeutics", Eighth Edition, 1990, McGraw-Hill, Inc. (Health Professions Division). Toxins can be proteins such as, for example, pokeweed anti-viral protein, cholera toxin, pertussis toxin, ricin, gelonin, abrin, diphtheria exotoxin, or *Pseudomonas* exotoxin. Toxin moieties can also be high energy-emitting radionuclides such as cobalt-60.

In some embodiments, antibodies prepared according to the invention are specific for complexes of MHC molecules and the CT antigens described herein.

When "disorder" is used herein, it refers to any pathological condition where the CT antigens are expressed. An example of such a disorder is cancer, including but not limited to: biliary tract cancer; bladder cancer; breast cancer; brain cancer including glioblastomas and medulloblastomas; cervical cancer; choriocarcinoma; colon cancer; endometrial cancer; esophageal cancer; gastric cancer; head and neck cancer; hematological neoplasms including acute lymphocytic and myelogenous leukemia, multiple myeloma, AIDS-associated leukemias and adult T-cell leukemia lymphoma; intraepithelial neoplasms including Bowen's disease and Paget's disease; liver cancer; lung cancer including small cell lung cancer and non-small cell lung cancer; lymphomas including Hodgkin's disease and lymphocytic lymphomas; neuroblastomas; oral cancer including squamous cell carcinoma; ovarian cancer including those arising from epithelial cells, stromal cells, germ cells and mesenchymal cells; pancreatic cancer; prostate cancer; rectal cancer; sarcomas including leiomyosarcoma, rhabdomyosarcoma, liposarcoma, fibrosarcoma, synovial sarcoma and osteosarcoma; skin cancer including melanoma, Kaposi's sarcoma, basocellular cancer, and squamous cell cancer; testicular cancer including germinal tumors such as seminoma, non-seminoma

- 47 -

(teratomas, choriocarcinomas), stromal tumors, and germ cell tumors; thyroid cancer including thyroid adenocarcinoma and medullar carcinoma; transitional cancer and renal cancer including adenocarcinoma and Wilms tumor.

Samples of tissue and/or cells for use in the various methods described herein can be obtained through standard methods such as tissue biopsy, including punch biopsy and cell scraping, and collection of blood or other bodily fluids by aspiration or other methods.

In certain embodiments of the invention, an immunoreactive cell sample is removed from a subject. By "immunoreactive cell" is meant a cell which can mature into an immune cell (such as a B cell, a helper T cell, or a cytolytic T cell) upon appropriate stimulation.

Thus immunoreactive cells include CD34⁺ hematopoietic stem cells, immature T cells and immature B cells. When it is desired to produce cytolytic T cells which recognize a CT antigen, the immunoreactive cell is contacted with a cell which expresses a CT antigen under conditions favoring production, differentiation and/or selection of cytolytic T cells; the differentiation of the T cell precursor into a cytolytic T cell upon exposure to antigen is similar to clonal selection of the immune system.

Some therapeutic approaches based upon the disclosure are premised on a response by a subject's immune system, leading to lysis of antigen presenting cells, such as cancer cells which present one or more CT antigens. One such approach is the administration of autologous CTLs specific to a CT antigen/MHC complex to a subject with abnormal cells of the phenotype at issue. It is within the ability of one of ordinary skill in the art to develop such CTLs *in vitro*. An example of a method for T cell differentiation is presented in International Application number PCT/US96/05607. Generally, a sample of cells taken from a subject, such as blood cells, are contacted with a cell presenting the complex and capable of provoking CTLs to proliferate. The target cell can be a transfectant, such as a COS cell. These transfectants present the desired complex of their surface and, when combined with a CTL of interest, stimulate its proliferation. COS cells are widely available, as are other suitable host cells. Specific production of CTL clones is well known in the art. The clonally expanded autologous CTLs then are administered to the subject.

Another method for selecting antigen-specific CTL clones has recently been described (Altman et al., *Science* 274:94-96, 1996; Dunbar et al., *Curr. Biol.* 8:413-416, 1998), in which fluorogenic tetramers of MHC class I molecule/peptide complexes are used to detect specific CTL clones. Briefly, soluble MHC class I molecules are folded *in vitro* in the

- 48 -

presence of β_2 -microglobulin and a peptide antigen which binds the class I molecule. After purification, the MHC/peptide complex is purified and labeled with biotin. Tetramers are formed by mixing the biotinylated peptide-MHC complex with labeled avidin (e.g. phycoerythrin) at a molar ratio of 4:1. Tetramers are then contacted with a source of CTLs such as peripheral blood or lymph node. The tetramers bind CTLs which recognize the peptide antigen/MHC class I complex. Cells bound by the tetramers can be sorted by fluorescence activated cell sorting to isolate the reactive CTLs. The isolated CTLs then can be expanded *in vitro* for use as described herein.

To detail a therapeutic methodology, referred to as adoptive transfer (Greenberg, *J. Immunol.* 136(5): 1917, 1986; Riddel et al., *Science* 257: 238, 1992; Lynch et al, *Eur. J. Immunol.* 21: 1403-1410, 1991; Kast et al., *Cell* 59: 603-614, 1989), cells presenting the desired complex (e.g., dendritic cells) are combined with CTLs leading to proliferation of the CTLs specific thereto. The proliferated CTLs are then administered to a subject with a cellular abnormality which is characterized by certain of the abnormal cells presenting the particular complex. The CTLs then lyse the abnormal cells, thereby achieving the desired therapeutic goal.

The foregoing therapy assumes that at least some of the subject's abnormal cells present the relevant HLA/CT antigen complex. This can be determined very easily, as the art is very familiar with methods for identifying cells which present a particular HLA molecule, as well as how to identify cells expressing DNA of the pertinent sequences, in this case a CT antigen sequence. Once cells presenting the relevant complex are identified via the foregoing screening methodology, they can be combined with a sample from a patient, where the sample contains CTLs. If the complex presenting cells are lysed by the mixed CTL sample, then it can be assumed that a CT antigen is being presented, and the subject is an appropriate candidate for the therapeutic approaches set forth *supra*.

Adoptive transfer is not the only form of therapy that is available in accordance with the invention. CTLs can also be provoked *in vivo*, using a number of approaches. One approach is the use of non-proliferative cells expressing the complex. The cells used in this approach may be those that normally express the complex, such as irradiated tumor cells or cells transfected with one or both of the genes necessary for presentation of the complex (i.e. the antigenic peptide and the presenting HLA molecule). Chen et al. (*Proc. Natl. Acad. Sci. USA* 88: 110-114, 1991) exemplifies this approach, showing the use of transfected cells

- 49 -

expressing HPVE7 peptides in a therapeutic regime. Various cell types may be used. Similarly, vectors carrying one or both of the genes of interest may be used. Viral or bacterial vectors are especially preferred. For example, nucleic acids which encode a CT antigen polypeptide or peptide may be operably linked to promoter and enhancer sequences which direct expression of the CT antigen polypeptide or peptide in certain tissues or cell types. The nucleic acid may be incorporated into an expression vector. Expression vectors may be unmodified extrachromosomal nucleic acids, plasmids or viral genomes constructed or modified to enable insertion of exogenous nucleic acids, such as those encoding CT antigen, as described elsewhere herein. Nucleic acids encoding a CT antigen also may be inserted into a retroviral genome, thereby facilitating integration of the nucleic acid into the genome of the target tissue or cell type. In these systems, the gene of interest is carried by a microorganism, e.g., a Vaccinia virus, pox virus, herpes simplex virus, retrovirus or adenovirus, and the materials de facto "infect" host cells. The cells which result present the complex of interest, and are recognized by autologous CTLs, which then proliferate.

A similar effect can be achieved by combining the CT antigen or an immune response stimulatory fragment thereof with an adjuvant to facilitate incorporation into antigen presenting cells *in vivo*. The CT antigen polypeptide is processed to yield the peptide partner of the HLA molecule while a CT antigen peptide may be presented without the need for further processing. Generally, subjects can receive an intradermal injection of an effective amount of the CT antigen. Initial doses can be followed by booster doses, following immunization protocols standard in the art.

The invention involves the use of various materials disclosed herein to "immunize" subjects or as "vaccines". As used herein, "immunization" or "vaccination" means increasing or activating an immune response against an antigen. It does not require elimination or eradication of a condition but rather contemplates the clinically favorable enhancement of an immune response toward an antigen. Generally accepted animal models can be used for testing of immunization against cancer using a CT antigen nucleic acid. For example, human cancer cells can be introduced into a mouse to create a tumor, and one or more CT antigen nucleic acids can be delivered by the methods described herein. The effect on the cancer cells (e.g., reduction of tumor size) can be assessed as a measure of the effectiveness of the CT antigen nucleic acid immunization. Of course, testing of the foregoing animal model using more conventional methods for immunization include the administration of one or more

- 50 -

CT antigen polypeptides or peptides derived therefrom, optionally combined with one or more adjuvants and/or cytokines to boost the immune response. Methods for immunization, including formulation of a vaccine composition and selection of doses, route of administration and the schedule of administration (e.g. primary and one or more booster doses), are well known in the art. The tests also can be performed in humans, where the end point is to test for the presence of enhanced levels of circulating CTLs against cells bearing the antigen, to test for levels of circulating antibodies against the antigen, to test for the presence of cells expressing the antigen and so forth.

As part of the immunization compositions, one or more CT antigens or stimulatory fragments thereof are administered with one or more adjuvants to induce an immune response or to increase an immune response. An adjuvant is a substance incorporated into or administered with antigen which potentiates the immune response. Adjuvants may enhance the immunological response by providing a reservoir of antigen (extracellularly or within macrophages), activating macrophages and stimulating specific sets of lymphocytes.

Adjuvants of many kinds are well known in the art. Specific examples of adjuvants include monophosphoryl lipid A (MPL, SmithKline Beecham); a congener obtained after purification and acid hydrolysis of *Salmonella minnesota* Re 595 lipopolysaccharide; saponins including QS21 (SmithKline Beecham), a pure QA-21 saponin purified from *Quillja saponaria* extract; DQS21, described in PCT application WO96/33739 (SmithKline Beecham); QS-7, QS-17, QS-18, and QS-L1 (So et al., *Mol. Cells* 7:178-186, 1997); incomplete Freund's adjuvant; complete Freund's adjuvant; montanide; immunostimulatory oligonucleotides (see e.g. CpG oligonucleotides described by Kreig et al., *Nature* 374:546-9, 1995); vitamin E and various water-in-oil emulsions prepared from biodegradable oils such as squalene and/or tocopherol. Preferably, the peptides are administered mixed with a combination of DQS21/MPL. The ratio of DQS21 to MPL typically will be about 1:10 to 10:1, preferably about 1:5 to 5:1 and more preferably about 1:1. Typically for human administration, DQS21 and MPL will be present in a vaccine formulation in the range of about 1 µg to about 100 µg. Other adjuvants are known in the art and can be used in the invention (see, e.g. Goding, *Monoclonal Antibodies: Principles and Practice*, 2nd Ed., 1986). Methods for the preparation of mixtures or emulsions of peptide and adjuvant are well known to those of skill in the art of vaccination.

- 51 -

Other agents which stimulate the immune response of the subject can also be administered to the subject. For example, other cytokines are also useful in vaccination protocols as a result of their lymphocyte regulatory properties. Many other cytokines useful for such purposes will be known to one of ordinary skill in the art, including interleukin-12 (IL-12) which has been shown to enhance the protective effects of vaccines (*see, e.g., Science* 268: 1432-1434, 1995), GM-CSF and IL-18. Thus cytokines can be administered in conjunction with antigens and adjuvants to increase the immune response to the antigens.

There are a number of immune response potentiating compounds that can be used in vaccination protocols. These include costimulatory molecules provided in either protein or nucleic acid form. Such costimulatory molecules include the B7-1 and B7-2 (CD80 and CD86 respectively) molecules which are expressed on dendritic cells (DC) and interact with the CD28 molecule expressed on the T cell. This interaction provides costimulation (signal 2) to an antigen/MHC/TCR stimulated (signal 1) T cell, increasing T cell proliferation and effector function. B7 also interacts with CTLA4 (CD152) on T cells and studies involving CTLA4 and B7 ligands indicate that the B7-CTLA4 interaction can enhance antitumor immunity and CTL proliferation (Zheng P., et al. *Proc. Natl. Acad. Sci. USA* 95 (11):6284-6289 (1998)).

B7 typically is not expressed on tumor cells so they are not efficient antigen presenting cells (APCs) for T cells. Induction of B7 expression would enable the tumor cells to stimulate more efficiently CTL proliferation and effector function. A combination of B7/IL-6/IL-12 costimulation has been shown to induce IFN-gamma and a Th1 cytokine profile in the T cell population leading to further enhanced T cell activity (Gajewski et al., *J. Immunol.*, 154:5637-5648 (1995)). Tumor cell transfection with B7 has been discussed in relation to *in vitro* CTL expansion for adoptive transfer immunotherapy by Wang et al., (*J. Immunol.*, 19:1-8 (1986)). Other delivery mechanisms for the B7 molecule would include nucleic acid (naked DNA) immunization (Kim J., et al. *Nat Biotechnol.*, 15:7:641-646 (1997)) and recombinant viruses such as adeno and pox (Wendtner et al., *Gene Ther.*, 4:7:726-735 (1997)). These systems are all amenable to the construction and use of expression cassettes for the coexpression of B7 with other molecules of choice such as the antigens or fragment(s) of antigens discussed herein (including polytopes) or cytokines. These delivery systems can be used for induction of the appropriate molecules *in vitro* and for *in vivo* vaccination situations. The use of anti-CD28 antibodies to directly stimulate T

- 52 -

cells *in vitro* and *in vivo* could also be considered. Similarly, the inducible co-stimulatory molecule ICOS which induces T cell responses to foreign antigen could be modulated, for example, by use of anti-ICOS antibodies (Hutloff et al., *Nature* 397:263-266, 1999).

Lymphocyte function associated antigen-3 (LFA-3) is expressed on APCs and some tumor cells and interacts with CD2 expressed on T cells. This interaction induces T cell IL-2 and IFN-gamma production and can thus complement but not substitute, the B7/CD28 costimulatory interaction (Parra et al., *J. Immunol.*, 158:637-642 (1997), Fenton et al., *J. Immunother.*, 21:2:95-108 (1998)).

Lymphocyte function associated antigen-1 (LFA-1) is expressed on leukocytes and interacts with ICAM-1 expressed on APCs and some tumor cells. This interaction induces T cell IL-2 and IFN-gamma production and can thus complement but not substitute, the B7/CD28 costimulatory interaction (Fenton et al., *J. Immunother.*, 21:2:95-108 (1998)). LFA-1 is thus a further example of a costimulatory molecule that could be provided in a vaccination protocol in the various ways discussed above for B7.

Complete CTL activation and effector function requires Th cell help through the interaction between the Th cell CD40L (CD40 ligand) molecule and the CD40 molecule expressed by DCs (Ridge et al., *Nature*, 393:474 (1998), Bennett et al., *Nature*, 393:478 (1998), Schoenberger et al., *Nature*, 393:480 (1998)). This mechanism of this costimulatory signal is likely to involve upregulation of B7 and associated IL-6/IL-12 production by the DC (APC). The CD40-CD40L interaction thus complements the signal 1 (antigen/MHC-TCR) and signal 2 (B7-CD28) interactions.

The use of anti-CD40 antibodies to stimulate DC cells directly, would be expected to enhance a response to tumor antigens which are normally encountered outside of a inflammatory context or are presented by non-professional APCs (tumor cells). In these situations Th help and B7 costimulation signals are not provided. This mechanism might be used in the context of antigen pulsed DC based therapies or in situations where Th epitopes have not been defined within known TRA precursors.

A CT antigen polypeptide, or a fragment thereof, also can be used to isolate their native binding partners. Isolation of such binding partners may be performed according to well-known methods. For example, isolated CT antigen polypeptides can be attached to a substrate (e.g., chromatographic media, such as polystyrene beads, or a filter), and then a solution suspected of containing the binding partner may be applied to the substrate. If a

- 53 -

binding partner which can interact with CT antigen polypeptides is present in the solution, then it will bind to the substrate-bound CT antigen polypeptide. The binding partner then may be isolated.

It will also be recognized that the invention embraces the use of the CT antigen cDNA sequences in expression vectors, as well as to transfect host cells and cell lines, be these prokaryotic (e.g., *E. coli*), or eukaryotic (e.g., dendritic cells, B cells, CHO cells, COS cells, yeast expression systems and recombinant baculovirus expression in insect cells). Especially useful are mammalian cells such as human, mouse, hamster, pig, goat, primate, etc. They may be of a wide variety of tissue types, and include primary cells and cell lines. Specific examples include keratinocytes, peripheral blood leukocytes, bone marrow stem cells and embryonic stem cells. The expression vectors require that the pertinent sequence, i.e., those nucleic acids described *supra*, be operably linked to a promoter.

The invention also contemplates delivery of nucleic acids, polypeptides or peptides for vaccination. Delivery of polypeptides and peptides can be accomplished according to standard vaccination protocols which are well known in the art. In another embodiment, the delivery of nucleic acid is accomplished by *ex vivo* methods, i.e. by removing a cell from a subject, genetically engineering the cell to include a CT antigen, and reintroducing the engineered cell into the subject. One example of such a procedure is the use of dendritic cells as delivery and antigen presentation vehicles for the administration of CT antigens in vaccine therapies. Another example of such a procedure is outlined in U.S. Patent 5,399,346 and in exhibits submitted in the file history of that patent, all of which are publicly available documents. In general, it involves introduction *in vitro* of a functional copy of a gene into a cell(s) of a subject, and returning the genetically engineered cell(s) to the subject. The functional copy of the gene is under operable control of regulatory elements which permit expression of the gene in the genetically engineered cell(s). Numerous transfection and transduction techniques as well as appropriate expression vectors are well known to those of ordinary skill in the art, some of which are described in PCT application WO95/00654. *In vivo* nucleic acid delivery using vectors such as viruses and targeted liposomes also is contemplated according to the invention.

In preferred embodiments, a virus vector for delivering a nucleic acid encoding a CT antigen is selected from the group consisting of adenoviruses, adeno-associated viruses, poxviruses including vaccinia viruses and attenuated poxviruses, Semliki Forest virus,

Venezuelan equine encephalitis virus, retroviruses, Sindbis virus, and Ty virus-like particle. Examples of viruses and virus-like particles which have been used to deliver exogenous nucleic acids include: replication-defective adenoviruses (e.g., Xiang et al., *Virology* 219:220-227, 1996; Eloit et al., *J. Virol.* 71:5375-5381, 1997; Chengalvala et al., *Vaccine* 15:335-339, 1997), a modified retrovirus (Townsend et al., *J. Virol.* 71:3365-3374, 1997), a nonreplicating retrovirus (Irwin et al., *J. Virol.* 68:5036-5044, 1994), a replication defective Semliki Forest virus (Zhao et al., *Proc. Natl. Acad. Sci. USA* 92:3009-3013, 1995), canarypox virus and highly attenuated vaccinia virus derivative (Paoletti, *Proc. Natl. Acad. Sci. USA* 93:11349-11353, 1996), non-replicative vaccinia virus (Moss, *Proc. Natl. Acad. Sci. USA* 93:11341-11348, 1996), replicative vaccinia virus (Moss, *Dev. Biol. Stand.* 82:55-63, 1994), Venezuelan equine encephalitis virus (Davis et al., *J. Virol.* 70:3781-3787, 1996), Sindbis virus (Pugachev et al., *Virology* 212:587-594, 1995), and Ty virus-like particle (Allsopp et al., *Eur. J. Immunol* 26:1951-1959, 1996). In preferred embodiments, the virus vector is an adenovirus or an alphavirus.

Another preferred virus for certain applications is the adeno-associated virus, a double-stranded DNA virus. The adeno-associated virus is capable of infecting a wide range of cell types and species and can be engineered to be replication-deficient. It further has advantages, such as heat and lipid solvent stability, high transduction frequencies in cells of diverse lineages, including hematopoietic cells, and lack of superinfection inhibition thus allowing multiple series of transductions. The adeno-associated virus can integrate into human cellular DNA in a site-specific manner, thereby minimizing the possibility of insertional mutagenesis and variability of inserted gene expression. In addition, wild-type adeno-associated virus infections have been followed in tissue culture for greater than 100 passages in the absence of selective pressure, implying that the adeno-associated virus genomic integration is a relatively stable event. The adeno-associated virus can also function in an extrachromosomal fashion.

In general, other preferred viral vectors are based on non-cytopathic eukaryotic viruses in which non-essential genes have been replaced with the gene of interest. Non-cytopathic viruses include retroviruses, the life cycle of which involves reverse transcription of genomic viral RNA into DNA with subsequent proviral integration into host cellular DNA. Adenoviruses and retroviruses have been approved for human gene therapy trials. In general, the retroviruses are replication-deficient (i.e., capable of directing synthesis of the desired

proteins, but incapable of manufacturing an infectious particle). Such genetically altered retroviral expression vectors have general utility for the high-efficiency transduction of genes *in vivo*. Standard protocols for producing replication-deficient retroviruses (including the steps of incorporation of exogenous genetic material into a plasmid, transfection of a packaging cell lined with plasmid, production of recombinant retroviruses by the packaging cell line, collection of viral particles from tissue culture media, and infection of the target cells with viral particles) are provided in Kriegler, M., "Gene Transfer and Expression, A Laboratory Manual," W.H. Freeman Co., New York (1990) and Murry, E.J. Ed. "Methods in Molecular Biology," vol. 7, Humana Press, Inc., Clifton, New Jersey (1991).

Preferably the foregoing nucleic acid delivery vectors: (1) contain exogenous genetic material that can be transcribed and translated in a mammalian cell and that can induce an immune response in a host, and (2) contain on a surface a ligand that selectively binds to a receptor on the surface of a target cell, such as a mammalian cell, and thereby gains entry to the target cell.

Various techniques may be employed for introducing nucleic acids of the invention into cells, depending on whether the nucleic acids are introduced *in vitro* or *in vivo* in a host. Such techniques include transfection of nucleic acid-CaPO₄ precipitates, transfection of nucleic acids associated with DEAE, transfection or infection with the foregoing viruses including the nucleic acid of interest, liposome mediated transfection, and the like. For certain uses, it is preferred to target the nucleic acid to particular cells. In such instances, a vehicle used for delivering a nucleic acid of the invention into a cell (e.g., a retrovirus, or other virus; a liposome) can have a targeting molecule attached thereto. For example, a molecule such as an antibody specific for a surface membrane protein on the target cell or a ligand for a receptor on the target cell can be bound to or incorporated within the nucleic acid delivery vehicle. Preferred antibodies include antibodies which selectively bind a CT antigen, alone or as a complex with a MHC molecule. Especially preferred are monoclonal antibodies. Where liposomes are employed to deliver the nucleic acids of the invention, proteins which bind to a surface membrane protein associated with endocytosis may be incorporated into the liposome formulation for targeting and/or to facilitate uptake. Such proteins include capsid proteins or fragments thereof tropic for a particular cell type, antibodies for proteins which undergo internalization in cycling, proteins that target intracellular localization and enhance intracellular half life, and the like. Polymeric delivery

- 56 -

systems also have been used successfully to deliver nucleic acids into cells, as is known by those skilled in the art. Such systems even permit oral delivery of nucleic acids.

When administered, the therapeutic compositions of the present invention can be administered in pharmaceutically acceptable preparations. Such preparations may routinely contain pharmaceutically acceptable concentrations of salt, buffering agents, preservatives,
5 compatible carriers, supplementary immune potentiating agents such as adjuvants and cytokines and optionally other therapeutic agents.

The therapeutics of the invention can be administered by any conventional route, including injection or by gradual infusion over time. The administration may, for example,
10 be oral, intravenous, intraperitoneal, intramuscular, intracavity, subcutaneous, or transdermal. When antibodies are used therapeutically, a preferred route of administration is by pulmonary aerosol. Techniques for preparing aerosol delivery systems containing antibodies are well known to those of skill in the art. Generally, such systems should utilize components which will not significantly impair the biological properties of the antibodies, such as the paratope
15 binding capacity (see, for example, Sciarra and Cutie, "Aerosols," in Remington's Pharmaceutical Sciences, 18th edition, 1990, pp. 1694-1712; incorporated by reference). Those of skill in the art can readily determine the various parameters and conditions for producing antibody aerosols without resort to undue experimentation. When using antisense preparations of the invention, slow intravenous administration is preferred.

20 The compositions of the invention are administered in effective amounts. An "effective amount" is that amount of a CT antigen composition that alone, or together with further doses, produces the desired response, e.g. increases an immune response to the CT antigen. In the case of treating a particular disease or condition characterized by expression of one or more CT antigens, such as cancer, the desired response is inhibiting the progression
25 of the disease. This may involve only slowing the progression of the disease temporarily, although more preferably, it involves halting the progression of the disease permanently. This can be monitored by routine methods or can be monitored according to diagnostic methods of the invention discussed herein. The desired response to treatment of the disease or condition also can be delaying the onset or even preventing the onset of the disease or
30 condition.

Such amounts will depend, of course, on the particular condition being treated, the severity of the condition, the individual patient parameters including age, physical condition,

- 57 -

size and weight, the duration of the treatment, the nature of concurrent therapy (if any), the specific route of administration and like factors within the knowledge and expertise of the health practitioner. These factors are well known to those of ordinary skill in the art and can be addressed with no more than routine experimentation. It is generally preferred that a maximum dose of the individual components or combinations thereof be used, that is, the highest safe dose according to sound medical judgment. It will be understood by those of ordinary skill in the art, however, that a patient may insist upon a lower dose or tolerable dose for medical reasons, psychological reasons or for virtually any other reasons.

The pharmaceutical compositions used in the foregoing methods preferably are sterile and contain an effective amount of CT antigen or nucleic acid encoding CT antigen for producing the desired response in a unit of weight or volume suitable for administration to a patient. The response can, for example, be measured by determining the immune response following administration of the CT antigen composition via a reporter system by measuring downstream effects such as gene expression, or by measuring the physiological effects of the CT antigen composition, such as regression of a tumor or decrease of disease symptoms. Other assays will be known to one of ordinary skill in the art and can be employed for measuring the level of the response.

The doses of CT antigen compositions (e.g., polypeptide, peptide, antibody, cell or nucleic acid) administered to a subject can be chosen in accordance with different parameters, in particular in accordance with the mode of administration used and the state of the subject. Other factors include the desired period of treatment. In the event that a response in a subject is insufficient at the initial doses applied, higher doses (or effectively higher doses by a different, more localized delivery route) may be employed to the extent that patient tolerance permits.

In general, for treatments for eliciting or increasing an immune response, doses of CT antigen are formulated and administered in doses between 1 ng and 1 mg, and preferably between 10 ng and 100 μ g, according to any standard procedure in the art. Where nucleic acids encoding CT antigen or variants thereof are employed, doses of between 1 ng and 0.1 mg generally will be formulated and administered according to standard procedures. Other protocols for the administration of CT antigen compositions will be known to one of ordinary skill in the art, in which the dose amount, schedule of injections, sites of injections, mode of administration (e.g., intra-tumoral) and the like vary from the foregoing. Administration of

- 58 -

CT antigen compositions to mammals other than humans, e.g. for testing purposes or veterinary therapeutic purposes, is carried out under substantially the same conditions as described above.

Where CT antigen peptides are used for vaccination, modes of administration which effectively deliver the CT antigen and adjuvant, such that an immune response to the antigen is increased, can be used. For administration of a CT antigen peptide in adjuvant, preferred methods include intradermal, intravenous, intramuscular and subcutaneous administration. Although these are preferred embodiments, the invention is not limited by the particular modes of administration disclosed herein. Standard references in the art (e.g., *Remington's Pharmaceutical Sciences*, 18th edition, 1990) provide modes of administration and formulations for delivery of immunogens with adjuvant or in a non-adjuvant carrier.

When administered, the pharmaceutical preparations of the invention are applied in pharmaceutically-acceptable amounts and in pharmaceutically-acceptable compositions. The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredients. Such preparations may routinely contain salts, buffering agents, preservatives, compatible carriers, and optionally other therapeutic agents. When used in medicine, the salts should be pharmaceutically acceptable, but non-pharmaceutically acceptable salts may conveniently be used to prepare pharmaceutically-acceptable salts thereof and are not excluded from the scope of the invention. Such pharmacologically and pharmaceutically-acceptable salts include, but are not limited to, those prepared from the following acids: hydrochloric, hydrobromic, sulfuric, nitric, phosphoric, maleic, acetic, salicylic, citric, formic, malonic, succinic, and the like. Also, pharmaceutically-acceptable salts can be prepared as alkaline metal or alkaline earth salts, such as sodium, potassium or calcium salts.

A CT antigen composition may be combined, if desired, with a pharmaceutically-acceptable carrier. The term "pharmaceutically-acceptable carrier" as used herein means one or more compatible solid or liquid fillers, diluents or encapsulating substances which are suitable for administration into a human. The term "carrier" denotes an organic or inorganic ingredient, natural or synthetic, with which the active ingredient is combined to facilitate the application. The components of the pharmaceutical compositions also are capable of being co-mingled with the molecules of the present invention, and with each other, in a manner

such that there is no interaction which would substantially impair the desired pharmaceutical efficacy.

The pharmaceutical compositions may contain suitable buffering agents, including: acetic acid in a salt; citric acid in a salt; boric acid in a salt; and phosphoric acid in a salt.

5 The pharmaceutical compositions also may contain, optionally, suitable preservatives, such as: benzalkonium chloride; chlorobutanol; parabens and thimerosal.

The pharmaceutical compositions may conveniently be presented in unit dosage form and may be prepared by any of the methods well-known in the art of pharmacy. All methods include the step of bringing the active agent into association with a carrier which constitutes
10 one or more accessory ingredients. In general, the compositions are prepared by uniformly and intimately bringing the active compound into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product.

Compositions suitable for oral administration may be presented as discrete units, such as capsules, tablets, lozenges, each containing a predetermined amount of the active
15 compound. Other compositions include suspensions in aqueous liquids or non-aqueous liquids such as a syrup, elixir or an emulsion.

Compositions suitable for parenteral administration conveniently comprise a sterile aqueous or non-aqueous preparation of CT antigen polypeptides or nucleic acids, which is preferably isotonic with the blood of the recipient. This preparation may be formulated
20 according to known methods using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation also may be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition,
25 sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono-or di-glycerides. In addition, fatty acids such as oleic acid may be used in the preparation of injectables. Carrier formulation suitable for oral, subcutaneous, intravenous, intramuscular, etc. administrations can be found in *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, PA.

30 As used herein with respect to nucleic acids, the term "isolated" means: (i) amplified *in vitro* by, for example, polymerase chain reaction (PCR); (ii) recombinantly produced by cloning; (iii) purified, as by cleavage and gel separation; or (iv) synthesized by, for example,

- 60 -

chemical synthesis. An isolated nucleic acid is one which is readily manipulable by recombinant DNA techniques well known in the art. Thus, a nucleotide sequence contained in a vector in which 5' and 3' restriction sites are known or for which polymerase chain reaction (PCR) primer sequences have been disclosed is considered isolated but a nucleic acid sequence existing in its native state in its natural host is not. An isolated nucleic acid may be substantially purified, but need not be. For example, a nucleic acid that is isolated within a cloning or expression vector is not pure in that it may comprise only a tiny percentage of the material in the cell in which it resides. Such a nucleic acid is isolated, however, as the term is used herein because it is readily manipulable by standard techniques known to those of ordinary skill in the art. An isolated nucleic acid as used herein is not a naturally occurring chromosome.

As used herein with respect to polypeptides, "isolated" means separated from its native environment and present in sufficient quantity to permit its identification or use. Isolated, when referring to a protein or polypeptide, means, for example: (i) selectively produced by expression cloning or (ii) purified as by chromatography or electrophoresis. Isolated proteins or polypeptides may, but need not be, substantially pure. The term "substantially pure" means that the proteins or polypeptides are essentially free of other substances with which they may be found in nature or *in vivo* systems to an extent practical and appropriate for their intended use. Substantially pure polypeptides may be produced by techniques well known in the art. Because an isolated protein may be admixed with a pharmaceutically acceptable carrier in a pharmaceutical preparation, the protein may comprise only a small percentage by weight of the preparation. The protein is nonetheless isolated in that it has been separated from the substances with which it may be associated in living systems, i.e. isolated from other proteins.

25

Examples

Example 1: Identification of CT antigens

Much attention has been given to the potential of CT antigens as targets for cancer vaccine development, and, other than mutational antigens and virus encoded antigens, they clearly represent the most specific tumor antigens discovered to date. However, the CT

30

antigens also provide a new way to think about cancer and its evolution during the course of the disease.

The starting point for this view is the fact that CT antigen expression is restricted to early germ cell development and cancer. Germ cells give rise to gametes (oocytes and spermatocytes) and trophoblastic cells that contribute to the formation of the chorion and the placenta. Primitive germ cells arise in the wall of the yolk sack and during embryogenesis migrate to the future site of the gonads. In oogenesis, the process begins before birth, with oogonia differentiating into primary oocytes. The primary oocytes, which reach their maximal numbers during fetal development, are arrested at the initial phase of meiosis, and do not renew and complete meiosis until ovulation and fertilization. In contrast, spermatogenesis begins at puberty and is a continuous process of mitosis to maintain the spermatogonia pool and meiosis to generate the mature sperm population. CT antigens, like SCP-1 and OY-TES-1, the proacrosomal binding protein precursor, are clearly important in gametogenesis, and it is likely that the other CT antigens with their restricted expression in gametes and trophoblasts also play a critical role in early germ cell development.

One possibility to account for aberrant CT expression in cancer relates to the global demethylation associated with certain cancers (42). The promoter region of the MAGE gene has binding sites for transcriptional activators and these sites are methylated in normal somatic cells but demethylated in MAGE-expressing cancer cells and testis. Although cancer-associated demethylation could therefore account for CT (MAGE) expression in tumors, it does not easily accommodate the usual observation of non-coordinate expression patterns (sets) of different CT antigens in most tumors. Also, the marked heterogeneity in CT expression in some tumors (34, 43) is also not easily explicable by a global demethylation process.

Another mechanism for reactivating CT expression in cancer has to do with mutations in regulatory regions of the CT genes. Although no mutations in CT genes have been found to date, more extensive sequencing, particularly in the promoter region, needs to be done before this can be excluded. However, mutation of CT genes is unlikely to be a common mechanism for the induction of CT expression in cancer.

Another possibility to account for the appearance of CT antigens in cancer is the induction or activation of a gametogenic program in cancer. According to this view, the different CT sets seen in cancer would replicate the corresponding sets of CT antigens

- 62 -

normally expressed during different stages of gametogenesis or trophoblast development. Triggering events for inducing the gametogenic program could be a mutation in an as yet unidentified master switch in germ cell development, or an activation of this master switch by threshold mutations in oncogenes, suppressor genes, or other genes in cancer. It is also possible that activation of a single CT gene could be the switch for activating other genes in the gametogenic program. Supporting evidence for this idea comes from the study of synovial sarcoma, where a translocation event involving the SYT gene on chromosome 18 and the SSX-1 or SSX-2 gene on chromosome X is associated with high expression of unrelated CT antigens, such as NY-ESO-1 and MAGE (44, 45). Extending this line of reasoning and relating it to the role of demethylation in the appearance of CT antigens, a demethylation state in cancer (whatever its cause) could induce the gametogenic program and result in the activation of silent CT genes. Alternatively, demethylation may be an intrinsic part of the gametogenic program and therefore a consequence, not a cause, of switching on the gametogenic program and CT genes in cancer.

In addition to questions about mechanisms for reactivating CT antigen expression in cancer, another important issue is whether expression of these genes in the cancer cell contributes to its malignant behavior. The finding that gametes, trophoblasts and cancers share a battery of antigens restricted to these cell types suggests extending the search for other shared characteristics.

It was a similarity in the biological features of trophoblasts and cancer cells that prompted the Scottish embryologist John Beard at the turn of the last century to propose his trophoblastic theory of cancer (46, 47). In his view, cancers arise from germ cells that stray or are arrested in their trek to the gonads. Under the influence of carcinogenic stimuli, such cells undergo a conversion to malignant trophoblastic cells. These malignant trophoblastic cells take on features of the resident cell types in different organs, but the resulting cancers, no matter their site of origin or how distinct they appear morphologically, are of trophoblastic origin. Beard ascribed the invasive, destructive and metastatic features of cancer to functions normally displayed by trophoblastic cells, e.g., invasion of blood vessels, growth into the uterine wall, and spread beyond the uterus. From a contemporary perspective, Beard's idea that cancers are derived from arrested germ cells seems incompatible with our growing knowledge of serological and molecular markers that distinguish different pathways of normal differentiation and their preservation in cancer. Beard's insight that trophoblasts and

- 63 -

cancer cells share common features is better explained by the induction of a gametogenic program in resident cancer cells, rather than the derivation of cancer from an aberrant germ cell. The end result, however, would be the same - selected features of cells undergoing gametogenesis and trophoblast development being imposed on transformed somatic cells.

5 In addition to CT antigens, other features shared by germ cells and cancer are identified. For example, SCP-1, a critical element in the meiotic program, is expressed in non-germ cell cancers. The induction of a meiotic program in a somatic cell, normal or malignant, likely leads to chromosomal anarchy, a prime feature of advanced cancers. Accordingly, other proteins uniquely associated with meiosis and expressed in cancer cells
10 also are identified as candidate CT antigens.

OY-TES-1, the proacrosin binding protein precursor that is part of the unique program leading to the formation of spermatozoa, has been identified as a CT antigen. Accordingly, other mature sperm-specific gene products that are expressed in cancer cells also are identified as candidate CT antigens.

15 In addition, expression of CT antigens by trophoblasts sheds new light on an old issue - the much studied sporadic production of human chorionic gonadotropin (HCG) and other trophoblastic hormones by human cancers (e.g., 48, 49, 50). The production of HCG by cancer cells has been generally viewed as yet another indication of the genetic instability of cancer cells, resulting in the random and aberrant activation of silent genes during
20 carcinogenesis and tumor progression. However, it can also be viewed as a consequence of the induction of a gametogenic/trophoblastic program in cancer, one that would also result in the semi-coordinate expression of CT antigens. Activation of this program would also confer other properties of germ cells, gametes, and trophoblasts on cancer cells, but these are more difficult to relate in any precise fashion. Nonetheless, immortalization, invasion, lack
25 of adhesion, migratory behavior, induction of blood vessels, demethylation, and downregulation of MHC, are some features shared by cancer and by cells undergoing germ cell/gamete/trophoblast differentiation pathways. The metastatic properties of cancer may also have counterparts in the migratory behavior of germ cells, and in the propensity of normal trophoblast cells to migrate to other organs, such as the lung, during normal
30 pregnancy, but then to undergo involution at term.

In pursuing the idea of a program change in cancer leading to the expression of gametogenic features, a hypothesis termed "Gametogenic Program Induction in Cancer"

(GPIC), it might be well to distinguish at least four different pathways involved in germ cell development: A) germ cell → germ cell, B) germ cell → oogonia → oocytes, C) germ cell → spermatogonia → sperm, and D) germ cell → trophoblast. The meiotic program would be common to B and C, proteins like OY-TES-1 would be restricted to C, and HCG would be a characteristic of D. The reason for distinguishing these pathways and ultimately stages in each pathway is that the variety of patterns or sets of CT antigens observed in different cancers may be a reflection of the germ cell program, e.g., pathway and stage that has been induced in these cancers.

With this background and framework of thinking about the relation of gametogenesis and cancer development, there are a number of approaches to be taken to identify additional CT antigens.

1. The search for new CT antigens is accomplished using several methodologies, including SEREX (see, for example, ref. 10), particularly with libraries from testis, normal or malignant trophoblasts, or tumors or tumor cell lines (growing with or without demethylating agents) that express a range of CT antigens, and by extending the use of representational difference analysis. Bioinformatics and chip technology are used for mining databanks for transcripts that show cancer/gamete/trophoblast specificity (e.g., screening annotation of sequence records).

2. The expression pattern of known CT antigens in normal gametogenesis and trophoblast development is determined to identify markers that distinguish different pathways and stages in the normal gametogenic program. This information provides a basis for interpreting the complex patterns of CT expression in cancers in relation to gametogenic pathways/stages, and provides new ways to classify cancer on the basis of CT phenotypes.

3. The frequency of expression of individual CT antigens in different tumor types has been defined for those CT antigens known to date. In addition to analyzing frequency of expression for CT antigens identified by the methods described herein, additional information is gathered about the composite CT phenotype of individual tumors, and how frequently these composite CT patterns are seen in tumors of different origin. Databases of clinical, genotypic, phenotypic and CT antigen expression data for individual tumors are established to compare the properties of individual tumors and establish correlations between the data. With this information, correlations of CT expression with other biological features of the

- 65 -

tumor, e.g., growth rate, local vs. invasive, primary vs. metastatic, different metastatic deposits in the same patient, etc. can be established.

4. Determining which stage in the life history of cancer that CT (gametogenic) features are induced can be approached in model systems in the mouse, *in vitro* systems with human cells, or with naturally occurring tumors in man that show incremental stages in tumor progression. As discussed above, there is evidence that CT expression is a sign of greater malignancy.

5. The heterogeneous expression of CT antigens in a large proportion of human cancers needs to be understood. This may reflect a quantitative difference in levels of mRNA/protein in CT⁺ and CT⁻ cells, or there may be a qualitative distinction between CT⁺ and CT⁻ cells in CT mRNA/protein expression. Laser dissection microscopy may be one way to analyze this question and cloning of tumor cells from a tumor with heterogeneous CT expression is another approach to understand heterogeneous expression. There is a growing impression that established human cancer cell lines show a higher frequency of CT antigen expression than what would be expected from CT typing of the corresponding tumor type, particularly tumors with a low frequency of CT expression. This could be a secondary consequence of *in vitro* culture, or it could be that CT⁺ cells (even if they represent only a minority population of the tumor) have a growth advantage for propagating *in vitro*, and possibly also *in vivo*.

6. Although CT antigens provide a strong link between the gametogenic program and cancer, it is determined whether other distinguishing features of gamete development are expressed by cancer and whether their expression is correlated with CT antigen expression. The many reports over the last three decades of HCG production by certain human cancers provides a specific starting point to explore this issue and ask whether the production of HCG is correlated with CT antigen expression, particularly a unique pattern of CT expression, such as a pattern reflecting the trophoblast program.

7. Transgenic and knock-out approaches using mouse CT counterparts, and transfection analysis with CT coding genes in normal and malignant human cells are performed to define the role of CT antigens in gametogenesis and trophoblast development and their functional significance in cancer.

Example 2: Identification of CT gene products

In order to identify new CT gene products, the Unigene database, a compilation of both EST and Genbank databases, was mined for transcripts expressed exclusively in cancer and normal testis. Subsequent RT-PCR analysis of candidate transcripts identified several gene products with highly restricted mRNA expression patterns, including three newly defined CT genes.

Methods and Materials***Bioinformatic Identification of Cancer/Testis-Associated Unigene Clusters***

The cDNA X profiler tool of the Cancer Genome Anatomy Project (<http://cgap.nci.nih.gov/Tissues/xProfiler>) was used to search the Unigene database in the following manner. First, 2 pools of expressed sequence tags (ESTs) were established. Pool A consisted of ESTs derived from 6 normal testis cDNA libraries, and Pool B consisted of ESTs derived from 188 tumor-derived cDNA libraries (all histological types). The X profiler search engine was directed to identify those Unigene clusters containing ESTs from both Pool A and Pool B, and exclude Unigene clusters containing ESTs from any other normal tissue cDNA library. Tissue expression patterns of the resultant Unigene clusters were also analyzed by *in silico* Serial Analysis of Gene Expression (SAGE) using the SAGE:Gene to tag mapping tool associated with each Unigene cluster entry. Their relation to known gene products was determined by BLAST searches of nucleotide and protein databases (<http://www.ncbi.nlm.nih.gov/BLAST/>) or by motif analysis of putative protein translations (<http://motif.genome.ad.jp>). Furthermore, BLAST searches of representative ESTs from all identified Unigene clusters were performed against the human genome sequence database in order to obtain gene mapping information and to determine intron/exon boundaries used in PCR primer design.

Reverse Transcriptase-PCR (RT-PCR) analysis

Total RNA from 20 different normal human tissues was purchased from Clontech Laboratories Incorporated (Palo Alto, CA) and Ambion Incorporated (Austin, Texas). Tumor tissues were derived from surgical specimens obtained from Memorial Sloan-Kettering Cancer Center, Weill Medical College of Cornell University and Krankenhaus Nordwest (Frankfurt, Germany). Total RNA from tumor tissues was prepared by the guanidinium thiocyanate method.

- 67 -

The cDNA preparations used as templates in the RT-PCR reactions were prepared using the Superscript first strand synthesis kit (Invitrogen Life Technologies, Carlsbad, CA). The cDNA was synthesized by incubating 5 µg of total RNA in 40 µl of 1X reverse transcriptase buffer containing 100 ng random hexamers, 0.5 mM dNTP, 5.0 mM MgCl₂, 10 µM DTT, 80 U ribonuclease inhibitor and 100 U Superscript II reverse transcriptase at 42°C for 50 min. Control templates for assessing amplification of genomic DNA were prepared as duplicate samples lacking reverse transcriptase.

Oligonucleotide primers, homologous to ESTs present in selected Unigene clusters, were synthesized commercially (Invitrogen Life Technologies). DNA sequences of relevant primer pairs are provided below.

CT15 forward: 5' AGGAATTATGAAACCACTTG (SEQ ID NO:1)

CT15 reverse: 5' GACAACAGTTGTATCAGACC (SEQ ID NO:2)

CT16 forward: 5' CAAGGAGAGGTCGTGTCTTCG (SEQ ID NO:3)

CT16 reverse: 5' GGATCTTGTTACATGCTCACTCATATC (SEQ ID NO:4)

CT16.2 forward: 5' CCAGATTAAGAATAACGTTC (SEQ ID NO:5)

CT16.2 reverse: 5' AGAGGAAATGACCAAGAGTC (SEQ ID NO:6)

CT17 forward: 5' ACAAGACTAGCTTATGTGTGG (SEQ ID NO:7)

CT17 reverse: 5' TTGAGCAAGAATCTTGACTTC (SEQ ID NO:8)

RT-PCR was performed as follows. Twenty-five µl PCR reaction mixtures, consisting of 2 µl cDNA (or 2.0 µl of genomic DNA amplification controls), 0.2 mM dNTP, 1.5 mM MgCl₂, 0.25 µM gene specific forward and reverse primers, and 2.5 U Platinum Taq DNA polymerase (Invitrogen Life Technologies), were heated to 94°C for 2 min., followed by 34 thermal cycles of 94°C for 30 seconds, 55°C for 30 seconds and 72°C for 1 min., and a final cycle of 94°C for 30 seconds, 55°C for 30 and 72°C for 5 min. Thermal cycling was performed using an ABI 7700 Sequence Detector. Resultant PCR products were analyzed in 2% Agarose/Tris- Acetate-EDTA gels and their identity was verified by DNA sequencing.

Real-time quantitative reverse transcription(RT)-PCR

Total RNA samples from 8 different normal adult tissues and 8 tumor specimens were prepared and reverse transcribed into cDNA as described above. Gene-specific TaqMan

- 68 -

probes and PCR primers were designed using Primer Express software (PE Biosystems, Foster City CA) and synthesized commercially (PE Biosystems). DNA sequences of relevant taqman primer pairs and probes are provided below.

- 5 CT15taqman forward: 5' GGGAGTATTGACAGTGGCAATTT (SEQ ID NO:9)
- CT15taqman reverse: 5' TGTTCTCAATGTAGCGCCTTTC (SEQ ID NO:10)
- CT15taqman probe: 5' CCACCTGTAGCTATAACCAGCCAGACTCCC (SEQ ID NO:11)
- CT16taqman forward: 5' GCAGAGTCCCCTCCCTGAC (SEQ ID NO:12)
- CT16taqman reverse: 5' ACAGGAACTGGCTCTGCTTAAGA (SEQ ID NO:13)
- 10 CT16taqman probe: 5' TCAGGACCATCTCCAGGTGCATCCTC (SEQ ID NO:14)
- CT17taqman forward: 5' CCAGAGTCTCATGTAAAATCACTTACA (SEQ ID NO:15)
- CT17taqman reverse: 5' GAAACACTTCCTCTCTTTCTTTAAGTACAA (SEQ ID NO:16)
- CT17taqman probe: 5' ACCCAGAAAGACCACCACTTTGCAGGTA (SEQ ID NO:17)

- 15 Multiplex PCR reactions were prepared using 2.0 µl of cDNA (or 2.0 µl of genomic DNA amplification controls), diluted in TaqMan Universal PCR Master Mix supplemented with 200 nM Fam (6-carboxy-fluorescein) labeled gene-specific TaqMan probe, 300-900 nM gene specific forward and reverse primers (predetermined optimum concentration), and Vic labeled human beta glucuronidase, or phosphoglycero kinase endogenous control
- 20 probe/primer mixtures (proprietary dye, PE Biosystems). Six 25 µl PCR reactions were prepared for each cDNA sample (3 per each endogenous control). PCR consisted of 40 cycles of 95°C denaturation (15 seconds) and 60°C annealing/extension (60 seconds). Thermal cycling and fluorescent monitoring were performed using an ABI 7700 sequence analyzer (PE Biosystems). The cycle interval at which a PCR product is first detected above a
- 25 fixed threshold, termed cycle threshold (Ct), was determined for each sample, and the average of triplicate samples was recorded. The copy number of gene-specific transcripts per µg of RNA starting material was determined by comparison with a standard curve of Ct values generated from known concentrations of cDNA encoding the homologous gene product. To normalize the quantity of mRNA present in the total RNA samples, the Ct values
- 30 obtained from the endogenous control were subtracted from the gene specific Ct values ($\Delta Ct = Ct \text{ FAM} - Ct \text{ VIC}$). Real-time RT-PCR of triplicate samples yielded two sets of three ΔCt values per each RNA sample (1 set per each endogenous control), and the mean of the six

- 69 -

ΔCt values was calculated. The concentration of gene specific mRNA in normal or tumor-derived tissue, relative to normal testis was calculated by equating the normalized Ct values ($\Delta\Delta\text{Ct} = \Delta\text{Ct}$ of normal or tumor tissue - ΔCt of normal testis), and determining the relative concentration (Relative Concentration = $2^{-\Delta\Delta\text{Ct}}$). The transcript copy number per μg of

5 normalized total RNA was calculated by multiplying the mean relative concentration for each cDNA sample by the copy number in testicular tissue, which was determined from the standard curve (copy number = $2^{-\Delta\Delta\text{Ct}}$ x copy number testis).

Results

10 ***Bioinformatic Analyses***

1325 different Unigene clusters with *in silico* expression profiles resembling CT antigens were identified by mining the Unigene database for gene clusters containing expressed sequence tags (ESTs) derived exclusively from both tumor tissue and normal testis cDNA libraries. These cancer/testis-associated Unigene clusters represented 61 known genes

15 and 1264 uncharacterized genes. As shown in Table 2, the Unigene clusters were placed into 2 categories. Group I consisted of 859 different gene clusters containing ESTs derived exclusively from testis and tumor cDNA libraries, termed *cancer/testis (CT)-related* Unigene clusters. Group II consisted of 400 different gene clusters containing ESTs derived exclusively from testis and germ cell tumors (but not other types of cancer), termed *testis-*

20 *related* Unigene clusters. An additional 66 gene clusters were not pursued further since their respective Unigene database entries were modified during the course of this study, or literature reports of known gene products indicated they were expressed in other normal tissues, in addition to testis. In accordance with the Unigene database, the present study designates specific gene clusters as Homo sapiens.numerical description (e.g. Hs.123456).

Table 2. *In Silico* classification of cancer/testis-associated Unigene clusters

Category of Unigene Cluster	Category Description	Sub-Catagory	Sub- Category Description	Number of Unigene Clusters in Each Sub-Catagory
Group I	Cancer/Testis-related Unigene Clusters: contain ESTs only from testis (or germ cell tumors) and tumor derived cDNA libraries	IA	SAGE tags present only in tumor and/or cell line SAGE libraries	311
		IB	No reliable SAGE tags	265
		IC	SAGE tags present in normal tissue-derived SAGE libraries	283
Group II	Testis-related Unigene Clusters: contain ESTs only from testis and germ cell tumor cDNA libraries	IIA	SAGE tags present only in tumor and/or cell line SAGE libraries	139
		IIB	No reliable SAGE tags	171
		IIC	SAGE tags present in normal tissue-derived SAGE libraries	90

- 5 The mRNA expression patterns of Group I and Group II Unigene clusters were further analyzed by *in silico* serial analysis of gene expression (SAGE). As shown in Table 2, group I and II Unigene clusters were further subdivided into subgroups *A*, *B*, and *C*, based on the presence and tissue distribution of homologous SAGE tags. Subgroups IA and IIA have SAGE tags that are present only in tumor and/or cell line derived SAGE libraries.
- 10 Subgroups IB and IIB have no reliable SAGE tags. Subgroups IC and IIC have SAGE tags that are present in normal tissue SAGE libraries. Four known cancer testis antigens were identified among the 1325 Unigene clusters, including CT11p/Hs.293266 (Group IA), GAGE 4/Hs.183199 (Group IB), MAGEB1/Hs.73021 (Group IC), and SAGE/Hs.195292 (Group IIA).

15

Identification of tissue- restricted mRNA transcripts by RT-PCR

- The mRNA expression patterns of 73 of the 1325 Unigene clusters identified in the current study were analyzed by RT-PCR using a panel of RNA samples derived from 20 normal tissues. Several criteria were used for choosing these particular cancer/testis-
- 20 associated Unigene clusters for RT-PCR analysis. Since a large proportion of known CT antigens map to chromosome X, all cancer/testis-associated Unigene clusters mapping to chromosome X were tested (19 total). Also, since melanoma and sarcoma express a large number of CT antigens, 10 cancer/testis-associated Unigene clusters having ESTs derived

from melanoma or sarcoma libraries were tested. Those cancer/testis-associated Unigene clusters having functional significance in relation to cancer (e.g., transcription factors, adhesion molecules) were also tested (21 total). The remaining 23 Unigene clusters analyzed were chosen at random. In relation to cancer/testis-associated Unigene cluster sub-groupings, 59 *CT-related* Unigene clusters (38 from Group IA, 9 from Group IB, 12 from Group IC) and 14 *testis-related* Unigene clusters (6 from Group IIA, 7 from Group IIB and 1 from Group IIC) were analyzed by RT-PCR.

As shown in Fig. 1, ten of the 73 Unigene clusters analyzed by RT-PCR were considered differentially expressed, with transcripts detected in a limited number of normal tissues, i.e., mRNA expression detected in less than 7/20 normal tissues, and are listed in Table 3.

Table 3. Cancer/Testis (CT)-associated Unigene clusters identified by database mining having restricted expression profiles in normal tissues as determined by conventional RT-PCR

Unigene cluster	Category of CT-associated Unigene Cluster (Table 2)	Expression Profiles ¹	Gene Product Description
Hs.121554	IA	Testis only	An uncharacterized gene product with homology to members of the cystatin family of protease inhibitors
Hs.183009	IA	Testis and brain	Regulatory factor X, 4 (RFX4)
Hs.178062	IA	Testis only	An uncharacterized gene product with homology to phospholipase A1
Hs.245431	IB	Testis only	An uncharacterized gene product with homology to GAGE genes
Hs.177959	IC	Testis only	A disintegrin and metalloproteinase 2 (ADAM2/fertilin β)
Hs.97643	IC	Testis only	An uncharacterized gene product termed testis-specific protein TSP-NY
Hs.128836	IC	Testis, ovary, lung, cervix,	An uncharacterized gene product with no protein motifs or similarities
Hs.195932	IIA	Testis only ²	An uncharacterized gene product termed testis transcript Y 12 (TTY12)
Hs.293317	IIA	Testis, prostate, ovary, lung, colon, breast	An uncharacterized gene product with homology to GAGE genes
Hs.189184	IIA	Testis only	Ubiquilin 3 (Ubqln 3)

¹Normal tissue RNA panel included brain, testis, kidney, liver, pancreas, placenta, small intestine, heart, prostate, adrenal gland, spleen, fetal brain, colon, stomach, lung, bladder, ovary, breast, cervix and skeletal muscle

²Gene maps to chromosome Y. For this reason, RNA samples derived solely from female donors (kidney, colon, bladder, placenta, ovary, breast, cervix) are not applicable.

The mRNA expression patterns of the remaining 63 gene products were ubiquitously expressed in normal tissues (43 Unigene gene clusters), or yielded ambiguous RT-PCR results resulting from amplification of intronless DNA (8 Unigene gene clusters), non-specific amplification (4 Unigene gene clusters), or could not be amplified (8 Unigene gene clusters). Of the 10 differentially expressed transcripts identified, 7 were expressed only in testis (0/19 other normal tissue), and 3 other gene products were detected in a limited number of normal tissues besides testis and ovary (Fig. 1A). Of the 7 testis-restricted transcripts, 2 encode known proteins, Ubiquilin 3 (Ubqln 3, Hs.189184, Group IIA) and disintegrin and metalloproteinase 2 or fertilin β (ADAM2, Hs.177959, Group IC) and 5 encode uncharacterized gene products, Hs.121554 (Group IA), Hs.178062 (Group IA), Hs.245431 (Group IB), Hs.97643 (Group IC) and Hs.195932 (Group IIA). With regard to the presence of SAGE tags corresponding to known gene product ADAM2/ Hs.177959 in normal colon tissue (Group IC), our RT-PCR expression data provides no evidence for ADAM2/ Hs.177959 expression in normal colon (Fig. 1A). In addition to the 7 testis-restricted transcripts, 3 other Unigene clusters were expressed in a limited number of normal tissues. Transcripts encoding Regulatory factor X4 (RFX4, Hs.183009, Group IA) were detected only in testis and brain (0/18 other normal tissues). Two uncharacterized transcripts, Hs.128836 (Group IC) and Hs.293317 (IIA) were expressed in testis, ovary, cervix and lung (0/16 other normal tissues) and testis, prostate, ovary, lung, breast and colon (0/14 other normal tissues), respectively.

Expression of CT-associated Unigene clusters in cancer

All seven of the testis-restricted transcripts can be considered CT gene products based on the presence of identical sequences in tumor derived EST libraries (Group I Unigene clusters) or SAGE libraries (Group IIA Unigene clusters). To confirm this *in silico* expression profile, the tissue restricted transcripts defined in the current study were analyzed by RT-PCR using a panel of RNA samples derived from a variety of malignant tissues. As shown in Fig. 1B, 3 of the 7 testis-restricted transcripts, ADAM2/Hs.177959, Hs.245431, and Hs.178062 were also expressed in tumor tissue, and represent newly defined CT genes. These CT gene products represent 1 known gene product and 2 uncharacterized transcripts. The known protein, ADAM2/Hs.177959, was expressed exclusively in testis and in 2/16 cases of renal cancer (Tables 3 and 4).

Table 4. Conventional RT-PCR analysis of mRNA expression frequencies of newly defined Cancer/Testis (CT) genes in normal and malignant tissues

Tissues	CT genes		
	Hs.177959/ CT15 (ADAM2)	Hs.245431/ CT16	Hs.178062/ CT17
Normal Tissues	Testis only	Testis only	Testis only
Melanoma	0/18	4/18	0/18
Lung Cancer	0/18	7/18	0/18
Colon Cancer	0/9	1/9	0/9
Breast Cancer	0/18	1/18	1/18
Renal Cancer	2/16	7/16	4/16
Ovarian Cancer	0/4	0/4	0/4
Melanoma Cell lines ²	0/8	4/8	0/8
Other Tumor Cell lines ²	0/4	SW1045, LU-17	0/4

¹Normal tissue RNA panel included brain, testis, kidney, liver, pancreas, placenta, small intestine, heart, prostate, adrenal gland, spleen, fetal brain, colon, stomach, lung, bladder, ovary, breast, cervix and skeletal muscle

²Melanoma cell lines included SK-MEL-28, -23, -19, -109, -37, -10, -30, and -139

³Additional tumor cell lines tested include SK-LU-14 and SK-LU-17 lung cancer cells, and SW1045 and Fuji sarcoma cells

In accordance with proposed nomenclature for CT antigens (21), ADAM2 was given the CT designation CT15. ADAM2/CT15 is a member of the metalloproteinase-like, disintegrin-like cysteine-rich domain family of sperm surface proteins involved in egg/sperm interactions (51). The nucleotide and amino acid sequences for CT15/Hs.177959 are set forth as SEQ ID NOs:18 and 19.

Another of the CT gene products identified in the current study, designated CT16, is an uncharacterized transcript represented by the Hs.245431 Unigene cluster.

CT16/Hs.245431 was expressed in 4/18 melanomas, 7/18 lung cancers 1/18 breast cancers, 1/9 colon cancers and 7/16 renal cancers (Tables 3 and 4). It was also expressed in several tumor cell lines, including SK-LU-17 lung cancer, SW1045 sarcoma, and 4/8 melanoma cell lines (SK-MEL-19, -109, -37, and -10), but not in normal melanocytes. The CT16/Hs.245431 cDNA sequence consists of 763 nucleotides (Genbank Acc# BC009230), containing a complete open reading frame, which encodes a putative full-length protein of 110 amino acids. The predicted CT16/Hs.245431 amino acid sequence is 30%-40% identical to members of the CT antigen family, GAGE-A (15), and 40%-50% identical to the

- 74 -

GAGE-B/PAGE-1 (52). The nucleotide and amino acid sequences of Hs.245431 are presented as SEQ ID Nos:20 and 21, respectively.

The third newly defined CT gene product, designated CT17, represents the Hs.178062 Unigene cluster, and was expressed in 1/18 breast cancers and 4/16 renal cancers (Tables 3 and 4). The CT17/Hs.178062 cDNA sequence is composed of 877 nucleotides (SEQ ID NO:22; Genbank accession # AA470035), encoding a partial protein of 202 amino acids (SEQ ID NO:23), which is 30% identical to phosphatidylserine-specific phospholipase A1 (53).

Expression of the remaining 4 testis-restricted gene products, TSPNY/Hs.97643 (SEQ ID NOs:24 and 25), TTY12/Hs.195932 (SEQ ID Nos: 26 and 27), Ubqln 3/Hs.189184 (SEQ ID Nos:28 and 29) and Hs.121554 (SEQ ID Nos:30 and 31) (Table 2), was not detected in tumor tissue.

Three gene products defined in the current study as being expressed in a limited number of normal tissues were also expressed in tumor tissue (Table 5).

Table 5. Conventional RT-PCR analysis of mRNA expression frequencies of differentially expressed, non-CT genes in normal and malignant tissues

Tissues	Differentially Expressed Non-CT genes		
	Hs.183009 (RFX4)	Hs.128836	Hs.293317 (CT16.2)
Normal Tissues ¹	Testis, Brain	Testis, Ovary, Lung, Cervix	Testis, Ovary, Lung, Colon, Breast, Prostate
Melanoma	0/18	0/18	9/18
Lung Cancer	0/18	7/18	14/18
Colon Cancer	1/9	1/9	3/9
Breast Cancer	0/18	2/18	6/18
Renal Cancer	0/16	2/16	14/16
Ovarian Cancer	0/4	2/4	2/4
Melanoma Cell lines ²	4/8	0/8	0/8
Other Tumor Cell lines ²	0/4	LU-14	SW1045, LU-17

¹Normal tissue RNA panel included brain, testis, kidney, liver, pancreas, placenta, small intestine, heart, prostate, adrenal gland, spleen, fetal brain, colon, stomach, lung, bladder, ovary, breast, cervix and skeletal muscle

²Melanoma cell lines included SK-MEL-28, -23, -19, -109, -37, -10, -30, and -139

³Additional tumor cell lines tested include SK-LU-14 and SK-LU-17 lung cancer cells, and SW1045 and Fuji sarcoma cells

- 75 -

The known gene, Regulatory factor X 4 (RFX4, Hs.183009), was expressed exclusively in testis and brain, and also in 1/9 colon cancers, and 4/8 melanoma cell lines (SK-MEL-19, -37, -10, and -30), but not in normal melanocytes (Tables 3 and 5).

RFX4/Hs.183009 (SEQ ID NOs:32 and 33) is presented in the Unigene database as a translocation product in breast cancer involving the ubiquitously expressed estrogen receptor 1 gene located on chromosome 6 and a novel, RFX-like gene (RFX-4) on chromosome 12 (54).

A second differentially expressed transcript, represented by the Hs.128836 Unigene cluster, was expressed in normal testis, ovary, cervix and lung, and also in 7/18 lung cancers, 2/4 ovarian cancers, 2/18 breast cancers, 1/9 colon cancers and 2/16 renal cancers (Tables 3 and 5). The cDNA sequence of Hs.128836 is composed of 558 nucleotides (SEQ ID NO:34) encoding a putative partial protein of 164 amino acids (SEQ ID NO:35) with no similarity to characterized proteins or known protein motifs.

A third differentially expressed transcript, represented by the Hs.293317 Unigene cluster, was expressed in normal testis, ovary, lung, breast, prostate and colon, and also in 9/18 melanomas, 14/18 lung cancers, 6/18 breast cancers, 14/16 renal cancers, 2/4 ovarian cancers, and 3/9 colon cancers (Tables 3 and 5). Transcripts were also detected in 2 tumor cell lines, SW1045 sarcoma and SK-LU-17 lung cancer, but not in 8 melanoma cell lines, although it was expressed in normal melanocytes. Hs.293317 is a novel cDNA sequence, composed of 549 nucleotides (GenBank # AW002915) having a complete open reading frame encoding a putative full length protein of 110 amino acids that is 89% identical to the newly defined CT gene, CT16/Hs.245431 described above. Based on the similarity with CT16/Hs.245431, Hs.293317 has been designated CT16.2. The contig for the gene identified by Unigene cluster Hs.293317 is presented as SEQ ID NO:36. The polypeptide translation of the contig is presented as SEQ ID NO:37.

Quantitative analysis of Cancer/Testis gene expression

To further investigate the mRNA expression profiles of CT15, CT16 and CT17, quantitative real time RT-PCR was performed using an RNA panel derived from various normal tissues and tumor specimens. For comparison, prototype CT antigens, NY-ESO-1 (18) and MAGE-3 (55), were also analyzed in this manner. The normalized level of CT gene

expression in normal tissues and cancer, relative to their expression level in testis, is given in Table 6.

Table 6. Quantitative analysis of mRNA encoding Cancer/Testis gene products in normal and malignant tissues relative to testis

Tissue	Expression Level of mRNA Transcripts Encoding CT Gene Products in Various Tissues Relative to mRNA in Normal Testis				
	CT15/ ADAM2	CT16/ Hs.245431	CT17/ Hs.178062	NY-ESO-1	MAGE-3
Brain	0	0	0	3%	0
Kidney	0	0.1%	0	0	0
Liver	0	0.4%	0	0	0
Pancreas	1.0%	0	0	0	0
Colon	0	0	0	2%	0
Lung	0	0	0	3%	0
Ovary	0	0	0	52%	0
Tumor #1 ¹	2%	310%	289%	14%	8%
Tumor #2	0.8%	6400%	19%	19%	11%
Tumor #3	0.07%	320%	0	6%	30%

¹ Expression CT15/ADAM2 was analyzed in 3 renal cancer specimens (Tumor #1, RCC1; tumor #2, RCC5; tumor #3, RCC6). Expression of CT16 was analyzed in 2 melanoma specimens (tumor #1, Mel-1; tumor #2 Mel-11) and a breast cancer specimen (tumor #3, HBR-297). Expression of CT17 was analyzed in a breast cancer (tumor #1, HBR-297), renal cancer (tumor #2, RCC5) and a melanoma specimen (tumor #3, Mel-1). Expression of NY-ESO-1 was analyzed in two lung cancer specimens (tumor #1, LU356; tumor #2, LU339) and a renal cancer specimen (tumor #3, RCC1). Expression of MAGE-3 was analyzed in two lung cancer specimens (tumor #1, Mel-1; tumor #2, Mel-11) and a lung cancer specimen (tumor #3, LU356).

Overall, real time RT-PCR analyses revealed either no expression, or considerably lower levels (3% or less) of CT gene transcripts in normal, non-gametogenic tissues compared with normal testis. In normal tissues, CT15 expression was detected in pancreas at 1% of the level detected in testis. In the case of CT16 mRNA expression in normal tissues, transcripts were detected only in kidney and liver, at 0.1% and 0.4% of the level detected in testis, respectively. Expression of both CT17 and MAGE-3 mRNA was restricted to testis. In the case of NY-ESO-1, the expression level in normal brain, colon and lung was 3%, 2% and 3%, respectively, of the level detected in testis. NY-ESO-1 was also detected in normal ovary at 52% of the level detected in testis. The copy number of CT transcripts per μ g of total RNA was also calculated based on these relative expression levels (Table 6) and a comparison with a standard curve of homologous cDNA of known copy number. The expression level of CT genes in testis showed wide variation, with CT15 having the highest

copy number (445,000 copies/ μ g RNA), followed by CT16 (149,000 copies/ μ g RNA), NY-ESO-1 (31,300 copies/ μ g RNA), CT17 (16,100 copies/ μ g RNA) and MAGE-3 (15,060 copies/ μ g RNA).

The expression level of CT genes in tumor tissue was also analyzed by quantitative real time RT-PCR. In renal cancer specimens, RCC1, RCC5 and RCC6, the expression level of CT15 was 2%, 0.07% and 0.8% of the level detected in testis (Table 6), respectively. Both the RCC1 and RCC6 tumors were positive for CT15 expression by conventional RT-PCR, while RCC5 was negative (Fig. 1B). As shown in Table 6, the level of CT16 expression in two melanoma samples was 3.1 and 64 times the level, respectively. In a breast cancer specimen, the level of CT16 expression was 3.2 times the level detected in testis. These two melanoma samples, and the breast cancer sample, were positive for CT16 expression when analyzed by conventional RT-PCR (Fig. 1B). In a breast cancer specimen (HBR297) and renal cancer specimen (RCC5), the level of CT17 expression was 2.89 and 0.19 times the level detected in testis (Table 6), respectively, which is consistent with conventional RT-PCR results. The level of NY-ESO-1 expression in two lung cancer specimens was 14% and 19% of the level detected in testis (Table 6), respectively. In a renal cancer specimen, NY-ESO-1 was expressed at a level that was 6% of the level detected in testis. Finally, MAGE-3 expression in two melanoma specimens and a lung cancer specimen was 8%, 11% and 30% of the level detected in testis, respectively.

Discussion

Expressed sequence tag (EST) databases are a repository of the human transcriptome, containing a wealth of nucleic acid sequence information and mRNA expression data. An extension of the EST database is Unigene, which pools information from public domain sequencing projects, including, EST, Genbank, ORESTES, and human genome projects, and links this information to a number of relevant databases, e.g., those dedicated to scientific literature, the human genome, the proteome, single nucleotide polymorphisms, and gene mutations. In conjunction with the Cancer Genome Anatomy Project, the Unigene database also provides tools for analyzing EST data, including *in silico* serial analysis of gene expression (SAGE), gene expression profiling, and digital differential display. In view of the immunotherapeutic importance of CT antigens, i.e., that they represent promising target

molecules for antigen-specific cancer vaccines, the current study mined the Unigene database for gene clusters containing ESTs derived exclusively from cancer and testis cDNA libraries.

The current bioinformatic analysis identified approximately 1300 different cancer/testis-associated Unigene clusters. Preliminary evidence in support of the approach used to search the Unigene database was provided by the presence of four known CT antigens, CT11p, GAGE 4, MAGEB1, and SAGE, among these 1300 cancer/testis-associated Unigene clusters identified in the current study. Conversely, this bioinformatic analysis failed to identify members of 9 other previously identified CT gene families cited in the literature. The reason for this is that the database search tool (X profiler) used in the current study does not cross-reference more than two groups of cDNA libraries. Unigene clusters corresponding to the CT antigens not identified in the present study contain ESTs derived from cDNA libraries outside of the two cross-referenced pools (normal testis and cancer). For example, NY-ESO-1, SSX-2/HOM-MEL-40, and CT-7 Unigene clusters contain ESTs from placenta; BAGE, SCP-1, and CT-10 Unigene clusters contain ESTs from cell lines; the BRDT/CT9 Unigene cluster contains an EST from a subtracted testis library; and the sp32/OY-TES-1 Unigene cluster contains ESTs from normal retina and fetal heart. Also, the CTAGE-1 Unigene cluster contains only normal testis ESTs, but not tumor-derived ESTs.

The mRNA expression patterns of 73 of these cancer/testis-associated Unigene clusters were examined by RT-PCR using a panel of RNA samples derived from various normal and malignant tissues. Three of the 73 gene products, CT15/Hs.177959, CT16/Hs.245431, and CT17/Hs.178062, were shown by conventional RT-PCR to be expressed exclusively in testis and malignant tissues, and therefore have expression profiles analogous to CT antigens. Other similarities exist between the newly defined CT genes and known CT antigens. Two of the identified CT genes, CT16/Hs.245431 and CT17/Hs.178062, represent Unigene clusters that contain ESTs from testis, as well as melanoma and sarcoma cDNA libraries, respectively. These two tumor types are known to express a large proportion of the known CT antigens (56). Also, CT16/Hs.245431 maps to chromosome X, the site in the genome where 8 of the 14 known CT antigens map. Furthermore, the frequency of mRNA expression of the newly defined CT genes in cancer is consistent with those of previously defined CT antigens (20% - 40% of a given tumor type, ref. 21), ranging from 11% - 44% in the case of CT16 expression in colon cancer and renal cancer, respectively, and 5% - 25% in the case of CT17 expression in breast cancer and renal

cancer, respectively. Conversely, the apparent restricted nature of CT15/ADAM2 expression in normal testis and renal cancer is unique among CT genes. However, a relatively small sample size was examined in the current study, and a much broader mRNA expression may provide a more definitive conclusion regarding their expression frequencies in cancer.

5 With the exception of a proacrosin binding protein, OY-TES-1 (30), and synaptonemal complex protein-1 (20), the biological functions of CT antigens are not known. In the current study, two of the identified CT gene products encode proteins with known functions or functional motifs. ADAM2/CT15/Hs.177959, is a member of the metalloproteinase-like, disintegrin-like cysteine-rich domain family of cell surface
10 proteases/adhesion molecules, and is believed to be involved egg /sperm membrane interactions (51). Although ADAM2/CT15 lacks a functional metalloproteinase domain it does contain a disintegrin domain, which may bind to integrin $\alpha_6\beta_1$, or other similar molecules (57). Another CT gene product, CT17/Hs.178062 has similarity with phospholipases, which during fertilization play a role in sperm acrosomal exocytosis (58).

15 The remaining CT gene, CT16/Hs.245431, and its relative CT16.2/Hs.293317, are 30-50% similar to GAGE proteins (15, 52). Based on the similarities among the GAGE A family (90% or greater amino acid identity), and between the GAGE-A and GAGE-B families (40 – 50% amino acid identity), it was concluded that Hs.245431/CT16 represents a member of a new GAGE gene family, tentatively termed the CT16 family, which also includes the tissue-
20 restricted gene product, CT16.2/Hs.293317. The biological functions of GAGE proteins are not known, and few immunological responses to GAGE proteins have been reported. With the exception of GAGE-A1 and CT16, the majority of GAGE genes, including CT16.2, are expressed in a narrow range of normal adult tissues (59). Given the similarity among members of individual GAGE gene families, it is possible that the lack of an immune
25 response to GAGE proteins reflects tolerance to highly similar, and more universally expressed GAGE genes.

In addition to CT genes, the current study also identified three highly tissue restricted gene products, RFX4/Hs.183009, Hs.128836, and Hs.293317, which are also expressed in cancer. RFX4 was expressed only in normal testis and brain, as well as in 1/9 colon cancers
30 and 4/8 melanoma cell lines. RFX4 can therefore be considered a putative member of a group of proteins, termed cancer/testis/brain antigens (CTB antigens). Other CTB antigens include CDR (60), Ma1(61), and Ma2 (62), which were identified by Posner and colleagues

as the target molecules recognized by autoantibodies in patients with paraneoplastic syndromes. RFX4 belongs to a family of DNA binding proteins that regulate transcription of MHC class II genes (63). Defects in genes encoding RFX proteins, such as RFXANK, RFX5 and RFXAP, lead to the development of Bare Lymphocyte Syndrome, a severe autosomal recessive immunodeficiency disease (reviewed in 64). Given the down-regulated expression of MHC genes in testis, brain and cancer, expression of RFX genes in these tissues may be of significance. Two uncharacterized transcripts, Hs.128836 and Hs.293317, also had mRNA expression profiles restricted to a limited number of normal tissues and cancer. Due to a lack of functional domains, the biological significance of these gene products remains to be determined.

In addition to the 3 CT genes and 3 tissue restricted transcripts, 4 other gene products having testis-restricted expression profiles were identified, including Hs.121554, Hs.97643, Hs.195932, and Hs.189184. Unigene clusters corresponding to these 4 testis restricted gene products also contain ESTs and/or SAGE tags derived from tumor tissue.

Continued expression analysis of these gene products, using enlarged panels of RNA derived from a wider variety of malignant tissues, may lead to their detection in tumor tissue and subsequent classification as CT genes. With regard to the remaining 1200 cancer/testis-associated Unigene clusters which were not examined by RT-PCR, further study will focus on those gene products having *in silico* expression profiles corresponding to *CT-related* (Group I) Unigene clusters and *testis-related* Unigene clusters with SAGE tags derived from tumor tissues (Group IIA). A method described by Loging and colleagues for rapid expression screening by real-time RT-PCR should advance these studies (65).

The use of individual CT gene products as target molecules for generic cancer vaccines may be inadequate based on their relatively low expression frequencies among cancer patient populations, heterogeneous expression within the tumor itself and antigen loss by a given tumor. An alternative is the development of polyvalent cancer vaccine containing epitopes encoded by many different CT genes. Such polyvalent vaccines would be an effective way to increase the number of cancer patients eligible for vaccination and may also overcome some of the obstacles associated with tumor heterogeneity and immune escape. To this end, the current study added CT15, CT16 and CT17 to the repertoire of proteins available for polyvalent CT cancer vaccines. Furthermore, ADAM2/CT15 can be considered a target molecule with dual immunotherapeutic value, since its cell surface localization makes it a

potential target for monoclonal antibody based immunotherapies as well. In conclusion, the Unigene database contains a wealth of information, that when tapped into, can lead to the discovery of new cancer-related genes of therapeutic significance.

5 **Example 3: Identification of an additional CT gene product and related genes**

A search of the Unigene database for ESTs with similarity to the CT antigen CT16, identified as described above, yielded two Unigene clusters, Hs.43879 and Hs.16323. These clusters were designated (for reasons described below) CT19.2 (nucleic acid: SEQ ID NO:38; polypeptide: SEQ ID NO:39) and CT19.3 (nucleic acid: SEQ ID NO:40; polypeptide: SEQ
10 ID NO:41), respectively. Using specific primers for the sequences (CT19.2 primers: SEQ ID NOs:42 and 43; CT19.3 primers: SEQ ID NOs:44 and 45), it was determined by RT-PCR analysis that both Hs.43879/CT19.2 and Hs.16323/CT19.3 were expressed in a limited number of normal tissues, in addition to cancer and testis.

To determine if other family members existed, the Human Genome database was
15 searched for homologous genes using sequences within the Hs.43879/CT19.2 Unigene cluster. This search yielded a hypothetical transcript on chromosome X (located within bp 179682 to 182918 of ref[NT_025297.5|HsX_25453 Homo sapiens chromosome X working draft sequence segment). This sequence, designated CT19.1 (nucleic acid: SEQ ID NO:46; polypeptide: SEQ ID NO:47), was determined to be 90% and 84% identical to
20 Hs.43879/CT19.2 and Hs.16323/CT19.3, respectively, and to have the same intron/exon structure as Hs.43879/CT19.2 and Hs.16323/CT19.3.

Primers were designed to the most unique region of CT19.1. The CT19.1 primers (see below, SEQ ID NO:58 and 59) and do not amplify Hs.43879/CT19.2 or Hs.16323/CT19.3 sequences. Expression of a CT19.1 transcript was detected in fetal brain,
25 testis, and a variety of tumors (hence its designation as a CT antigen, CT19.1, see below). In some cases, two bands were detected by RT-PCR, with the resultant low molecular weight band detected consistently, while the higher molecular weight band was detected more sporadically. Both bands were sequenced, and only the low molecular weight band (SEQ ID NO:46) gave a predicted protein product (SEQ ID NO:47) similar to Hs.43879/CT19.2 and
30 Hs.16323/CT19.3, while the higher molecular weight band yielded a translated protein which was truncated (there is a stop codon in the additional sequence). Thus, the low molecular weight band is the CT19.1 sequence.

Expression analysis

The mRNA expression profiles of CT19.1, CT19.2 and CT19.3 were determined in normal and malignant tissues using the gene-specific primers identified below in 35 cycles of RT-PCR (as described in Example 2). The results are presented in Table 7, below.

CT19.1 primers:

GEF1: ACCAAGGAGAAGCGTACCAC (SEQ ID NO:58)

GER2: GGGACCATCTCTGCATTCATC (SEQ ID NO:59)

Hs.43879/CT19.2 primers

GDF: AGGCCGAGGAGAAGTGTACC (SEQ ID NO:42)

GDR: AACCTGTGGTTGCCTGTCAC (SEQ ID NO:43)

Hs.16323/CT19.3 primers

GD2F:AGCCGTCTGGACTCTTTCTC (SEQ ID NO:44)

GD2R: TGATTTCCTTCACCTGCTTC (SEQ ID NO:45)

Table 7. RT-PCR analysis of mRNA expression frequencies of newly defined CT19 genes in normal and malignant tissues

Tissues	CT19 genes		
	CT19.1	Hs.43879/ CT19.2	Hs.16323/ CT19.3
Normal Tissues ¹	Testis, fetal brain only	Testis, placenta, prostate, lung, breast	Testis, ovary, placenta, prostate, lung, cervix
Melanoma	1/14		
Lung Cancer	2/22	3/18	11/18
Colon Cancer	2/9		2/9
Renal Cancer	1/11	1/11	2/11

¹Normal tissue RNA panel included brain, testis, kidney, liver, pancreas, placenta, small intestine, heart, prostate, adrenal gland, spleen, fetal brain, colon, stomach, lung, bladder, ovary, breast, cervix and skeletal muscle

Protein Alignments

The alignment of CT19.2 with the GAGE-A1 protein sequence (SEQ ID NO:57) is shown below. Vertical lines indicate amino acid identity between these sequences.

5 GAGE A1 DEGASAGQGPKPEAHSQEQGHPQTGCECEDGPDGQEMDPNPEEVKTPEEGEKQSQC
| | | | | | | | | | | | | | | | | | | | | |
CT19.2 DQGAETQVPDLEADLQELSQSKTGGECGNGPDDQGXILPKSEQFKMPEGGDRQPV

The alignment of the CT19.1, CT19.2 and CT 19.3 protein sequences is shown below.

10 CT19.1 MIWRVSTYRPRPRRSVPPPELIGPMLEPSDEEPQQEPPPTESRDPTP-----
CT19.2 MIWRGRSTYRPRPRRSVPPPELIGPMLEPGDEEPQQEPPPTESRDPAPGQEREEDQGAAE
15 CT19.3 MSWRGRSTYRPRPRRSLQPPELIGAMLEPTDEEPKEEKPPTKSRNPTPDQKREDDQGAAE
CT19.1 --VPDLETDLQELSQSKTGDECRDGPDDKGKILPKSEQFKMPEGG
20 CT19.2 TQVPDLEADLQELSQSKTGGECGNGPDDQGKILPKSEQFKMPEGGDRQPQV
CT19.3 IQVPDLEADLQELCQTKTGDGCEGGTDVKGKILPKAEHFKMPEAGEGKSQV

Underlined amino acids in a sequence differ from the amino acids at the same
25 positions in the other two aligned CT19 sequences. Dashes indicate gaps in a sequence
relative to the other sequences. The sequence alignments show that there is 81% identity
between CT19.1 and CT19.2 polypeptides, 69% identity between CT19.1 and CT19.3
polypeptides, and 73% identity between CT19.2 and CT19.3 polypeptides.

Example 4: Identification of choriocarcinoma/tumor (ChT) gene products

The Unigene database was mined for ESTs found exclusively in ESTs libraries from choriocarcinoma and cancer as in the CT antigen mining described above in Example 2.

Briefly, two pools of Expressed Sequence Tags (ESTs) were established. Pool A consisted of all ESTs from 3 choriocarcinoma cDNA libraries and Pool B consisted of all ESTs from 3,289 tumor-derived cDNA libraries (of many histological types). The Xprofiler tool of CGAP was used to search the UniGene database for UniGene clusters containing ESTs from both Pool A and Pool B, and exclude clusters containing ESTs from normal tissue cDNA libraries.

This search yielded 49 Choriocarcinoma/Tumor (ChT)-related UniGene clusters, including four known gene products (three of which were CT antigens: LAGE, MAGE-A6, MAGE-A12) and 45 were novel. 31 of the 49 ChT-related Unigene clusters represented

intronless sequences (single exons, pseudogenes, genomic contaminants) and were not studied. The remaining 18 ChT-related Unigene clusters had definitive intron/exon boundaries and 15 (after excluding known CT antigen sequences) were analyzed by RT-PCR in a panel of normal and malignant tissues. Two of the ChT gene products, Hs.313507/CT 20 (SEQ ID NO:48) and Hs.197664 (SEQ ID NO:51), had interesting mRNA expression profiles as described below. In addition, the Hs.313507/CT 20 Unigene cluster had two types of transcripts, a testis cDNA sequence termed FLJ32909 and 11 tumor derived ESTs, with bp 770-961 of FLJ32909 missing from the tumor derived ESTs. These different transcripts, i.e., putative splice variants, encode two different protein products: isoform A (SEQ ID NO:49) is the product of the EST transcripts and isoform B (SEQ ID NO:50), is the product of the testis transcript. Hs.197664 encodes a single protein product (SEQ ID NO:52), which is 30% similar to NY-CO-41/methyl CpG binding protein 2.

Expression Analysis

RT-PCR was performed for 35 cycles as described above using the following primers. The results are presented in Table 8.

Hs.313507/CT 20 primers:

CCCT11F: TGGGACATCCATCAGATAAG (SEQ ID NO:53)

CCCT11R: TTTATGGCTGCATAGTATTC (SEQ ID NO:54)

Hs.197664 primers:

CCCT5F: GCTATGGGAGAACCTGCGTTC (SEQ ID NO:55)

CCCT5R: TCCCTGGCTTTCTTCACCCTC (SEQ ID NO:56)

Table 8. RT-PCR analysis of mRNA expression frequencies in normal and malignant tissues

Tissues	Hs.313507/ CT20	Hs.197664
Normal Tissues ¹	Testis only	Testis, ovary, prostate only
Melanoma	5/14	2/13
Lung Cancer	6/22	
Colon Cancer	1/9	
Renal Cancer	2/11	2/11

¹Normal tissue RNA panel included brain, testis, kidney, liver, pancreas, placenta, small intestine, heart, prostate, adrenal gland, spleen, fetal brain, colon, stomach, lung, bladder, ovary, breast, cervix and skeletal muscle

5 **Example 5: Confirming the identity of the CT antigens**

The length of the sequences identified above can be extended, providing additional sequence regions with which to search for related sequences in the gene databases.

Elongation of the sequences described above is done using standard methods, (e.g. PCR) to extend the DNA sequences beyond the regions currently known, particularly for those
10 sequences that encode an apparently incomplete protein. PCR-based amplification methods include 5'RACE, which allows the isolation of the missing 5' ends of the known, partial cDNAs. In addition, 3' RACE is also used to extend the missing 3' ends of the cDNAs. These additional end regions are sequenced, and the information used to screen the databases for matches and homologies.

15 Another method for lengthening the known sequences is through traditional library screening procedures, which allow isolation of longer sequences from libraries. Once extended sequences are identified, they are used to search the gene databases for sequence matches and the subsequent examination of expression patterns. The libraries used in the screening procedures are general libraries, or more tissue-specific or developmental stage-
20 specific libraries.

Example 6: Preparation of recombinant CT antigens

CT antigens (e.g., CT15, CT16, CT17, CT19.1 and CT20) were expressed as his-tagged proteins in *E. coli* using histidine-tag-containing vector pQE30 (Qiagen, Valencia,
25 CA) as described in ref. 40. The induction of recombinant protein synthesis and subsequent purification by Ni⁺² column were performed as described (Chen et al., *Proc. Natl. Acad. Sci. USA*. 91:1004-1008, 1994).

In alternative methods, the clones encoding CT antigens are subcloned into a baculovirus expression vector, and the recombinant expression vectors are introduced into
30 appropriate insect cells. Baculovirus/insect cloning systems are preferred because post-translational modifications are carried out in the insect cells. Another preferred eukaryotic system is the *Drosophila* Expression System from Invitrogen. Clones which express high amounts of the recombinant protein are selected and used to produce the recombinant

proteins. Other systems, including yeast expression systems and mammalian cell culture systems also can be used.

Example 7: Preparation of antibodies to CT antigens

5 The recombinant CT antigens produced as in Example 6 above are used to generate polyclonal antisera and monoclonal antibodies according to standard procedures. The antisera and antibodies so produced are tested for correct recognition of the CT antigens by using the antisera/antibodies in assays of cell extracts of patients known to express the particular CT antigen (e.g. an ELISA assay). These antibodies can be used for experimental
10 purposes (e.g. localization of the CT antigens, immunoprecipitations, Western blots, etc.) as well as diagnostic purposes (e.g., testing extracts of tissue biopsies, testing for the presence of CT antigens).

 The antibodies are useful for accurate and simple typing of cancer tissue samples for expression of the CT antigens.

15

Example 8: Expression of CT antigens in cancers of similar and different origin.

 The expression of one or more of the CT antigens is tested in a range of tumor samples to determine which, if any, other malignancies should be diagnosed and/or treated by the methods described herein. Tumor cell lines and tumor samples are tested for CT antigen
20 expression, preferably by RT-PCR or real time PCR according to the procedures described above. Northern blots also are used to test the expression of the CT antigens. Antibody based assays, such as ELISA and western blot, also can be used to determine protein expression. A preferred method of testing expression of CT antigens (in other cancers and in additional same type cancer patients) is allogeneic serotyping using a modified SEREX
25 protocol.

 In all of the foregoing, extracts from the tumors of patients who provided sera for the initial isolation of the CT antigens are used as positive controls. The cells containing recombinant expression vectors described in the Examples above also can be used as positive controls.

30

 The results generated from the foregoing experiments provide panels of multiple cancer associated nucleic acids and/or polypeptides for use in diagnostic (e.g. determining the

existence of cancer, determining the prognosis of a patient undergoing therapy, etc.) and therapeutic methods (e.g., vaccine composition, etc.).

Example 9: HLA typing of patients positive for CT antigens

5 To determine which HLA molecules present peptides derived from the CT antigens of the invention, cells of the patients which express the CT antigens are HLA typed. Peripheral blood lymphocytes are taken from the patient and typed for HLA class I or class II, as well as for the particular subtype of class I or class II. Tumor biopsy samples also can be used for typing. HLA typing can be carried out by any of the standard methods in the art of clinical
10 immunology, such as by recognition by specific monoclonal antibodies, or by HLA allele-specific PCR (e.g. as described in WO97/31126).

Example 10: Characterization of CT antigen peptides presented by MHC class I and class II molecules.

15 Antigens which provoke an antibody response in a subject may also provoke a cell-mediated immune response. Cells process proteins into peptides for presentation on MHC class I or class II molecules on the cell surface for immune surveillance. Peptides presented by certain MHC/HLA molecules generally conform to motifs. These motifs are known in some cases, and can be used to screen the CT antigens for the presence of potential class I
20 and/or class II peptides. Summaries of class I and class II motifs have been published (e.g., Rammensee et al., *Immunogenetics* 41:178-228, 1995). Based on the results of experiments such as those described above, the HLA types which present the individual CT antigens are known. Motifs of peptides presented by these HLA molecules thus are preferentially searched.

25 One also can search for class I and class II motifs using computer algorithms. For example, computer programs for predicting potential CTL epitopes based on known class I motifs has been described (see, e.g., Parker et al., *J. Immunol.* 152:163, 1994; D'Amaro et al., *Human Immunol.* 43:13-18, 1995; Drijfhout et al., *Human Immunol.* 43:1-12, 1995).
Computer programs for predicting potential T cell epitopes based on known class II motifs
30 has also been described (see, e.g. Sturniolo et al., *Nat Biotechnol* 17(6):555-61, 1999). HLA binding predictions can conveniently be made using an algorithm available via the Internet on the National Institutes of Health World Wide Web site at URL <http://bimas.dcrt.nih.gov> . See

also the website of: SYFPEITHI: An Internet Database for MHC Ligands and Peptide Motifs
(access via <http://www.uni-tuebingen.de/uni/kxi/> or
<http://134.2.96.221/scripts/hlaserver.dll/EpPredict.htm>. Methods for determining HLA class
II peptides and making substitutions thereto are also known (e.g. Strominger and
5 Wucherpennig (PCT/US96/03182)).

Example 11: Identification of the portion of a cancer associated polypeptide encoding an antigen

To determine if the CT antigens identified and isolated as described above can
10 provoke a cytolytic T lymphocyte response, the following method is performed. CTL clones
are generated by stimulating the peripheral blood lymphocytes (PBLs) of a patient with
autologous normal cells transfected with one of the clones encoding a CT antigen polypeptide
or with irradiated PBLs loaded with synthetic peptides corresponding to the putative protein
and matching the consensus for the appropriate HLA class I molecule (as described above) to
15 localize an antigenic peptide within the CT antigen clone (*see, e.g., Knuth et al., Proc. Natl.
Acad. Sci. USA 81:3511-3515, 1984; van der Bruggen et al., Eur. J. Immunol. 24:3038-3043,
1994*). These CTL clones are screened for specificity against COS cells transfected with the
CT antigen clone and autologous HLA alleles as described by Brichard et al. (*Eur. J.
Immunol. 26:224-230, 1996*). CTL recognition of a CT antigen is determined by measuring
20 release of TNF from the cytolytic T lymphocyte or by ^{51}Cr release assay (Herin et al., *Int. J.
Cancer 39:390-396, 1987*). If a CTL clone specifically recognizes a transfected COS cell,
then shorter fragments of the CT antigen clone transfected in that COS cell are tested to
identify the region of the gene that encodes the peptide. Fragments of the CT antigen clone
are prepared by exonuclease III digestion or other standard molecular biology methods.
25 Synthetic peptides are prepared to confirm the exact sequence of the antigen.

Optionally, shorter fragments of CT antigen cDNAs are generated by PCR. Shorter
fragments are used to provoke TNF release or ^{51}Cr release as above.

Synthetic peptides corresponding to portions of the shortest fragment of the CT
antigen clone which provokes TNF release are prepared. Progressively shorter peptides are
30 synthesized to determine the optimal CT antigen tumor rejection antigen peptides for a given
HLA molecule.

- 89 -

A similar method is performed to determine if the CT antigen contains one or more HLA class II peptides recognized by T cells. One can search the sequence of the CT antigen polypeptides for HLA class II motifs as described above. In contrast to class I peptides, class II peptides are presented by a limited number of cell types. Thus for these experiments,
5 dendritic cells or B cell clones which express HLA class II molecules preferably are used.

References

1. Boyse EA, Miyazawa M, Aoki T, Old LJ. Ly-A and Ly-B: two systems of
10 lymphocyte isoantigens in the mouse. *Proc Royal Soc Brit* 1968; 170: 175-193.
(PMID:4385242)
2. Boyse EA, Old LJ. Some aspects of normal and abnormal cell surface genetics. *Ann
Rev Genet* 1969; 3: 269-290.
- 15 3. DeLeo AB, Jay G, Appella E, Dubois GC, Law LW, Old LJ. Detection of a
transformation-related antigen in chemically induced sarcomas and other transformed
cells of the mouse. *Proc Natl Acad Sci USA* 1979; 76: 2420-2424. (PMID: 221923)
- 20 4. Lilly F, Boyse EA, Old LJ. Genetic basis of susceptibility to viral leukemogenesis.
Lancet 1965; ii:1207-1209.
5. Carswell EA, Old LJ, Kassel RL, Green S, Fiore NC, Williamson B. An
endotoxin-induced serum factor that causes necrosis of tumors. *Proc Natl Acad Sci
25 USA* 1975; 72: 3666-3670. (PMID: 1103152)
6. Traversari C, van der Bruggen P, Van den Eynde B, Hainaut P, Lemoine C, Ohta N,
Old LJ, Boon T. Transfection and expression of a gene coding for a human
melanoma antigen recognized by autologous cytolytic T lymphocytes.
30 *Immunogenetics* 1992; 35: 145-152. (PMID: 1537606)
7. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde

- 90 -

B, Knuth A, and Boon, T, A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. *Science* 1991; 254:1643-1647. (PMID: 1840703)

- 5 8. Old LJ. Cancer immunology: The search for specificity. *Cancer Res* 1981; 41: 361-375. (PMID: 7004632)
9. Knuth A, Danowski B, Oettgen HF, Old LJ. T cell-mediated cytotoxicity against malignant melanoma: Analysis with IL-2-dependent T cell cultures. *Proc Natl Acad Sci USA* 1984; 81: 3511-3515. (PMID: 6610177)
- 10 10. Sahin, U, Türeci Ö, Schmitt, Cochlovius B, Johannes T, Schmits R, Stenner F, Luo G, Schobert I, Pfreundschuh M. Human neoplasms elicit multiple specific immune responses in the autologous host. *Proc Natl Acad Sci USA* 1995; 92:11810-11813. (PMID: 8524854)
- 15 11. Old LJ, Chen YT. New paths in human cancer serology. *J Exp Med* 1998; 187:1163-1167. (PMID: 9547328)
- 20 12. De Plaen E, Arden K, Traversari C, Gaforio JJ, Szikora JP, De Smet C, Brasseur F, van der Bruggen P, Lethé B, Lurquin C, Brasseur R, Chomez P, De Backer O, Cavenee W, and Boon T. Structure, chromosomal localization and expression of twelve genes of the MAGE family. *Immunogenetics* 1994; 40: 360-369. (PMID: 7927540)
- 25 13. Muscatelli F, Walker AP, De Plaen E, Stafford AN, Monaco AP. Isolation and characterization of a new MAGE gene family in the Xp21.3 region. *Proc Natl Acad Sci USA* 1995; 92: 4987-4991. (PMID: 7761436)
- 30 14. Boël P, Wildmann C, Sensi ML, Brasseur R, Renauld JC, Coulie P, Boon T, van der Bruggen P. BAGE, a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. *Immunity* 1995; 2: 167-175. (PMID: 7895173)

15. Van den Eynde B, Peeters O, De Backer O, Gaugler B, Lucas S, Boon T. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. *J Exp Med* 1995;182: 689-698. (PMID: 7544395)
16. De Backer O, Arden KC, Boretta M, Vantomme V, De Smet C, Czekay S, Viars CS, De Plaen E, Brasseur F, Chomez P, Van den Eynde B, Boon T, van der Bruggen P. Characterization of the GAGE genes that are expressed in various human cancer and in normal testis. *Cancer Res* 1999; 59: 3157-65. (PMID: 10397259)
17. Güre AO, Türeci Ö, Sahin U, Tsang S, Scanlan MJ, Jager E, Knuth A, Pfreundschuh M, Old LJ, Chen YT. SSX, a multigene family with several members transcribed in normal testis and human cancer. *Int. J. Cancer* 1997; 72: 965-971. (PMID: 9378559)
18. Chen YT, Scanlan MJ, Sahin U, Türeci Ö, Güre AO, Tsang S, Williamson B, Stockert E, Pfreundschuh M, Old LJ. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. *Proc. Natl. Acad. Sci USA* 1997; 94: 1914-1918. (PMID: 9050879)
19. Lethe B, Lucas S, Michaux L, De Smet C, Godelaine D, Serrano A, De Plaen E, Boon T. LAGE-1: a new gene with tumor specificity. *Int J Cancer* 1998;76:903-908. (PMID: 9626360)
20. Türeci Ö, Sahin U, Zwick C, Koslowski M, Seitz G, Pfreundschuh M. Identification of a meiosis-specific protein as a new member of the class of cancer/testis antigens. *Proc Natl Acad Sci USA* 1998; 95: 5211-5216. (PMID: 9560255)
21. Chen YT, Güre AO, Tsang S, Stockert E, Jäger E, Knuth A, Old LJ. Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. *Proc Natl Acad Sci USA* 1998; 95: 6919-6923. (PMID: 9618514)

22. Lucas S, De Smet C, Arden KC, Viars CS, Lethe B, Lurquin C, Boon T. Identification of a new MAGE gene with tumor-specific expression by representational difference analysis. *Cancer Res* 1998; 58: 743-752. (PMID: 9485030)
- 5 23. Sahin U, Koslowski M., Türeci Ö, Eberle T, Zwick C, Romeike B, Moringlane JR, Schwechheimer K, Feiden W., Pfreundschuh M. Expression of cancer/testis genes in human brain tumors. *Clin Cancer Res* 2000;10: 3916-3922. (PMID: 11051238)
- 10 24. Scanlan MJ, Altorki NK, Güre AO, Williamson B, Jungbluth A, Chen YT, Old LJ. Expression of cancer-testis antigens in lung cancer: definition of bromodomain testis-specific gene (BRDT) as a new CT gene CT9. *Cancer Lett.* 2000; 150:155-164. (PMID: 10704737)
- 15 25. Güre AO, Stockert E, Arden KC, Boyer AD, Viars CS, Scanlan MJ, Old LJ, Chen YT. CT10: a new cancer-testis (CT) antigen homologous to CT7 and the MAGE family, identified by representational difference analysis. *Int. J. Cancer* 2000; 85: 726-732. (PMID: 10699956)
- 20 26. Lucas S, De Plaen E, Boon T. MAGE-B5, MAGE-B6, MAGE-C2 and MAGE-C3: four new members of the MAGE family with tumor-specific expression. *Int. J. Cancer* 2000; 87 :55-60. (PMID: 10861452)
- 25 27. Zendman AJ, Cornelissen IM, Weidle UH, Ruiter DJ, van Muijen GN. CTp11, a novel member of the family of human cancer/testis antigens. *Cancer Res.* 1999, 59: 6223-6239. (PMID: 10626816)
- 30 28. Martelange V, De Smet C, De Palen E, Lurquin C, Boon, T. Identification on a human sarcoma of two new genes with tumor-specific expression. *Cancer Res* 2000; 60: 3848-3855. (PMID: 10919659)
29. Eichmüller S, Usener D, Dummer R, Stein A, Thiel D, Schadendorf D. Serological detection of cutaneous T cell lymphoma-associated antigens. *Proc Natl Acad Sci*

USA 2001; 98: 629-634. (PMID: 11149944)

30. Ono T, Kurashige T, Harada N, Noguchi Y, Saika T, Niikawa N, Aoe M, Nakamura S, Higashi T, Hiraki A, Wada H, Kumon H, Old L, Nakayama E. Identification of proacrosin binding protein sp32 precursor as a human cancer/testis antigen. *Proc Natl Acad Sci. USA* 2001; 98:3 282-3287. (PMID: 11248070)
31. Jungbluth A, Busam K, Kolb D, Iversen K, Coplan K, Chen YT, Spagnoli GC, Old LJ. Expression of MAGE-antigens in normal tissues and cancer. *Int J Cancer*. 2000; 85 :460-5. (PMID: 10699915)
32. Jungbluth A, Busam K, Iversen, K, Kolb D, Coplan K, Chen YT, Stockert E, Zhang P, Old, LJ. Cancer-Testis (CT) antigens MAGE-1, MAGE-3, NY-ESO-1, and CT7 are expressed in female germ cells. *Mod Path*. In press 2001.
33. Jungbluth A, Iversen K, Kolb D, Coplan K, Chen YT, Stockert E, Old LJ, Vogel M. Expression of CT (Cancer/Testis) antigens MAGE, NY-ESO-1, and CT7 in placenta. *German Soc for Path*. Submitted 2001.
34. Jungbluth A, Stockert E, Chen YT, Kolb D, Iversen K, Coplan K, Williamson B, Altorki N, Busam KJ, Old LJ. Monoclonal antibody MA454 reveals a heterogeneous expression pattern of MAGE-1 antigen in formalin-fixed paraffin embedded lung tumours. *British Journ Cancer* 2000; 83: 493-497. (PMID: 10945497)
35. Meuwissen RJL, Offenberg, HH, Dietrich AJ, Riesewijk A, van Iersel M, Heting C. A coiled-coil related protein specific for synapsed regions of meiotic prophase chromosomes. *EMBO J* 1992;11: 5091-5100. (PMID: 1464329)
36. Baba T, Niida Y, Michikawa Y, Kashiwabara S, Kodaira K, Takenaka M, Kohno N, Gerton GL, Arai Y. An acrosomal protein, sp32, in mammalian sperm is a binding protein specific for two proacrosins and an acrosin intermediate. *J Biochem* 1994; 269:10133-10140. (PMID: 8144514)

37. Brasseur F, Rimoldi D, Liénard D, Lethe B, Carrel S, Arienti F, Suter L, Vanwijck R, Bourlond A, Humblet Y, Vacca A, Conese M, Lahaye T, Degiovanni G, Deraemaecker R, Beauduin M, Sastre X, Salamon E, Dréno B, Jäger E, Knuth A, Chevreau C, Suciú S, Lachapelle J-M, Pouillart P, Parmiani G, Lejeune F, Cerottini J-C, Boon T, Marchand M. Expression of MAGE gene in primary and metastatic cutaneous melanoma. *Int J Cancer* 1995; 63 :375-380. (PMID: 7591235)
38. Patard JJ, Brasseur F, Gil-Diez S, Radvanyi F, Marchand M, Francois P, Abi-Aad A, VanCangh P, Abbou CC, Chopin D, Boon T. Expression of MAGE genes in transitional-cell carcinomas of the urinary bladder. *Int J Cancer* 1995; 64:60-64. PMID: 7665250)
39. Kurashige T, Noguchi Y, Saika T, Ono T, Nagata Y, Jungluth A, Ritter G, Chen YT, Stockert E, Tsushima T, Kumon H, Old LJ, Nakayama E. NY-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor grade. *Cancer Res.* 2001; 61:4671-4674.
40. Stockert E., Jäger E, Chen YT, Scanlan M, Gout I, Karbach J, Arand M, Knuth A, Old, LJ. A survey of the humoral response of cancer patients to a panel of human tumor antigens. *J Exp Med* 1998;187:1349-1354. (PMID: 9547346)
41. Jäger E., Nagata Y, Gnjjatic S, Wada H, Stockert E, Karbach J, Dunbar PR, Lee SY, Jungbluth A, Jäger D, Arand M, Ritter G, Cerundolo V, Dupont B, Chen YT, Old LJ, Knuth A. Monitoring CD8 T cell responses to NY-ESO-1: Correlation of humoral and cellular immune responses. *Proc Natl Acad Sci USA* 2000; 97: 4760-4765. (PMID: 10781081)
42. De Smet C, De Backer O, Faraoni I, Lurquin C, Brasseur F, Boon T. The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. *Proc. Natl. Acad. Sci USA* 1996; 93:7149-7153 (.PMID: 8692960)

43. Jungbluth A, Chen YT, Stockert E, Busam KJ, Kolb D, Iversen K, Coplan K, Williamson B, Altorki N, Old LJ. Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant tumors. *Int J Cancer*. 2001; 92:856-860.
- 5 44. Jungbluth A, Antonescu C, Busam K, Iversen K, Kolb D, Coplan K, Chen YT, Stockert E, Ladanyi M, Old, LJ. Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1, but not MAGE-A1 or CT7. *Int J Cancer*. 2001; 94(2):252-6.
- 10 45. Antonescu C, Busam K, Iversen K, Kolb D, Coplan K, Spagnoli G, Ladanyi M, Old LJ, Jungbluth, A. MAGE antigen expression in monophasic and biphasic synovial sarcoma. *Mod Path*. Submitted 2001.
46. Beard J. The cancer problem. *Lancet* 1905;1:281-203.
- 15 47. Gurchot C. The trophoblast theory of cancer. *Oncology* 1975; 31: 310-333. (PMID: 1107920)
48. Iles RK, Chard T. Human Chorionic Gonadotropin Expression by Bladder Cancers: Biology and Clinical Potential. *J Urol* 1991; 145 :453-458. (PMID: 1705292)
- 20 49. Acevedo HF, Tong JY, Hartsock RJ. Human Chorionic Gonadotropin-Beta Subunit Gene Expression in Cultured Human Fetal and Cancer Cells of Different Types and Origins. *Cancer* 1995; 76: 1467-1475. (PMID: 8620425)
- 25 50. Dirnhofer S, Koessler P, Ensigner C, Feichtinger H, Madersbacher S, Berger P. Production of Trophoblastic Hormones by Transitional Cell Carcinoma of the Bladder: Association to Tumor Stage and Grade. *Hum Path* 1998; 29: 377-382. (PMID: 9563788)
- 30 51. Vidaeus CM, von Kapp-Herr C, Golden WL, Eddy RL, Shows TB, Herr JC. Human fertilin beta: identification, characterization, and chromosomal mapping of an ADAM

gene family member. *Mol Reprod Dev.* 1997;46:363-9.

52. Brinkmann U, Vasmatazis G, Lee B, Yerushalmi N, Essand M, Pastan I. PAGE-1, an X chromosome-linked GAGE-like gene that is expressed in normal and neoplastic prostate, testis, and uterus. *Proc. Natl. Acad. Sci. USA* 1998;95:10757-62.
53. Nagai Y, Aoki J, Sato T, Amano K, Matsuda Y, Arai H, et al. An alternative splicing form of phosphatidylserine-specific phospholipase A1 that exhibits lysophosphatidylserine-specific lysophospholipase activity in humans. *J. Biol. Chem.* 1999;274:11053-9.
54. Dotzlaw H, Alkhalaf M, Murphy LC. Characterization of estrogen receptor variant mRNAs from human breast cancers. *Mol Endocrinol.* 1992;6:773-85.
55. Gaugler B, Van den Eynde B, van der Bruggen P, Romero P, Gaforio JJ, De Plaen E, et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. *J. Exp. Med.* 1994;179:921-30.
56. Chen YT, Scanlan M J, Obata Y, Old LJ. Identification of human tumor antigens by serological expression cloning. (2000) In: Rosenberg SA. Principles and Practice of Biologic Therapy of Cancer. Philadelphia: Lippincott Williams & Wilkins. 2000:557-70.
57. Primakoff P, Myles DG. The ADAM gene family: surface proteins with adhesion and protease activity. *Trends Genet.* 2000;16:83-7.
58. Roldan ER. Role of phospholipases during sperm acrosomal exocytosis. *Front Biosci.* 1998; 3:D1109-19.
59. Scarcella DL, Chow CW, Gonzales MF, Economou C, Brasseur F, Ashley DM. Expression of MAGE and GAGE in high-grade brain tumors: a potential target for specific immunotherapy and diagnostic markers. *Clin Cancer Res.* 1999; 5:335-41.

60. Dropcho EJ, Chen YT, Posner JB, Old LJ. Cloning of a brain protein identified by autoantibodies from a patient with paraneoplastic cerebellar degeneration. *Proc Natl Acad Sci U S A*. 1987;84:4552-56.
- 5 61. Dalmau J, Gultekin SH, Voltz R, Hoard R, DesChamps T, Balmaceda C, et al. Ma1, a novel neuron- and testis-specific protein, is recognized by the serum of patients with paraneoplastic neurological disorders. *Brain*. 1999;122: 27-39.
- 10 62. Voltz R, Gultekin SH, Rosenfeld MR, Gerstner E, Eichen J, Posner JB, et al. A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer. *N Engl J Med*. 1999;340:1788-95.
- 15 63. Steimle V, Durand B, Barras E, Zufferey M, Hadam MR, Mach B, et al. A novel DNA-binding regulatory factor is mutated in primary MHC class II deficiency (bare lymphocyte syndrome). *Genes Dev* 1995;9:1021-32.
64. Mach B, Steimle V, Reith W. MHC class II-deficient combined immunodeficiency: a disease of gene regulation. *Immunol Rev*. 1994;138:207-21.
- 20 65. Loging WT, Lal A, Siu IM, Loney TL, Wikstrand CJ, Marra MA, et al. Identifying potential tumor markers and antigens by database mining and rapid expression screening. *Genome Res*. 2000;10:1393-1402.

25 EQUIVALENTS

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

All references disclosed herein are incorporated by reference in their entirety.

30 We claim:

- 98 -

Claims

1. A method of diagnosing a cancer, comprising:

contacting a non-testis biological sample isolated from a subject with an agent that specifically binds to a nucleic acid molecule, an expression product thereof, a fragment of the expression product thereof complexed with an HLA molecule, or an antibody that binds the expression product or fragment, wherein the nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs:18, 20, 22, 46 and 48, and determining the interaction between the agent and the nucleic acid molecule or the expression product to diagnose the cancer in the subject.

2. The method of claim 1, wherein the agent is selected from the group consisting of

(a) a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:18, 20, 22, 46 and 48 or a fragment thereof,

(b) an antibody that binds to an expression product of a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:18, 20, 22, 46 and 48,

(c) an agent that binds to a complex of an HLA molecule and a fragment of an expression product of a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:18, 20, 22, 46 and 48 and

(d) a polypeptide that binds the antibody that binds the expression product or fragment.

3. The method of claim 1, wherein the cancer is characterized by expression of a

plurality of human CT antigen precursors and wherein the agent is a plurality of agents, each

of which is specific for a different human CT antigen precursor, and wherein said plurality of agents is at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, or at least 8, at least 9 or at least 10 such agents.

4. A method of diagnosing a cancer, comprising:

contacting a non-testis, non-brain biological sample isolated from a subject with an agent that specifically binds to a nucleic acid molecule, an expression product thereof, a fragment of the expression product thereof complexed with an HLA molecule, or an antibody

- 99 -

that binds the expression product or fragment, wherein the nucleic acid molecule comprises a nucleotide sequence set forth as SEQ ID NO:32, and

determining the interaction between the agent and the nucleic acid molecule or the expression product to diagnose the cancer in the subject.

5

5. A method of diagnosing a cancer, comprising:

contacting a non-testis, non-ovary, non-cervix, non-lung biological sample isolated from a subject with an agent that specifically binds to a nucleic acid molecule, an expression product thereof, a fragment of the expression product thereof complexed with an HLA molecule, or an antibody that binds the expression product or fragment, wherein the nucleic acid molecule comprises a nucleotide sequence set forth as SEQ ID NO:34, and

10

determining the interaction between the agent and the nucleic acid molecule or the expression product to diagnose the cancer in the subject.

15

6. A method of diagnosing a cancer, comprising:

contacting a non-testis, non-ovary, non-lung, non-breast, non-prostate, non-colon biological sample isolated from a subject with an agent that specifically binds to a nucleic acid molecule, an expression product thereof, a fragment of the expression product thereof complexed with an HLA molecule, or an antibody that binds the expression product or fragment, wherein the nucleic acid molecule comprises a nucleotide sequence set forth as SEQ ID NO:36, and

20

determining the interaction between the agent and the nucleic acid molecule or the expression product to diagnose the cancer in the subject.

25

7. A method of diagnosing a cancer, comprising:

contacting a non-testis, non-placenta, non-lung, non-breast, non-prostate biological sample isolated from a subject with an agent that specifically binds to a nucleic acid molecule, an expression product thereof, a fragment of the expression product thereof complexed with an HLA molecule, or an antibody that binds the expression product or fragment, wherein the nucleic acid molecule comprises a nucleotide sequence set forth as SEQ ID NO:38, and

30

- 100 -

determining the interaction between the agent and the nucleic acid molecule or the expression product to diagnose the cancer in the subject.

8. A method of diagnosing a cancer, comprising:

5 contacting a non-testis, non-ovary, non-placenta, non-lung, non-prostate, non-cervix biological sample isolated from a subject with an agent that specifically binds to a nucleic acid molecule, an expression product thereof, a fragment of the expression product thereof complexed with an HLA molecule, or an antibody that binds the expression product or fragment, wherein the nucleic acid molecule comprises a nucleotide sequence set forth as
10 SEQ ID NO:40, and

 determining the interaction between the agent and the nucleic acid molecule or the expression product to diagnose the cancer in the subject.

9. A method of diagnosing a cancer, comprising:

15 contacting a non-testis, non-ovary, non-prostate biological sample isolated from a subject with an agent that specifically binds to a nucleic acid molecule, an expression product thereof, a fragment of the expression product thereof complexed with an HLA molecule, or an antibody that binds the expression product or fragment, wherein the nucleic acid molecule comprises a nucleotide sequence set forth as SEQ ID NO:51, and

20 determining the interaction between the agent and the nucleic acid molecule or the expression product to diagnose the cancer in the subject.

10. A method for determining regression, progression or onset of a cancer characterized by expression of abnormal levels of a protein encoded by a nucleic acid molecule comprising
25 a nucleotide sequence selected from the group consisting of SEQ ID NOs:18, 20, 22, 46 and 48, comprising

 monitoring a plurality of non-testis samples obtained at different times from a subject who has or is suspected of having the cancer, for a parameter selected from the group consisting of

- 30 (i) the protein,
 (ii) a peptide derived from the protein,
 (iii) an antibody which selectively binds the protein or peptide,

- 101 -

(iv) cytolytic T cells specific for a complex of the peptide derived from the protein and an MHC molecule, and

(v) a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:18, 20, 22, 46 and 48; and

5 comparing the parameters from the plurality of samples to determine regression, progression or onset of the cancer.

11. The method of claim 10, wherein the sample is a body fluid, a body effusion, cell or a tissue.

10 12. The method of claim 10, wherein the step of monitoring comprises contacting the sample with a detectable agent selected from the group consisting of

(a) an antibody or fragment thereof which selectively binds the protein of (i), or the peptide of (ii),

15 (b) a protein or peptide which binds the antibody of (iii),

(c) a cell which presents the complex of the peptide and MHC molecule of (iv), and

(d) at least one nucleic acid probe or primer that hybridizes to the nucleic acid molecule of (v) or its complement.

20 13. The method of claim 12, wherein the antibody, the protein, the peptide, the cell or the nucleic acid probe or primer is labeled with a radioactive label or an enzyme.

25 14. The method of claim 10, wherein the protein is a plurality of proteins, the parameter is a plurality of parameters, each of the plurality of parameters being specific for a different of the plurality of proteins, at least one of which is a CT antigen protein encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:18, 20, 22, 46 and 48.

30 15. A pharmaceutical preparation for a human subject comprising an agent which when administered to the subject enriches selectively the presence of complexes of an HLA molecule and a human CT antigen peptide, and

- 102 -

a pharmaceutically acceptable carrier, wherein the human CT antigen peptide is a fragment of a human CT antigen encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:18, 20, 22, 46 and 48.

5 16. The pharmaceutical preparation of claim 15, wherein the agent comprises a plurality of agents, each of which enriches selectively in the subject complexes of an HLA molecule and a different human CT antigen peptide, wherein at least one of the human CT antigens is encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:18, 20, 22, 46 and 48.

10

17. The pharmaceutical preparation of claim 15, wherein the agent is selected from the group consisting of

- (1) an isolated polypeptide comprising the human CT antigen peptide,
- (2) an isolated nucleic acid operably linked to a promoter for expressing the isolated
- 15 polypeptide,
- (3) a host cell expressing the isolated polypeptide, and
- (4) isolated complexes of the polypeptide, and an HLA molecule.

20

18. The pharmaceutical preparation of claims 15-17, further comprising an adjuvant.

19. The pharmaceutical preparation of claim 15, wherein the agent is a cell expressing an isolated polypeptide comprising the human CT antigen peptide, and wherein the cell is nonproliferative.

25

20. The pharmaceutical preparation of claim 15, wherein the agent is a cell expressing an isolated polypeptide comprising the human CT antigen peptide, and wherein the cell expresses an HLA molecule that binds the polypeptide.

30

21. The pharmaceutical preparation of claim 20, wherein the cell expresses one or both of the polypeptide and HLA molecule recombinantly.

22. The pharmaceutical preparation of claim 20, wherein the cell is nonproliferative.

23. A composition comprising

an isolated agent that binds selectively a polypeptide comprising an amino acid
sequence selected from the group consisting of SEQ ID NOs:21, 23, 25, 27, 29, 31, 35, 37,
5 39, 41 and 52.

24. The composition of matter of claim 23, wherein the agent is an antibody or an
antigen-binding fragment thereof.

10 25. The composition of claim 24, wherein the antibody is a monoclonal antibody, a
chimeric antibody or a humanized antibody.

26. A composition of matter comprising a conjugate of the agent of claims 23 or 24 and a
therapeutic or diagnostic agent.

15

27. The composition of matter of claim 26, wherein the conjugate is of the agent and a
therapeutic or diagnostic that is a toxin.

28. A pharmaceutical composition comprising

20 an isolated nucleic acid molecule comprising a nucleotide sequence selected from the
group consisting of SEQ ID NOs:18, 20, 22, 46 and 48, and
a pharmaceutically acceptable carrier.

29. The pharmaceutical composition of claim 28, wherein the isolated nucleic acid
25 molecule comprises at least two isolated nucleic acid molecules coding for two different
polypeptides, each polypeptide comprising a different human CT antigen.

30. The pharmaceutical composition of claims 28 or 29 further comprising an expression
vector with a promoter operably linked to the isolated nucleic acid molecule.

30

31. The pharmaceutical composition of claims 28 or 29 further comprising a host cell
recombinantly expressing the isolated nucleic acid molecule.

32. A pharmaceutical composition comprising
an isolated polypeptide comprising a polypeptide encoded by a nucleic acid molecule
comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:18, 20,
5 22, 46 and 48, and
a pharmaceutically acceptable carrier.

33. The pharmaceutical composition of claim 32, wherein the isolated polypeptide
comprises at least two different polypeptides, each comprising a different human CT antigen.

10 34. The pharmaceutical composition of claims 32 or 33, further comprising an adjuvant.

35. A protein microarray comprising at least one polypeptide encoded by a nucleic acid
molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID
15 NOs:18, 20, 22, 46 and 48, or an antigenic fragment of the polypeptide.

36. The microarray of claim 35, wherein the at least one polypeptide comprises an amino
acid sequence selected from the group consisting of SEQ ID NOs:19, 21, 23, 47, 49 and 50.

20 37. A protein microarray comprising at least one polypeptide encoded by a nucleic acid
molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID
NOs:24, 26, 28 and 30, or an antigenic fragment of the polypeptide.

38. The microarray of claim 37, wherein the at least one polypeptide comprises an amino
25 acid sequence selected from the group consisting of SEQ ID NOs:25, 27, 29 and 31.

39. A protein microarray comprising at least one polypeptide encoded by a nucleic acid
molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID
NOs:32, 34, 36, 38, 40 and 51, or an antigenic fragment of the polypeptide.

30 40. The microarray of claim 39, wherein the at least one polypeptide comprises an amino
acid sequence selected from the group consisting of SEQ ID NOs:33, 35, 37, 39, 41 and 52.

41. A protein microarray comprising a plurality of antibodies or antigen-binding fragments thereof that specifically bind at least one polypeptide encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID
5 NOs:18, 20, 22, 46 and 48, or an antigenic fragment of the polypeptide.

42. The microarray of claim 41, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:19, 21, 23, 47, 49 and 50.

10 43. A protein microarray comprising a plurality of antibodies or antigen-binding fragments thereof that specifically bind at least one polypeptide encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:24, 26, 28 and 30, or an antigenic fragment of the polypeptide.

15 44. The microarray of claim 43, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:25, 27, 29 and 31.

45. A protein microarray comprising a plurality of antibodies or antigen-binding fragments thereof that specifically bind at least one polypeptide encoded by a nucleic acid
20 molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:32, 34, 36, 38, 40 and 51, or an antigenic fragment of the polypeptide.

46. The microarray of claim 45, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:33, 35, 37, 39, 41 and 52.

25 47. A nucleic acid microarray comprising at least one nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:18, 20, 22, 46 and 48, or a fragment thereof of at least 20 nucleotides that selectively hybridizes to its complement in a biological sample.

30 48. A nucleic acid microarray comprising at least one nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:24, 26, 28 and 30, or

- 106 -

a fragment thereof of at least 20 nucleotides that selectively hybridizes to its complement in a biological sample.

49. A nucleic acid microarray comprising at least one nucleic acid molecule comprising a
5 nucleotide sequence selected from the group consisting of SEQ ID NOs:32, 34, 36, 38, 40
and 51, or a fragment thereof of at least 20 nucleotides that selectively hybridizes to its
complement in a biological sample.

50. An isolated fragment of a human CT antigen which, or a portion of which, binds a
10 HLA molecule or a human antibody, wherein the CT antigen is encoded by a nucleic acid
molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID
NOs:18, 20, 22, 46 and 48.

51. The fragment of claim 50, wherein the fragment is part of a complex with the HLA
15 molecule.

52. The fragment of claim 50, wherein the fragment is between 8 and 12 amino acids in
length.

20 53. A kit for detecting the expression of two or more human CT antigens comprising
two or more pairs of isolated nucleic acid molecules, each of which consists
essentially of a nucleic acid molecule selected from the group consisting of (a) a 12-32
nucleotide contiguous segment of the nucleotide sequence of any of SEQ ID NOs:18, 20, 22,
46 or 48, and (b) complements of (a), wherein the contiguous segments are nonoverlapping,
25 and wherein the nucleic acid molecules in each of the pairs are specific for a human CT
antigen.

54. The kit of claim 53, wherein the pair of isolated nucleic acid molecules is constructed
and arranged to selectively amplify at least a fragment of an isolated nucleic acid molecule
30 selected from the group consisting of SEQ ID NOs:18, 20, 22, 46 and 48.

55. A method for treating a subject with a cancer characterized by expression of a human CT antigen, comprising

administering to the subject an amount of an agent, which enriches selectively in the subject the presence of complexes of a HLA molecule and a human CT antigen peptide,
5 effective to ameliorate the disorder, wherein the human CT antigen peptide is a fragment of a human CT antigen encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:18, 20, 22, 46 and 48.

56. The method of claim 55, wherein the cancer is characterized by expression of a
10 plurality of human CT antigens and wherein the agent is a plurality of agents, each of which enriches selectively in the subject the presence of complexes of an HLA molecule and a different human CT antigen peptide, wherein at least one of the human CT antigens is encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:18, 20, 22, 46 and 48.

15 57. The method of claim 55, wherein the agent is an isolated polypeptide encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:18, 20, 22, 46 and 48.

20 58. A method for treating a subject having a cancer characterized by expression of a human CT antigen in cells of the subject, comprising:

(i) removing an immunoreactive cell containing sample from the subject,
(ii) contacting the immunoreactive cell containing sample to the host cell under
conditions favoring production of cytolytic T cells against a human CT antigen peptide that is
25 a fragment of the human CT antigen,

(iii) introducing the cytolytic T cells to the subject in an amount effective to lyse cells which express the human CT antigen, wherein the host cell is transformed or transfected with an expression vector comprising an isolated nucleic acid molecule operably linked to a promoter, wherein the isolated nucleic acid molecule comprises a nucleotide sequence
30 selected from the group consisting of SEQ ID NOs:18, 20, 22, 46 and 48.

- 108 -

59. The method of claim 58, wherein the host cell recombinantly expresses an HLA molecule which binds the human CT antigen peptide.

60. The method of claim 58, wherein the host cell endogenously expresses an HLA molecule which binds the human CT antigen peptide.

61. A method for treating a subject having a cancer characterized by expression of a human CT antigen in cells of the subject, comprising:

(i) identifying a nucleic acid molecule expressed by the cells of the cancer,

wherein the nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs:18, 20, 22, 46 and 48, or a fragment thereof;

(ii) transfecting a host cell with a nucleic acid molecule selected from the group consisting of (a) the nucleic acid molecule identified, (b) a fragment of the nucleic acid identified which includes a segment coding for a human CT antigen, (c) degenerates of (a) or (b);

(iii) culturing said transfected host cells to express the transfected nucleic acid molecule, and;

(iv) introducing an amount of said host cells or an extract thereof to the subject effective to increase an immune response against the cells of the subject associated with the condition.

62. The method of claim 61, further comprising identifying an MHC molecule which presents a portion of an expression product of the nucleic acid molecule, wherein the host cell expresses the same MHC molecule as identified and wherein the host cell presents an MHC binding portion of the expression product of the nucleic acid molecule.

63. The method of claim 61, wherein the immune response comprises a B-cell response or a T cell response.

64. The method of claim 63, wherein the response is a T-cell response which comprises generation of cytolytic T-cells specific for the host cells presenting the portion of the

- 109 -

expression product of the nucleic acid molecule or cells of the subject expressing the human CT antigen.

65. The method of claim 61, wherein the nucleic acid molecule is selected from the group
5 consisting of SEQ ID NOs:18, 20, 22, 46 and 48.

66. The method of claims 61 or 62, further comprising treating the host cells to render them non-proliferative.

10 67. A method for treating or diagnosing or monitoring a subject having a cancer characterized by expression of a protein encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:18, 20, 22, 46 and 48, in cells or tissues other than testis, comprising

administering to the subject an antibody which specifically binds to the protein or a
15 peptide derived therefrom, the antibody being coupled to a therapeutically or diagnostically useful agent, in an amount effective to treat, diagnose or monitor the condition.

68. The method of claim 67, wherein the antibody is a monoclonal antibody or an antigen-binding fragment thereof.

20 69. The method of claim 68, wherein the monoclonal antibody is a chimeric antibody or a humanized antibody.

70. A method for treating a cancer characterized by expression of a protein encoded by a
25 nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:18, 20, 22, 46 and 48, in cells or tissues other than testis, comprising

administering to a subject a pharmaceutical composition of any one of claims 15-22 and 28-34 in an amount effective to prevent, delay the onset of, or inhibit the condition in the subject.

30 71. The method of claim 70, further comprising first identifying that the subject expresses abnormal amounts of the protein in a non-testis tissue.

72. A method for treating a subject having a cancer characterized by expression of a protein encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:18, 20, 22, 46 and 48, in cells or tissues other than testis, comprising

- (i) identifying cells from the subject which express abnormal amounts of the protein;
- (ii) isolating a sample of the cells;
- (iii) cultivating the cells, and
- (iv) introducing the cells to the subject in an amount effective to provoke an immune

response against the cells.

73. The method of claim 72, further comprising rendering the cells non-proliferative, prior to introducing them to the subject.

74. A method for treating a pathological cell condition characterized by expression of a protein encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:18, 20, 22, 46 and 48, in cells or tissues other than testis, comprising

administering to a subject in need thereof an effective amount of an agent which inhibits the expression or activity of the protein.

75. The method of claim 74, wherein the agent is an inhibiting antibody which selectively binds to the protein and wherein the antibody is a monoclonal antibody, a chimeric antibody, a humanized antibody or an antibody fragment.

76. The method of claim 74, wherein the agent is an antisense nucleic acid molecule which selectively binds to the nucleic acid molecule which encodes the protein.

77. A composition of matter useful in stimulating an immune response to a plurality of a proteins comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:19, 21, 23, 47, 49 and 50 comprising

- 111 -

a plurality of peptides that are fragments of the proteins, wherein the peptides bind to one or more MHC molecules presented on the surface of non-testis cells.

78. The composition of matter of claim 77, wherein at least a portion of the plurality of peptides bind to MHC molecules and elicit a cytolytic response thereto.

79. The composition of matter of claim 77, wherein at least one of the proteins is encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:18, 20, 22, 46 and 48.

80. The composition of matter of claim 77, further comprising an adjuvant.

81. The composition of matter of claim 80, wherein said adjuvant is selected from the group consisting of saponins, GM-CSF, interleukins, and immunostimulatory oligonucleotides.

82. An isolated antibody which selectively binds to a complex of:

(i) a peptide that is a fragment of a protein comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:19, 21, 23, 47, 49 and 50, and

(ii) a MHC molecule to which binds the peptide to form the complex, wherein the isolated antibody does not bind to (i) or (ii) alone.

83. The antibody of claim 82, wherein the antibody is a monoclonal antibody, a chimeric antibody, a humanized antibody, or an antigen-binding fragment thereof.



84. A method for treating or diagnosing or monitoring a subject having a cancer characterized by expression of a protein encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:18, 20, 22, 46 and 48, in cells or tissues other than testis, comprising

administering to the subject the antibody of claim 82, the antibody being coupled to a therapeutically or diagnostically useful agent, in an amount effective to treat, diagnose or monitor the condition.

- 112 -

85. A method for treating or diagnosing or monitoring a subject having a cancer characterized by expression of a protein encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:18, 20, 22, 46 and
5 48, in cells or tissues other than testis, comprising
administering to the subject the antibody of claim 83, the antibody being coupled to a therapeutically or diagnostically useful agent, in an amount effective to treat, diagnose or monitor the condition.

Fig. 1



SEQUENCE LISTING

<110> LUDWIG INSTITUTE FOR CANCER RESEARCH

OLD, LLOYD

SCANLAN, MATTHEW

CHEN, YAO-TSENG

<120> CANCER-TESTIS ANTIGENS

<130> L0461/7125WO(JRV)

<150> 10/054,683

<151> 2002-01-22

<150> 60/280,718

<151> 2001-03-30

<150> 60/285,154

<151> 2001-04-20

<150> 60/327,432

<151> 2001-10-05

<160> 59

<170> PatentIn version 3.0

<210> 1

<211> 20

-2-

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide

<400> 1

aggaattatg aaaccacttg

20

<210> 2

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide

<400> 2

gacaacagtt gtatcagacc

20

<210> 3

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide

<400> 3

caaggagagg tcgtgtcttc g

21

<210> 4

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide

<400> 4

ggatcttggtt acatgctcac tcatatc

27

<210> 5

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide

<400> 5

ccagattaag aataacgttc

20

<210> 6

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide

<400> 6

agaggaaatg accaagagtc

20

<210> 7

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide

<400> 7
acaagactag cttatgtgtg g

21

<210> 8

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide

<400> 8
ttgagcaaga atcttgactt c

21

<210> 9

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide

<400> 9
gggagtattg acagtggcaa ttt

23

<210> 10

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide

<400> 10
tggtctcaat gtagcgcctt tc

22

-5-

<210> 11

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide

<400> 11

ccacctgtag ctataccagc cagactccc

29

<210> 12

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide

<400> 12

gcagagtccc ctccctgac

19

<210> 13

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide

<400> 13

acaggaactg gctctgctta aga

23

<210> 14

<211> 26

-6-

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide

<400> 14

tcaggacat ctccaggtgc atcctc

26

<210> 15

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide

<400> 15

ccagagtctc atgttaaaat cacttaca

28

<210> 16

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide

<400> 16

gaaacacttc ctctctttct ttaagtacaa

30

<210> 17

<211> 28

<212> DNA

<213> Artificial Sequence

-7-

<220>

<223> Synthetic Oligonucleotide

<400> 17

accagaaag accaccactt tgcaggta

28

<210> 18

<211> 2640

<212> DNA

<213> Homo Sapiens

<400> 18

catctcgcac ttccaactgc cctgtaacca ccaactgccc ttattccggc tgggacccag	60
gacttcaagc catgtgggtc ttgtttctgc tcagcgggct cggcgggctg cggatggaca	120
gtaattttga tagtttacct gtgcaaatta cagttccgga gaaaatacgg tcaataataa	180
aggaaggaat tgaatcgcag gcacccctaca aaattgtaat tgaagggaaa ccatatactg	240
tgaatttaat gcaaaaaaac tttttacccc ataattttag agtttacagt tatagtggca	300
caggaattat gaaaccactt gaccaagatt ttcagaattt ctgccactac caagggtata	360
ttgaagggtta tccaaaatct gtggtgatgg ttagcacatg tactggactc aggggcgtac	420
tacagtttga aaatgttagt tatggaatag aacccttgga gtcttcagtt ggctttgaac	480
atgtaattta ccaagtaaaa cataagaaag cagatgtttc cttatataat gagaaggata	540
ttgaatcaag agatctgtcc tttaaattac aaagcgcaga gccacagcaa gattttgcaa	600
agtatataga aatgcatgtt atagttgaaa aacaattgta taatcatatg gggctctgata	660
caactgttgt cgctcaaaaa gttttccagt tgattggatt gacgaatgct atttttgttt	720
catttaatat tacaattatt ctgtcttcat tggagctttg gatagatgaa aataaaattg	780
caaccactgg agaagctaag gagttattac acacattttt aagatggaaa acatcttatc	840
ttgttttacg tcctcatgat gtggcatttt tacttgttta cagagaaaag tcaaattatg	900
ttggtgcaac ctttcaaggg aagatgtgtg atgcaaacta tgcaggaggt gttgttctgc	960
acccagaaac cataagtctg gaatcacttg cagttatttt agctcaatta ttgagcctta	1020
gtatggggat cacttatgat gacattaaca aatgccagtg ctcaggagct gtctgcatta	1080
tgaatccaga agcaattcat ttcagtgggtg tgaagatctt tagtaactgc agcttcgaag	1140

actttgcaca ttttatttca aagcagaagt cccagtgtct tcacaatcag cctcgcttag 1200
atcctttttt caaacagcaa gcagtgtgtg gtaatgcaaa gctggaagca ggagaggagt 1260
gtgactgtgg gactgaacag gattgtgccc ttattggaga aacatgctgt gatattgcca 1320
catgtagatt taaagccggt tcaaactgtg ctgaaggacc atgctgcgaa aactgtctat 1380
ttatgtcaaa agaaagaatg tgtaggcctt cctttgaaga atgcgacctc cctgaatatt 1440
gcaatggatc atctgcatca tgcccagaaa accactatgt tcagactggg catccgtgtg 1500
gactgaatca atggatctgt atagatggag tttgtatgag tggggataaa caatgtacag 1560
acacatttgg caaagaagta gagtttggcc cttcagaatg ttattctcac ctttaattcaa 1620
agactgatgt atctggaaac tgtggtataa gtgattcagg atacacacag tgtgaagctg 1680
acaatctgca gtgcggaaaa ttaatatgta aatatgtagg taaattttta ttacaaattc 1740
caagagccac tattatttat gccaacataa gtggacatct ctgcattgct gtggaatttg 1800
ccagtgatca tgcagacagc caaaagatgt ggataaaaga tggaacttct tgtggttcaa 1860
ataaggtttg caggaatcaa agatgtgtga gttcttcata cttgggttat gattgtacta 1920
ctgacaaatg caatgataga ggtgtatgca ataacaaaaa gcactgtcac tgtagtgcct 1980
catatttacc tccagattgc tcagttcaat cagatctatg gcctgggtggg agtattgaca 2040
gtggcaattt tccacctgta gctataaccag ccagactccc tgaaaggcgc tacattgaga 2100
acatttacca ttccaaacca atgagatggc catttttctt attcattcct ttctttatta 2160
ttttctgtgt actgattgct ataatggtga aagttaattt ccaaaggaaa aaatggagaa 2220
ctgaggacta ttcaagcgat gagcaacctg aaagtgagag tgaacctaaa gggtagtctg 2280
gacaacagag atgccatgat atcacttctt ctagagtaat tatctgtgat ggatggacac 2340
aaaaaaatgg aaagaaaaga atgtacatta cctggtttcc tgggattcaa acctgcatat 2400
tgtgatttta atttgaccag aaaatatgat atatatgtat aatttcacag ataatttact 2460
tatttaaaaa tgcattgataa tgagttttac attacaaatt tctgtttttt taaagttatc 2520
ttacgctatt tctgttggtt agtagacact aattctgtca gtaggggcat ggtataagga 2580
aatatcataa tgtaatgagg tggtactatg attaaaagcc actgttacat ttcaaaaaaa 2640

<210> 19

<211> 734

<212> PRT

<213> Homo Sapiens

<400> 19

Met	Trp	Val	Leu	Phe	Leu	Leu	Ser	Gly	Leu	Gly	Gly	Leu	Arg	Met	Asp	1	5	10	15
Ser	Asn	Phe	Asp	Ser	Leu	Pro	Val	Gln	Ile	Thr	Val	Pro	Glu	Lys	Ile	20	25	30	
Arg	Ser	Ile	Ile	Lys	Glu	Gly	Ile	Glu	Ser	Gln	Ala	Ser	Tyr	Lys	Ile	35	40	45	
Val	Ile	Glu	Gly	Lys	Pro	Tyr	Thr	Val	Asn	Leu	Met	Gln	Lys	Asn	Phe	50	55	60	
Leu	Pro	His	Asn	Phe	Arg	Val	Tyr	Ser	Tyr	Ser	Gly	Thr	Gly	Ile	Met	65	70	75	80
Lys	Pro	Leu	Asp	Gln	Asp	Phe	Gln	Asn	Phe	Cys	His	Tyr	Gln	Gly	Tyr	85	90	95	
Ile	Glu	Gly	Tyr	Pro	Lys	Ser	Val	Val	Met	Val	Ser	Thr	Cys	Thr	Gly	100	105	110	
Leu	Arg	Gly	Val	Leu	Gln	Phe	Glu	Asn	Val	Ser	Tyr	Gly	Ile	Glu	Pro	115	120	125	
Leu	Glu	Ser	Ser	Val	Gly	Phe	Glu	His	Val	Ile	Tyr	Gln	Val	Lys	His	130	135	140	
Lys	Lys	Ala	Asp	Val	Ser	Leu	Tyr	Asn	Glu	Lys	Asp	Ile	Glu	Ser	Arg	145	150	155	160
Asp	Leu	Ser	Phe	Lys	Leu	Gln	Ser	Ala	Glu	Pro	Gln	Gln	Asp	Phe	Ala	165	170	175	
Lys	Tyr	Ile	Glu	Met	His	Val	Ile	Val	Glu	Lys	Gln	Leu	Tyr	Asn	His	180	185	190	
Met	Gly	Ser	Asp	Thr	Thr	Val	Val	Ala	Gln	Lys	Val	Phe	Gln	Leu	Ile	195	200	205	
Gly	Leu	Thr	Asn	Ala	Ile	Phe	Val	Ser	Phe	Asn	Ile	Thr	Ile	Ile	Leu	210	215	220	
Ser	Ser	Leu	Glu	Leu	Trp	Ile	Asp	Glu	Asn	Lys	Ile	Ala	Thr	Thr	Gly	225	230	235	240
Glu	Ala	Asn	Glu	Leu	Leu	His	Thr	Phe	Leu	Arg	Trp	Lys	Thr	Ser	Tyr	245	250	255	
Leu	Val	Leu	Arg	Pro	His	Asp	Val	Ala	Phe	Leu	Leu	Val	Tyr	Arg	Glu	260	265	270	
Lys	Ser	Asn	Tyr	Val	Gly	Ala	Thr	Phe	Gln	Gly	Lys	Met	Cys	Asp	Ala	275	280	285	
Asn	Tyr	Ala	Gly	Gly	Val	Val	Leu	His	Pro	Arg	Thr	Ile	Ser	Leu	Glu				

-10-

290					295					300						
Ser	Leu	Ala	Val	Ile	Leu	Ala	Gln	Leu	Leu	Ser	Leu	Ser	Met	Gly	Ile	
305					310					315					320	
Thr	Tyr	Asp	Asp	Ile	Asn	Lys	Cys	Gln	Cys	Ser	Gly	Ala	Val	Cys	Ile	
				325					330					335		
Met	Asn	Pro	Glu	Ala	Ile	His	Phe	Ser	Gly	Val	Lys	Ile	Phe	Ser	Asn	
			340					345					350			
Cys	Ser	Phe	Glu	Asp	Phe	Ala	His	Phe	Ile	Ser	Lys	Gln	Lys	Ser	Gln	
		355					360					365				
Cys	Leu	His	Asn	Gln	Pro	Arg	Leu	Asp	Pro	Phe	Phe	Lys	Gln	Gln	Ala	
	370					375					380					
Val	Cys	Gly	Asn	Ala	Lys	Leu	Glu	Ala	Gly	Glu	Glu	Cys	Asp	Cys	Gly	
385					390					395					400	
Thr	Glu	Gln	Asp	Cys	Ala	Leu	Ile	Gly	Glu	Thr	Cys	Cys	Asp	Ile	Ala	
				405					410					415		
Thr	Cys	Arg	Phe	Lys	Ala	Gly	Ser	Asn	Cys	Ala	Glu	Gly	Pro	Cys	Cys	
			420					425					430			
Glu	Asn	Cys	Leu	Phe	Met	Ser	Lys	Glu	Arg	Met	Cys	Arg	Pro	Ser	Phe	
		435					440					445				
Glu	Glu	Cys	Asp	Leu	Pro	Glu	Tyr	Cys	Asn	Gly	Ser	Ser	Ala	Ser	Cys	
	450					455					460					
Pro	Glu	Asn	His	Tyr	Val	Gln	Thr	Gly	His	Pro	Cys	Gly	Leu	Asn	Gln	
465					470					475					480	
Trp	Ile	Cys	Ile	Asp	Gly	Val	Cys	Met	Ser	Gly	Asp	Lys	Gln	Cys	Thr	
				485					490					495		
Asp	Thr	Phe	Gly	Lys	Glu	Val	Glu	Phe	Gly	Pro	Ser	Glu	Cys	Tyr	Ser	
			500					505					510			
His	Leu	Asn	Ser	Lys	Thr	Asp	Val	Ser	Gly	Asn	Cys	Gly	Ile	Ser	Asp	
		515					520					525				
Ser	Gly	Tyr	Thr	Gln	Cys	Glu	Ala	Asp	Asn	Leu	Gln	Cys	Gly	Lys	Leu	
	530					535					540					
Ile	Cys	Lys	Tyr	Val	Gly	Lys	Phe	Leu	Leu	Gln	Ile	Pro	Arg	Ala	Thr	
545					550					555					560	
Ile	Ile	Tyr	Ala	Asn	Ile	Ser	Gly	His	Leu	Cys	Ile	Ala	Val	Glu	Phe	
				565					570					575		
Ala	Ser	Asp	His	Ala	Asp	Ser	Gln	Lys	Met	Trp	Ile	Lys	Asp	Gly	Thr	
			580					585					590			
Ser	Cys	Gly	Ser	Asn	Lys	Val	Cys	Arg	Asn	Gln	Arg	Cys	Val	Ser	Ser	
		595					600					605				

-11-

Ser Tyr Leu Gly Tyr Asp Cys Thr Thr Asp Lys Cys Asn Asp Arg Gly
610 615 620

Val Cys Asn Asn Lys Lys His Cys His Cys Ser Ala Ser Tyr Leu Pro
625 630 635 640

Pro Asp Cys Ser Val Gln Ser Asp Leu Trp Pro Gly Gly Ser Ile Asp
645 650 655

Ser Gly Asn Phe Pro Pro Val Ala Ile Pro Ala Arg Leu Pro Glu Arg
660 665 670

Arg Tyr Ile Glu Asn Ile Tyr His Ser Lys Pro Met Arg Trp Pro Phe
675 680 685

Phe Leu Phe Ile Pro Phe Phe Ile Ile Phe Cys Val Leu Ile Ala Ile
690 695 700

Met Val Lys Val Asn Phe Gln Arg Lys Lys Trp Arg Thr Glu Asp Tyr
705 710 715 720

Ser Ser Asp Glu Gln Pro Glu Ser Glu Ser Glu Pro Lys Gly
725 730

<210> 20

<211> 528

<212> DNA

<213> Homo Sapiens

<400> 20

```

ggcacgaggc ttcgttcttt ccgccatctt cgttctttcc aacatcttcg ttcttttctca      60
ctgaccgaga ctcagccgtg agagatatga gtgagcatgt aacaagatcc caatcctcag      120
aaagaggaaa tgaccaagag tcttcccagc cagttggacc tgtgattgtc cagcagccca      180
ctgaggaaaa acgtcaagaa gaggaaccac caactgataa tcagggtatt gcacctagtg      240
gggagatcaa aaatgaagga gcacctgctg ttcaagggaac tgatgtggaa gctttttcaac      300
aggaactggc tctgcttaag atagaggatg cacctggaga tggtcctgat gtcagggagg      360
ggactctgcc cacttttgat ccactaaag tgctggaagc aggtgaaggg caactatagg      420
tttaaaccaa gacaaatgaa gactgaaacc aagaatattg ttcttatgct ggaaatttga      480
ctgctaacat tctcttaata aagttttaca gttttctgca aaaaaaaaaa      528

```

<210> 21

<211> 110

-12-

<212> PRT

<213> Homo Sapiens

<400> 21

```

Met Ser Glu His Val Thr Arg Ser Gln Ser Ser Glu Arg Gly Asn Asp
1           5           10           15
Gln Glu Ser Ser Gln Pro Val Gly Pro Val Ile Val Gln Gln Pro Thr
          20           25           30
Glu Glu Lys Arg Gln Glu Glu Glu Pro Pro Thr Asp Asn Gln Gly Ile
          35           40           45
Ala Pro Ser Gly Glu Ile Lys Asn Glu Gly Ala Pro Ala Val Gln Gly
          50           55           60
Thr Asp Val Glu Ala Phe Gln Gln Glu Leu Ala Leu Leu Lys Ile Glu
65           70           75           80
Asp Ala Pro Gly Asp Gly Pro Asp Val Arg Glu Gly Thr Leu Pro Thr
          85           90           95
Phe Asp Pro Thr Lys Val Leu Glu Ala Gly Glu Gly Gln Leu
          100          105          110

```

<210> 22

<211> 877

<212> DNA

<213> Homo Sapiens

<400> 22

```

ggcacgagggc ttgttcatgg catctttaga aacaaactgc aattttatatt catttccttg      60
tcgttcatac aaagattaca agactagctt atgtgtggac tgtgactggt ttaaggaaaa      120
atcatgtcct cggctggggt atcaagccaa gctatttaaa ggtgttttaa aagaaaggat      180
ggaaggaaga cctcttagga ccactgtggt tttggataca agtggtacat atccattctg      240
tacctattat tttgttctca gtataattgt tccagataaa actatgatgg atggctcgtt      300
ttcattttaa ttattaaatc agcttgaaat gattgaagag ccaaggcttt atgaaaagaa      360
caaaccattt tataaacttc aagaagtcaa gattcttget caattttata atgactttgt      420
aaatatttca agcattgggt tgacatattt ccagagctca aatctgcagt gttccacatg      480
cacatacaag atccagagtc tcatgttaaa atcacttaca taccagaaa gaccaccact      540
ttgcagggtat aatattgtac ttaaagaaag agaggaagtg tttcttaatc caaacacatg      600

```


-13-

tacaccaaag aacacataag atgccttctt ccatcaaag cacttgcttg tgaattaatg 660
gacttgtaaa tgaaacaatg caatcagtct ttataatac actgttcaat ttgagattca 720
agtatttcta tttcttgga aaaatttttaa gaatcaaaaa taaagaaaat aaaaagtgca 780
tacagttaaa cattcaaaa aaaaaaaaaa aaaaaaaaaa aaaattggcg gccgcaagct 840
tattcccttt agtgagggtt aatttttagct tggcact 877

<210> 23

<211> 205

<212> PRT

<213> Homo Sapiens

<400> 23

Ala Arg Gly Leu Phe Met Ala Ser Leu Glu Thr Asn Cys Asn Phe Ile
1 5 10 15
Ser Phe Pro Cys Arg Ser Tyr Lys Asp Tyr Lys Thr Ser Leu Cys Val
20 25 30
Asp Cys Asp Cys Phe Lys Glu Lys Ser Cys Pro Arg Leu Gly Tyr Gln
35 40 45
Ala Lys Leu Phe Lys Gly Val Leu Lys Glu Arg Met Glu Gly Arg Pro
50 55 60
Leu Arg Thr Thr Val Phe Leu Asp Thr Ser Gly Thr Tyr Pro Phe Cys
65 70 75 80
Thr Tyr Tyr Phe Val Leu Ser Ile Ile Val Pro Asp Lys Thr Met Met
85 90 95
Asp Gly Ser Phe Ser Phe Lys Leu Leu Asn Gln Leu Glu Met Ile Glu
100 105 110
Glu Pro Arg Leu Tyr Glu Lys Asn Lys Pro Phe Tyr Lys Leu Gln Glu
115 120 125
Val Lys Ile Leu Ala Gln Phe Tyr Asn Asp Phe Val Asn Ile Ser Ser
130 135 140
Ile Gly Leu Thr Tyr Phe Gln Ser Ser Asn Leu Gln Cys Ser Thr Cys
145 150 155 160
Thr Tyr Lys Ile Gln Ser Leu Met Leu Lys Ser Leu Thr Tyr Pro Glu
165 170 175
Arg Pro Pro Leu Cys Arg Tyr Asn Ile Val Leu Lys Glu Arg Glu Glu
180 185 190

Val Phe Leu Asn Pro Asn Thr Cys Thr Pro Lys Asn Thr
 195 200 205

<210> 24

<211> 2270

<212> DNA

<213> Homo Sapiens

<400> 24

```

gggcacattg cagattgttc gggtaaattt aaaatgctag agcatgccct acgtgatgcc      60
aagatggcgg agacttgtat tgtgaaagaa aagcaagatt ataagcagaa attgaaggca      120
cttaagattg aagtcaacaa actaaaagag gacctcaatg aaaagacgac agaaaataat      180
gagcaacgag aagagatcat tcgcctcaag caagagaaaa gttgcctgca cgatgaattg      240
ctttttactg tagagagaga aaagaggaaa gatgaattgc ttaatatgtc gaagtcaaag      300
caagaacgca caaattcaga actgcacaat ctgagacaga tttatgtaaa acaacagagt      360
gatctgcagt ttcttaattt caatgtggaa aattctcagg aattaatata gatgtatgac      420
tcaaagatgg aggaatcaaa ggctctggac tccagcagag acatgtgttt atcagacctt      480
gaaaataacc acccaaaagt cgatattaag agggaaaaaa atcagaagtc actgtttaag      540
gaccagaaat ttgaagccat gttggttcag caaaataggt cagacaagag ctcttgcgat      600
gaatgcaaag agaagaaaca acagatcgat actgtgtttg gggagaaaag tgtaattacg      660
ctgtcatcca tattcaccaa agacttagta gagaaacaca acctcccttg gtctctggga      720
ggaaaaaccc agattgaacc cgaaaacaaa attacattgt gcaagatcca cacaaaatca      780
ccaaaatgtc atggcactgg ggttcagaac gaaggaaaac aaccctcaga aacacccact      840
ttatctgatg agaagcagtg gcatgatgtc agtgtttacc tgggcctgac caactgtcca      900
agttcaaaac atccagaaaa gctggatgta gaatgtcaag atcagatgga aaggtccgaa      960
atctcatgct gccagaaaaa tgaagcctgt ctgggcgaaa gtggcatgtg tgactccaag     1020
tgctgccacc cgagtaactt cataattgaa gcccaggcc acatgtctga cgtggagtgg     1080
atgagtattt tcaagccttc caaaatgcag agaattgtcc gcctcaaata tgggtgcacc     1140
tgttcagaaa gcatctgtgg cacacaacat gactccccgg caagtgagct aattgccatc     1200
caagattccc actctttggg ttcttcaaaa tctgccttga gagaagatga gacggagtcc     1260
tcttccaata aaaagaactc acctacgagt ttgttaatct acaaagatgc accagcattc     1320

```


-15-

```

aatgaaaagg cttcaattgt gttaccctcc caggatgatt tctcgccac gagcaagctc 1380
cagcggtttgc tggcggaatc tcgtcagatg gtgacggacc tggagctgaa cacactgctg 1440
cccatcagcc atgagaatct cactggcagt gccacaaata tttctcatct atgtggaagg 1500
cagaaagcag acaccaatac tgaatgaata cttaaccgta aaactgaaag aggattctag 1560
ttcttcataa acggcactta attccagctg ggagcagaac tagaaagtta atttttaaac 1620
atctacactt cattttcaag ttaaccattt ttgtgctgaa gaaatatttt catgtgtaag 1680
aaagtagacc ttattgtaca tatagaaagt tggaattatg ctaagaatga aaaagacttc 1740
tctgtaaaga tacagactac agttaaatgc tagagaagct ctttaaaaat gtgaatgtca 1800
aatagagaaa gaaccctgc atagaaagtg ctgttttaac tatctgattt ttaaaaaatc 1860
tgtgcataca tttaaattct aaacaatagc ttatcagagt cagctcaaaa tatatgagaa 1920
acagtattct ctcatgggtt tagcttttga ctttgctgtg taaatagaca taagggtgctt 1980
tgatataaaa tataaagtgt aactggaaaa tagctcgagg tccttctgtc ccaagctgag 2040
cagagcccca tctttctggg tctatattag tcccacctac tgacacaaac aaaagcttgc 2100
tggaagatcg agtttttagac gcatttttaa aaatcttaaa gactaaaaca cttccatttt 2160
aacttgtaaa gtaatttaat tttttaaaga ttatactata tgcctctgtg tcttctctaa 2220
aagaatagat caacttcagt ccataaaaga tatttttaat attaaagaaa 2270

```

<210> 25

<211> 497

<212> PRT

<213> Homo Sapiens

<400> 25

```

Met Leu Glu His Ala Leu Arg Asp Ala Lys Met Ala Glu Thr Cys Ile
1           5           10          15

```

```

Val Lys Glu Lys Gln Asp Tyr Lys Gln Lys Leu Lys Ala Leu Lys Ile
20          25          30

```

```

Glu Val Asn Lys Leu Lys Glu Asp Leu Asn Glu Lys Thr Thr Glu Asn
35          40          45

```

```

Asn Glu Gln Arg Glu Glu Ile Ile Arg Leu Lys Gln Glu Lys Ser Cys
50          55          60

```

```

Leu His Asp Glu Leu Leu Phe Thr Val Glu Arg Glu Lys Arg Lys Asp
65          70          75          80

```


-16-

Glu Leu Leu Asn Ile Ala Lys Ser Lys Gln Glu Arg Thr Asn Ser Glu
 85 90 95
 Leu His Asn Leu Arg Gln Ile Tyr Val Lys Gln Gln Ser Asp Leu Gln
 100 105 110
 Phe Leu Asn Phe Asn Val Glu Asn Ser Gln Glu Leu Ile Gln Met Tyr
 115 120 125
 Asp Ser Lys Met Glu Glu Ser Lys Ala Leu Asp Ser Ser Arg Asp Met
 130 135 140
 Cys Leu Ser Asp Leu Glu Asn Asn His Pro Lys Val Asp Ile Lys Arg
 145 150 155 160
 Glu Lys Asn Gln Lys Ser Leu Phe Lys Asp Gln Lys Phe Glu Ala Met
 165 170 175
 Leu Val Gln Gln Asn Arg Ser Asp Lys Ser Ser Cys Asp Glu Cys Lys
 180 185 190
 Glu Lys Lys Gln Gln Ile Asp Thr Val Phe Gly Glu Lys Ser Val Ile
 195 200 205
 Thr Leu Ser Ser Ile Phe Thr Lys Asp Leu Val Glu Lys His Asn Leu
 210 215 220
 Pro Trp Ser Leu Gly Gly Lys Thr Gln Ile Glu Pro Glu Asn Lys Ile
 225 230 235 240
 Thr Leu Cys Lys Ile His Thr Lys Ser Pro Lys Cys His Gly Thr Gly
 245 250 255
 Val Gln Asn Glu Gly Lys Gln Pro Ser Glu Thr Pro Thr Leu Ser Asp
 260 265 270
 Glu Lys Gln Trp His Asp Val Ser Val Tyr Leu Gly Leu Thr Asn Cys
 275 280 285
 Pro Ser Ser Lys His Pro Glu Lys Leu Asp Val Glu Cys Gln Asp Gln
 290 295 300
 Met Glu Arg Ser Glu Ile Ser Cys Cys Gln Lys Asn Glu Ala Cys Leu
 305 310 315 320
 Gly Glu Ser Gly Met Cys Asp Ser Lys Cys Cys His Pro Ser Asn Phe
 325 330 335
 Ile Ile Glu Ala Pro Gly His Met Ser Asp Val Glu Trp Met Ser Ile
 340 345 350
 Phe Lys Pro Ser Lys Met Gln Arg Ile Val Arg Leu Lys Ser Gly Cys
 355 360 365
 Thr Cys Ser Glu Ser Ile Cys Gly Thr Gln His Asp Ser Pro Ala Ser
 370 375 380
 Glu Leu Ile Ala Ile Gln Asp Ser His Ser Leu Gly Ser Ser Lys Ser

-17-

385		390		395		400									
Ala	Leu	Arg	Glu	Asp	Glu	Thr	Glu	Ser	Ser	Ser	Asn	Lys	Lys	Asn	Ser
			405						410					415	
Pro	Thr	Ser	Leu	Leu	Ile	Tyr	Lys	Asp	Ala	Pro	Ala	Phe	Asn	Glu	Lys
			420					425					430		
Ala	Ser	Ile	Val	Leu	Pro	Ser	Gln	Asp	Asp	Phe	Ser	Pro	Thr	Ser	Lys
		435					440					445			
Leu	Gln	Arg	Leu	Leu	Ala	Glu	Ser	Arg	Gln	Met	Val	Thr	Asp	Leu	Glu
	450					455					460				
Leu	Asn	Thr	Leu	Leu	Pro	Ile	Ser	His	Glu	Asn	Leu	Thr	Gly	Ser	Ala
465					470					475					480
Thr	Asn	Ile	Ser	His	Leu	Cys	Gly	Arg	Gln	Lys	Ala	Asp	Thr	Asn	Thr
				485					490					495	

Glu

<210> 26

<211> 996

<212> DNA

<213> Homo Sapiens

<400> 26

gtatgttcct ggcagaaaag ttgcataact tgggggttaa agacaggaat atggcacaat	60
gcccattgtg ggcagtgtcc agacagaaga agagactcat atcacctaaa tgacaaaccc	120
agaatatgtc acaatgtatc ctgttgaaag gaccagaaac gaggatgaat tgccacatca	180
tctggttctg agttctgaga tattcacaag tccccttaga aaacaactca ggcaagagag	240
ttacatcacc taggagcccg ttccaccctt atgtcacagt gcttcatgtg tacaggacta	300
agaagaaagt cacatcacct agatgataga cccagagaca cgtcacaaag ccttcctgaa	360
agcatggccc tggcaaaata gtacaatcac ctttgtacct ggtctagcaa tatgtcatta	420
ttcaagtgtg caggtaccaa ggagaggagc catactacct atgttatatg ccctgtgcta	480
tgtcaaaatg ctttcttttc agcatggccc tggaagaatg tatcatctca catgtgactg	540
gcctaggaag atgtcactat cctgccatgt gtgcagggcc cattttagag attagagtta	600
tgtcttcttc taagtcatgg acccagtgat atatcactat gatgtctgtg agaatgggca	660
ggcaggaatg taatgtcact tgcattctag atccagtgat gtcacaattc ttactgaggg	720
cagagcccag tcagaagagt catatctttt acaggttggc ccaagtagat gtcaaaaacc	780

-18-

cctatggatt agatttaciaa taccacacat ctcttgttt catgtaggag agttgcctgc 840
 attcatctgt gatgatgaaa gtccttactg tcagccaagt gtgcatatga gactcacaat 900
 ttcctctgtt tgctaaccac tattatgaca ctctctatcc aaccacaagg ttttataaaa 960
 catttgatcat tgttataaaa aaaaaaaaaa aaaaaa 996

<210> 27

<211> 90

<212> PRT

<213> Homo Sapiens

<400> 27

Met Ile Asp Pro Glu Thr Arg His Lys Ala Phe Leu Lys Ala Trp Pro
 1 5 10 15
 Trp Gln Asn Ser Thr Ile Thr Phe Val Pro Gly Leu Ala Ile Cys His
 20 25 30
 Tyr Ser Ser Val Gln Val Pro Arg Arg Gly Ala Ile Leu Pro Met Leu
 35 40 45
 Tyr Ala Leu Cys Tyr Val Lys Met Pro Ser Phe Gln His Gly Pro Gly
 50 55 60
 Arg Met Tyr His Leu Thr Cys Asp Trp Pro Arg Lys Met Ser Leu Ser
 65 70 75 80
 Cys His Val Cys Arg Ala His Phe Arg Asp
 85 90

<210> 28

<211> 2347

<212> DNA

<213> Homo Sapiens

<400> 28

gggaggtttg gagccctgca taaagagaag gacgggacca cagctgactg ctgtgtcccc 60
 acagatctgg gcctcctgct gccaccatgg ccaaagggtgg agaagccctg ccacagggca 120
 gccagcacc agtccaggat cccacacctca tcaaggtgac agtgaagacg cccaaagaca 180
 aggaggattt ctcatgtaca gacacatgca ctatccagca gctgaaggaa gagatatctc 240

agcgctttaa ggcccacccc gatcagcttg ttctaattctt tgctggcaaa atcctcaagg 300
atcctgactc actggcacag tgtggagtgc gagatggcct cactgtccac ctggatcatca 360
agaggcagca ccgtgccatg ggcaatgagt gccagctgc ctctgtccct acccagggcc 420
caagtccctgg atcactccct cagccaagct ccatttaccc agcagatggg cccctgcct 480
ttagcttagg tctcctcaca ggcctcagta ggctgggctt ggcctatcgt ggcttccctg 540
accagccaag ctccctgatg cggcagcatg tgtctgtgcc tgagtttgtg actcagctca 600
ttgatgacct cttcatcccg ggtctgctgt ccaacacagg cctagtacgc cagctgggtc 660
ttgacaacct ccatatgcag cagctgatcc agcacaacct tgagattggg catattctta 720
acaaccgga aattatgcgg cagacactgg agtttttacg taaccctgcc atgatgcagg 780
agatgatacg tagccaggac cgggtgctca gtaacttga gagcattcct ggtggctaca 840
atgtgctttg cactatgtac acagatatta tggaccaat gcttaacgca gtccaggagc 900
agtttggcgg caatcccttt gccactgcca ctactgataa tgccaccacc accaccagcc 960
aaccttcaag gatggagaat tgtgaccctc tccccaacct ctggacttcc acacatggag 1020
gctcaggtag caggcaagga aggcaggatg gggatcagga tgcacctgac attagaaata 1080
ggtttccaaa ctttctgggt attataaggc tctatgacta tctccagcaa ttacacgaga 1140
acccccagtc cctaggaact tatctacagg ggactgcac tgccctcagc caaagccagg 1200
aaccaccacc atcagtaaac agagttcccc catcgtcacc ctcatctcag gagcctgggt 1260
caggccagcc tctccccgag gagttagtag caatcaaggg aaggctctcc tgcccagctt 1320
tcctgagata cccacagag aacagtactg gacaagggtg agaccaagat ggtgcaggga 1380
aaagctctac tggacatagc acaaacttgc ctgatcttgt ctgggggctg ggagattctg 1440
ccaacagggt tccatttgct cccttatctt tttccccac ggcagccatt cctggaatcc 1500
ctgagcctcc ctggctgcca tccccggctt atccaagatc tctgaggcca gatggcatga 1560
atccagctcc acagttacag gatgagatac aaccacagct gccactgctg atgcaccttc 1620
aggcagccat ggcaaacccc cgtgccctgc aagccctgcg gcagattgag cagggtctac 1680
aggctctagc tactgaagca cctcgcctcc tactctgggt catgccttgc ctagcaggga 1740
cgggtagtgt ggcaggaggt atagagtcta gagaagatcc ccttatgtct gaggatcctc 1800
tcccaaatac acctcctgag gtgttcccag cactggactc tgcagagctg ggcttccctt 1860
cccctccctt tctccatatg ctgcaagatt tagttagtac aaatccccag cagctgcagc 1920
ctgaggctca ctttcagggt cagctggagc aactgcggtc catgggcttt ctgaatcgtg 1980
aagccaatct tcaggccctc attgctacgg ggggcgacgt ggatgctgct gtggagaagc 2040

-20-

tgagacagtc gtaggagcct tattcattca aaccatacgt tttcctctgt gcctttttcc 2100
 catatcctag ttccctagct ctcccatttt tgaatacagc tgcattataa accaaattta 2160
 ctatgaagtc ctttgctgtg gaggcaatgt tgttccagag tcaacgagga agactaatgg 2220
 ccaaaacata gtggaggtgc tgtgtgtgag tcaaccactt gtaccactat accactgggg 2280
 ggccccagtc taagctctgc ttatgcctat cttgagatgc aattacaccc aattttccaat 2340
 gtgaaaa 2347

<210> 29

<211> 655

<212> PRT

<213> Homo Sapiens

<400> 29

Met	Ala	Lys	Gly	Gly	Glu	Ala	Leu	Pro	Gln	Gly	Ser	Pro	Ala	Pro	Val	1	5	10	15
Gln	Asp	Pro	His	Leu	Ile	Lys	Val	Thr	Val	Lys	Thr	Pro	Lys	Asp	Lys	20	25	30	
Glu	Asp	Phe	Ser	Val	Thr	Asp	Thr	Cys	Thr	Ile	Gln	Gln	Leu	Lys	Glu	35	40	45	
Glu	Ile	Ser	Gln	Arg	Phe	Lys	Ala	His	Pro	Asp	Gln	Leu	Val	Leu	Ile	50	55	60	
Phe	Ala	Gly	Lys	Ile	Leu	Lys	Asp	Pro	Asp	Ser	Leu	Ala	Gln	Cys	Gly	65	70	75	80
Val	Arg	Asp	Gly	Leu	Thr	Val	His	Leu	Val	Ile	Lys	Arg	Gln	His	Arg	85	90	95	
Ala	Met	Gly	Asn	Glu	Cys	Pro	Ala	Ala	Ser	Val	Pro	Thr	Gln	Gly	Pro	100	105	110	
Ser	Pro	Gly	Ser	Leu	Pro	Gln	Pro	Ser	Ser	Ile	Tyr	Pro	Ala	Asp	Gly	115	120	125	
Pro	Pro	Ala	Phe	Ser	Leu	Gly	Leu	Leu	Thr	Gly	Leu	Ser	Arg	Leu	Gly	130	135	140	
Leu	Ala	Tyr	Arg	Gly	Phe	Pro	Asp	Gln	Pro	Ser	Ser	Leu	Met	Arg	Gln	145	150	155	160
His	Val	Ser	Val	Pro	Glu	Phe	Val	Thr	Gln	Leu	Ile	Asp	Asp	Pro	Phe	165	170	175	

-21-

Ile Pro Gly Leu Leu Ser Asn Thr Gly Leu Val Arg Gln Leu Val Leu
 180 185 190
 Asp Asn Pro His Met Gln Gln Leu Ile Gln His Asn Pro Glu Ile Gly
 195 200 205
 His Ile Leu Asn Asn Pro Glu Ile Met Arg Gln Thr Leu Glu Phe Leu
 210 215 220
 Arg Asn Pro Ala Met Met Gln Glu Met Ile Arg Ser Gln Asp Arg Val
 225 230 235 240
 Leu Ser Asn Leu Glu Ser Ile Pro Gly Gly Tyr Asn Val Leu Cys Thr
 245 250 255
 Met Tyr Thr Asp Ile Met Asp Pro Met Leu Asn Ala Val Gln Glu Gln
 260 265 270
 Phe Gly Gly Asn Pro Phe Ala Thr Ala Thr Thr Asp Asn Ala Thr Thr
 275 280 285
 Thr Thr Ser Gln Pro Ser Arg Met Glu Asn Cys Asp Pro Leu Pro Asn
 290 295 300
 Pro Trp Thr Ser Thr His Gly Gly Ser Gly Ser Arg Gln Gly Arg Gln
 305 310 315 320
 Asp Gly Asp Gln Asp Ala Pro Asp Ile Arg Asn Arg Phe Pro Asn Phe
 325 330 335
 Leu Gly Ile Ile Arg Leu Tyr Asp Tyr Leu Gln Gln Leu His Glu Asn
 340 345 350
 Pro Gln Ser Leu Gly Thr Tyr Leu Gln Gly Thr Ala Ser Ala Leu Ser
 355 360 365
 Gln Ser Gln Glu Pro Pro Pro Ser Val Asn Arg Val Pro Pro Ser Ser
 370 375 380
 Pro Ser Ser Gln Glu Pro Gly Ser Gly Gln Pro Leu Pro Glu Glu Ser
 385 390 395 400
 Val Ala Ile Lys Gly Arg Ser Ser Cys Pro Ala Phe Leu Arg Tyr Pro
 405 410 415
 Thr Glu Asn Ser Thr Gly Gln Gly Gly Asp Gln Asp Gly Ala Gly Lys
 420 425 430
 Ser Ser Thr Gly His Ser Thr Asn Leu Pro Asp Leu Val Ser Gly Leu
 435 440 445
 Gly Asp Ser Ala Asn Arg Val Pro Phe Ala Pro Leu Ser Phe Ser Pro
 450 455 460
 Thr Ala Ala Ile Pro Gly Ile Pro Glu Pro Pro Trp Leu Pro Ser Pro
 465 470 475 480
 Ala Tyr Pro Arg Ser Leu Arg Pro Asp Gly Met Asn Pro Ala Pro Gln
 485 490 495

-22-

Leu Gln Asp Glu Ile Gln Pro Gln Leu Pro Leu Leu Met His Leu Gln
 500 505 510
 Ala Ala Met Ala Asn Pro Arg Ala Leu Gln Ala Leu Arg Gln Ile Glu
 515 520 525
 Gln Gly Leu Gln Val Leu Ala Thr Glu Ala Pro Arg Leu Leu Leu Trp
 530 535 540
 Phe Met Pro Cys Leu Ala Gly Thr Gly Ser Val Ala Gly Gly Ile Glu
 545 550 555 560
 Ser Arg Glu Asp Pro Leu Met Ser Glu Asp Pro Leu Pro Asn Pro Pro
 565 570 575
 Pro Glu Val Phe Pro Ala Leu Asp Ser Ala Glu Leu Gly Phe Leu Ser
 580 585 590
 Pro Pro Phe Leu His Met Leu Gln Asp Leu Val Ser Thr Asn Pro Gln
 595 600 605
 Gln Leu Gln Pro Glu Ala His Phe Gln Val Gln Leu Glu Gln Leu Arg
 610 615 620
 Ser Met Gly Phe Leu Asn Arg Glu Ala Asn Leu Gln Ala Leu Ile Ala
 625 630 635 640
 Thr Gly Gly Asp Val Asp Ala Ala Val Glu Lys Leu Arg Gln Ser
 645 650 655

<210> 30

<211> 899

<212> DNA

<213> Homo Sapiens

<400> 30

ctagagagta tagggcagaa ggatggcaga tgagtgactc cacatccaga gctgcctccc 60
 tttaatccag gatcctgtcc ttcctgtcct gtaggagtgc ctgttgccag tgtgggggtga 120
 gacaagtttg tcccacaggg ctgtctgagc agataagatt aagggtggg tctgtgctca 180
 attaactcct gtgggcacgg gggctgggaa gagcaaagtc agcgggtgcct acagtcagca 240
 ccatgctggg cctgccgtgg aaggagggtc tgtcctgggc gctgctgctg cttctcttag 300
 gctcccagat cctgctgata tatgcctggc attccacga gcaaaggac tgtgatgaac 360
 acaatgtcat ggctcggttac ctccctgcca cagtggagtt tgctgtccac acattcaacc 420
 aacagagcaa ggactactat gcctacagac tggggcacat cttgaattcc tggaaggagc 480
 aggtggagtc caagactgta ttctcaatgg agctactgct ggggagaact aggtgtggga 540

-23-

aatttgaaga cgacattgac aactgccatt tccaagaaag cacagagctg aacaatactt 600
tcacctgctt cttcaccatc agcaccaggc cctggatgac tcagttcagc ctcctgaaca 660
agacctgctt ggagggattc cactgagtga aaccactca caggcttgtc catgtgctgc 720
tcccacattc cgtggacatc agcactactc tcttgaggac tcttcagtgg ctgagcagct 780
ttggacttgt ttgttatcct attttgcattg tgtttgagat ctcagatcag tgtttttagaa 840
aatccacaca tcttgagcct aatcatgtag tgtagatcat taaacatcag cattttaag 899

<210> 31

<211> 147

<212> PRT

<213> Homo Sapiens

<400> 31

Met Leu Gly Leu Pro Trp Lys Gly Gly Leu Ser Trp Ala Leu Leu Leu
1 5 10 15
Leu Leu Leu Gly Ser Gln Ile Leu Leu Ile Tyr Ala Trp His Phe His
20 25 30
Glu Gln Arg Asp Cys Asp Glu His Asn Val Met Ala Arg Tyr Leu Pro
35 40 45
Ala Thr Val Glu Phe Ala Val His Thr Phe Asn Gln Gln Ser Lys Asp
50 55 60
Tyr Tyr Ala Tyr Arg Leu Gly His Ile Leu Asn Ser Trp Lys Glu Gln
65 70 75 80
Val Glu Ser Lys Thr Val Phe Ser Met Glu Leu Leu Leu Gly Arg Thr
85 90 95
Arg Cys Gly Lys Phe Glu Asp Asp Ile Asp Asn Cys His Phe Gln Glu
100 105 110
Ser Thr Glu Leu Asn Asn Thr Phe Thr Cys Phe Phe Thr Ile Ser Thr
115 120 125
Arg Pro Trp Met Thr Gln Phe Ser Leu Leu Asn Lys Thr Cys Leu Glu
130 135 140
Gly Phe His
145

<210> 32

<211> 2186

<212> DNA

<213> Homo Sapiens

<400> 32

tggagaggcc acagctgctg gcttcctggg cttctccaaa ctctgtgtg tgcgcactgc	60
caccggcagg gagccaggag agagacagaa aggggctgag acagaatgat caaaaggaga	120
gccaccctg gtgcgggagg cgacaggacc aggcctcgac ggcgccgttc cactgagagc	180
tggattgaaa gatgtctcaa cgaaagtga aacaaacgtt attccagcca cacatctctg	240
gggaatgttt ctaatgatga aaatgaggaa aaagaaaata atagagcatc caagccccac	300
tccactcctg ctactctgca atggctggag gagaactatg agattgcaga gggggctctgc	360
atccctcgca gtgccctcta tatgcattac ctggatttct gcgagaagaa tgatacccaa	420
cctgtcaatg ctgccagctt tggaaagatc ataaggcagc agtttcctca gttaaccacc	480
agaagactcg ggacccgagg acagtcaaag taccattact atggcattgc agtgaaagaa	540
agctcccaat attatgatgt gatgtattcc aagaaaggag ctgcctgggt gagtgagacg	600
ggcaagaaag aagtgagcaa acagacagtg gcatattcac cccgggtccaa actcggaaca	660
ctgctgccag aatttcccaa tgtcaaagat ctaaactctgc cagccagcct gcctgaggag	720
aaggtttcta cttttattat gatgtacaga acacactgtc agagaatact ggacactgta	780
ataagagcca actttgatga ggttcaaagt ttccttctgc acttttggca aggaatgccg	840
ccccacatgc tgctgtgct gggctcctcc acggtgggtga acattgtcgg cgtgtgtgac	900
tccatcctct acaaagctat ctccgggggtg ctgatgccca ctgtgctgca ggcattacct	960
gacagcttaa ctgaggtgat tcgaaagttt gccaaagcaac tggatgagtg gctaaaagtg	1020
gctctccacg acctcccaga aaacttgca aacatcaagt tcgaattgtc gagaagggtc	1080
tcccaaattc tgagacggca aacatcacta aatcatctct gccaggcatc tcgaacagtg	1140
atccacagtg cagacatcac gttccaaatg ctggaagact ggaggaacgt ggacctgaac	1200
agcatcacca agcaaaccct ttacaccatg gaagactctc gcgatgagca ccggaaactc	1260
atcacccaat tatatcagga gtttgaccat ctcttggagg agcagtctcc catcgagtcc	1320
tacattgagt ggctggatac catggttgac cgctgtgttg tgaagggtggc tgccaagaga	1380
caagggtcct tgaagaaagt ggcccagcag ttcctcttga tgtggtcctg tttcggcaca	1440
agggtgatcc gggacatgac cttgcacagc gccccagct tcgggtcttt tcacctaatt	1500

-25-

cacttaatgt ttgatgacta cgtgctctac ctgttagaat ctctgcactg tcaggagcgg 1560
 gccaatgagc tcatgcgagc catgaaggga gaaggaagca ctgcagaagt ccgagaagag 1620
 atcatcttga cagaggctgc cgcaccaacc ccttcaccag tgccatcggt ttctccagca 1680
 aaatctgcca catctgtgga agtgccacct ccctcttccc ctgttagcaa tccttcccct 1740
 gagtacactg gcctcagcac tacaggtaat ggaaagtcct tcaaaaactt tgggtagtta 1800
 atgtttgaag aaagggtttt ctgccagcct gggcaacata gtgagacttc atttccacac 1860
 acacaaaaag ccagacatct tggctcacac ctgtagtccc agctacttgg gaggctgagg 1920
 tgggagaatt gcttgagccc aggagctacg atcgcaccac tgcattctag ccttagtgat 1980
 acagtgagac cttgtctcaa aaaaggaaaa acagggtttt ctggaaaaac attcttctcc 2040
 cacaatctcc aaaagataat gccaaaacct gggatatctc ctggatttgt gaatgacgta 2100
 caggtattca tttattcatt ggtacacatt ctgtatgctg ctgttttcaa gttggcaa 2160
 taagcatatg ataaaatccc aaaact 2186

<210> 33

<211> 563

<212> PRT

<213> Homo Sapiens

<400> 33

Met Ile Lys Arg Arg Ala His Pro Gly Ala Gly Gly Asp Arg Thr Arg
 1 5 10 15
 Pro Arg Arg Arg Arg Ser Thr Glu Ser Trp Ile Glu Arg Cys Leu Asn
 20 25 30
 Glu Ser Glu Asn Lys Arg Tyr Ser Ser His Thr Ser Leu Gly Asn Val
 35 40 45
 Ser Asn Asp Glu Asn Glu Glu Lys Glu Asn Asn Arg Ala Ser Lys Pro
 50 55 60
 His Ser Thr Pro Ala Thr Leu Gln Trp Leu Glu Glu Asn Tyr Glu Ile
 65 70 75 80
 Ala Glu Gly Val Cys Ile Pro Arg Ser Ala Leu Tyr Met His Tyr Leu
 85 90 95
 Asp Phe Cys Glu Lys Asn Asp Thr Gln Pro Val Asn Ala Ala Ser Phe
 100 105 110
 Gly Lys Ile Ile Arg Gln Gln Phe Pro Gln Leu Thr Thr Arg Arg Leu

-26-

115					120					125					
Gly	Thr	Arg	Gly	Gln	Ser	Lys	Tyr	His	Tyr	Tyr	Gly	Ile	Ala	Val	Lys
130						135					140				
Glu	Ser	Ser	Gln	Tyr	Tyr	Asp	Val	Met	Tyr	Ser	Lys	Lys	Gly	Ala	Ala
145					150					155					160
Trp	Val	Ser	Glu	Thr	Gly	Lys	Lys	Glu	Val	Ser	Lys	Gln	Thr	Val	Ala
				165					170					175	
Tyr	Ser	Pro	Arg	Ser	Lys	Leu	Gly	Thr	Leu	Leu	Pro	Glu	Phe	Pro	Asn
			180					185					190		
Val	Lys	Asp	Leu	Asn	Leu	Pro	Ala	Ser	Leu	Pro	Glu	Glu	Lys	Val	Ser
		195					200					205			
Thr	Phe	Ile	Met	Met	Tyr	Arg	Thr	His	Cys	Gln	Arg	Ile	Leu	Asp	Thr
	210					215					220				
Val	Ile	Arg	Ala	Asn	Phe	Asp	Glu	Val	Gln	Ser	Phe	Leu	Leu	His	Phe
225					230					235					240
Trp	Gln	Gly	Met	Pro	Pro	His	Met	Leu	Pro	Val	Leu	Gly	Ser	Ser	Thr
				245					250					255	
Val	Val	Asn	Ile	Val	Gly	Val	Cys	Asp	Ser	Ile	Leu	Tyr	Lys	Ala	Ile
			260					265					270		
Ser	Gly	Val	Leu	Met	Pro	Thr	Val	Leu	Gln	Ala	Leu	Pro	Asp	Ser	Leu
		275					280					285			
Thr	Gln	Val	Ile	Arg	Lys	Phe	Ala	Lys	Gln	Leu	Asp	Glu	Trp	Leu	Lys
	290					295					300				
Val	Ala	Leu	His	Asp	Leu	Pro	Glu	Asn	Leu	Arg	Asn	Ile	Lys	Phe	Glu
305					310					315					320
Leu	Ser	Arg	Arg	Phe	Ser	Gln	Ile	Leu	Arg	Arg	Gln	Thr	Ser	Leu	Asn
				325					330					335	
His	Leu	Cys	Gln	Ala	Ser	Arg	Thr	Val	Ile	His	Ser	Ala	Asp	Ile	Thr
			340					345					350		
Phe	Gln	Met	Leu	Glu	Asp	Trp	Arg	Asn	Val	Asp	Leu	Asn	Ser	Ile	Thr
		355					360					365			
Lys	Gln	Thr	Leu	Tyr	Thr	Met	Glu	Asp	Ser	Arg	Asp	Glu	His	Arg	Lys
		370				375					380				
Leu	Ile	Thr	Gln	Leu	Tyr	Gln	Glu	Phe	Asp	His	Leu	Leu	Glu	Glu	Gln
385					390					395					400
Ser	Pro	Ile	Glu	Ser	Tyr	Ile	Glu	Trp	Leu	Asp	Thr	Met	Val	Asp	Arg
				405					410					415	
Cys	Val	Val	Lys	Val	Ala	Ala	Lys	Arg	Gln	Gly	Ser	Leu	Lys	Lys	Val
			420					425					430		

-27-

Ala Gln Gln Phe Leu Leu Met Trp Ser Cys Phe Gly Thr Arg Val Ile
435 440 445

Arg Asp Met Thr Leu His Ser Ala Pro Ser Phe Gly Ser Phe His Leu
450 455 460

Ile His Leu Met Phe Asp Asp Tyr Val Leu Tyr Leu Leu Glu Ser Leu
465 470 475 480

His Cys Gln Glu Arg Ala Asn Glu Leu Met Arg Ala Met Lys Gly Glu
485 490 495

Gly Ser Thr Ala Glu Val Arg Glu Glu Ile Ile Leu Thr Glu Ala Ala
500 505 510

Ala Pro Thr Pro Ser Pro Val Pro Ser Phe Ser Pro Ala Lys Ser Ala
515 520 525

Thr Ser Val Glu Val Pro Pro Pro Ser Ser Pro Val Ser Asn Pro Ser
530 535 540

Pro Glu Tyr Thr Gly Leu Ser Thr Thr Gly Asn Gly Lys Ser Phe Lys
545 550 555 560

Asn Phe Gly

<210> 34

<211> 558

<212> DNA

<213> Homo Sapiens

<400> 34

acagacaaat ggtttatcta ctattggagc catgggtcct gggaatattg gaccacccca 60
aatagaagag ctcaaagtca tccctgaaac cagcgaggaa aataatgagg acatctggaa 120
ttcagaagag attccagaag gagcagaata tgatgatatg tgggatgtta gagaaatccc 180
agagtatgag attatattca gacagcaggt gggaactgaa gatataattt tagggttgtc 240
aaaaaaggac tcctcaacag gttgttgcag tgaactagt gctaaaatta aattgccaaa 300
tacaaaccct tctgatattc aaattgatat ccaggaaaca atccttgacc ttcgtactcc 360
tcagaagaag ctgttgataa ctcttcctga gctggtggaa tgtaccagt ccaaagcatt 420
ctatatccca gagactgaaa ctcttgaaat ccctatgact atgaaaagag agttagatat 480
tgctaatttc ttctgaaact gcatgaaaaa gataaaaagt agtaaaatgg cattggtaac 540
aataaaaaaa ctttgaaa 558

-28-

<210> 35

<211> 164

<212> PRT

<213> Homo Sapiens

<400> 35

Gln Thr Asn Gly Leu Ser Thr Ile Gly Ala Met Gly Pro Gly Asn Ile
1 5 10 15

Gly Pro Pro Gln Ile Glu Glu Leu Lys Val Ile Pro Glu Thr Ser Glu
20 25 30

Glu Asn Asn Glu Asp Ile Trp Asn Ser Glu Glu Ile Pro Glu Gly Ala
35 40 45

Glu Tyr Asp Asp Met Trp Asp Val Arg Glu Ile Pro Glu Tyr Glu Ile
50 55 60

Ile Phe Arg Gln Gln Val Gly Thr Glu Asp Ile Phe Leu Gly Leu Ser
65 70 75 80

Lys Lys Asp Ser Ser Thr Gly Cys Cys Ser Glu Leu Val Ala Lys Ile
85 90 95

Lys Leu Pro Asn Thr Asn Pro Ser Asp Ile Gln Ile Asp Ile Gln Glu
100 105 110

Thr Ile Leu Asp Leu Arg Thr Pro Gln Lys Lys Leu Leu Ile Thr Leu
115 120 125

Pro Glu Leu Val Glu Cys Thr Ser Ala Lys Ala Phe Tyr Ile Pro Glu
130 135 140

Thr Glu Thr Leu Glu Ile Pro Met Thr Met Lys Arg Glu Leu Asp Ile
145 150 155 160

Ala Asn Phe Phe

<210> 36

<211> 538

<212> DNA

<213> Homo Sapiens

<400> 36

ggcacgaggt cgaaaactcc tggaaccctc tgagagagga cagtttccag actcctcggt 60

agggacgcgg gaagagacca tgtgtgggaa atatgagtga gcatgtgaga acaagatccc 120

-29-

aatcctcaga aagaggaaat gaccaagagt cttcccagcc agttggatct gtgattgtcc 180
 aggagcccac tgaggaaaaa cgtcaagaag aggaaccacc aactgataat cagggatttg 240
 cacctagtgg ggagatcgaa aatgaaggag cacctgccgt tcaagggcct gacatggaag 300
 cttttcaaca ggaactggct ctgcttaaga tagaggatga gcctggagat ggtcctgatg 360
 tcagggaggg gattatgccc acttttgatc tcactaaagt gctggaagca ggtgatgcgc 420
 aaccataggt ttcaagcaag acaaataag actgaaacca agaacgttat tcttaatctg 480
 gaaatttgac tgataatatt ctcttaataa agttttaagt tttctgcaaa gaaaaaaa 538

<210> 37

<211> 111

<212> PRT

<213> Homo Sapiens

<400> 37

Met Ser Glu His Val Arg Thr Arg Ser Gln Ser Ser Glu Arg Gly Asn
 1 5 10 15
 Asp Gln Glu Ser Ser Gln Pro Val Gly Ser Val Ile Val Gln Glu Pro
 20 25 30
 Thr Glu Glu Lys Arg Gln Glu Glu Glu Pro Pro Thr Asp Asn Gln Gly
 35 40 45
 Ile Ala Pro Ser Gly Glu Ile Glu Asn Glu Gly Ala Pro Ala Val Gln
 50 55 60
 Gly Pro Asp Met Glu Ala Phe Gln Gln Glu Leu Ala Leu Leu Lys Ile
 65 70 75 80
 Glu Asp Glu Pro Gly Asp Gly Pro Asp Val Arg Glu Gly Ile Met Pro
 85 90 95
 Thr Phe Asp Leu Thr Lys Val Leu Glu Ala Gly Asp Ala Gln Pro
 100 105 110

<210> 38

<211> 520

<212> DNA

<213> Homo sapiens

-30-

<400> 38
gagttgtgag ggtgtgaggg tcgcgttcct gctgtctgga ctttttctgt cccactgaga 60
cgcagctgtg tgaaatatga tttggcgagg aagatcaaca tataggccta ggccgaggag 120
aagtgtacca cctcctgagc tgattggggc tatgctggag cccgggtgatg aggagcctca 180
gcaagaggaa ccaccaactg aaagtcggga tcctgcacct ggtcaggaga gagaagaaga 240
tcaggggtgca gctgagactc aagtgcctga cctggaagct gatctccagg agctgtctca 300
gtcaaagact ggggggtgaat gtggaaatgg tcctgatgac caggggaaga ttctgccaaa 360
atcagaacaa tttaaaatgc cagaaggagg tgacaggcaa ccacaggttt aaatgaagac 420
aagctgaaac aaccctaaaac tgtttttatt taagatatatt gacttaaaaa tatcgaaata 480
aacttttgca gcttttctcca aaaaaaaaaa aaaaaaaaaa 520

<210> 39

<211> 111

<212> PRT

<213> Homo sapiens

<400> 39

Met Ile Trp Arg Gly Arg Ser Thr Tyr Arg Pro Arg Pro Arg Arg Ser
1 5 10 15
Val Pro Pro Pro Glu Leu Ile Gly Pro Met Leu Glu Pro Gly Asp Glu
20 25 30
Glu Pro Gln Gln Glu Glu Pro Pro Thr Glu Ser Arg Asp Pro Ala Pro
35 40 45
Gly Gln Glu Arg Glu Glu Asp Gln Gly Ala Ala Glu Thr Gln Val Pro
50 55 60
Asp Leu Glu Ala Asp Leu Gln Glu Leu Ser Gln Ser Lys Thr Gly Gly
65 70 75 80
Glu Cys Gly Asn Gly Pro Asp Asp Gln Gly Lys Ile Leu Pro Lys Ser
85 90 95
Glu Gln Phe Lys Met Pro Glu Gly Gly Asp Arg Gln Pro Gln Val
100 105 110

<210> 40

<211> 756

<212> DNA

-31-

<213> Homo sapiens

<400> 40

```

aggctagtag aggctggggg tgtgaatcgg cagaggggttc tggacacctg cctcagtgtg      60
catgttcact gggcatcttc ccttcgaccc ctttgccac gtggtgaccg ctggggagct      120
gtgagagtgt gaggggcacg ttccagccgt ctggactctt tctctcctac tgagacgcag      180
cctatagggtc cgcaggccag tcctcccagg aactgaaata gtgaaatatg agttggcgag      240
gaagatcaac atataggcct aggccaagaa gaagtttaca gcctcctgag ctgattgggg      300
ctatgcttga acccactgat gaagagccta aagaagagaa accaccact aaaagtcgga      360
atcctacacc tgatcagaag agagaagatg atcaggggtgc agctgagatt caagtgcctg      420
acctggaagc cgatctccag gagctatgtc agacaaagac tggggatgga tgtgaagggtg      480
gtactgatgt caaggggaag attctaccaa aagcagagca ttttaaaatg ccagaagcag      540
gtgaaggga atcacaggtt taaaggaaga taagctgaaa caacacaaac tgtttttata      600
ttagatattt tactttaaaa tatcttaata aagttttaag cttttctcca aaaaaaaaaa      660
aaaaaaaaa aacttggggg ctctatgggg ggggggaaaa gggggttgga aggggcccggg      720
gccatggggg ttcccggacc cagttttttg gtccag      756

```

<210> 41

<211> 111

<212> PRT

<213> Homo sapiens

<400> 41

```

Met Ser Trp Arg Gly Arg Ser Thr Tyr Arg Pro Arg Pro Arg Arg Ser
1          5          10          15
Leu Gln Pro Pro Glu Leu Ile Gly Ala Met Leu Glu Pro Thr Asp Glu
20          25          30
Glu Pro Lys Glu Glu Lys Pro Pro Thr Lys Ser Arg Asn Pro Thr Pro
35          40          45
Asp Gln Lys Arg Glu Asp Asp Gln Gly Ala Ala Glu Ile Gln Val Pro
50          55          60
Asp Leu Glu Ala Asp Leu Gln Glu Leu Cys Gln Thr Lys Thr Gly Asp
65          70          75          80

```


-32-

Gly Cys Glu Gly Gly Thr Asp Val Lys Gly Lys Ile Leu Pro Lys Ala
85 90 95

Glu His Phe Lys Met Pro Glu Ala Gly Glu Gly Lys Ser Gln Val
100 105 110

<210> 42

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide

<400> 42

aggccgagga gaagtgtacc

20

<210> 43

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide

<400> 43

aacctgtggt tgcctgtcac

20

<210> 44

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide

<400> 44

agccgtctgg actctttctc

20

-33-

<210> 45

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide

<400> 45

tgatttcctt c

21

<210> 46

<211> 334

<212> DNA

<213> Homo sapiens

<400> 46

tgaggatcgc gttcctgctg tcgggacttt ttctgtcctg ctgagacgca gcgtgtgaaa 60

tatgatttgg agagtaagat caacatatag gcctagacca aggagaagcg taccacctcc 120

tgagctgatt gggcctatgc tggagcccag tgatgaggaa cctcagcaag aggaaccacc 180

aactgaaagt cgggataccta cacctgtacc tgacctggaa actgatctcc aggagctgtc 240

tcagtcaaag actggggatg aatgcagaga tgggtccgat gacaagggga agattctgcc 300

aaaatcagag caatttaaaa tgccagaagg aggt 334

<210> 47

<211> 91

<212> PRT

<213> Homo sapiens

<400> 47

Met	Ile	Trp	Arg	Val	Arg	Ser	Thr	Tyr	Arg	Pro	Arg	Pro	Arg	Arg	Ser
1				5					10					15	

Val	Pro	Pro	Pro	Glu	Leu	Ile	Gly	Pro	Met	Leu	Glu	Pro	Ser	Asp	Glu
			20					25					30		

-34-

Glu Pro Gln Gln Glu Glu Pro Pro Thr Glu Ser Arg Asp Pro Thr Pro
 35 40 45

Val Pro Asp Leu Glu Thr Asp Leu Gln Glu Leu Ser Gln Ser Lys Thr
 50 55 60

Gly Asp Glu Cys Arg Asp Gly Pro Asp Asp Lys Gly Lys Ile Leu Pro
 65 70 75 80

Lys Ser Glu Gln Phe Lys Met Pro Glu Gly Gly
 85 90

<210> 48

<211> 1878

<212> DNA

<213> Homo sapiens

<400> 48

acagagctgg tgggagctgg gaataggtga aaaccctgcc tccttgtgag ttggcaggac 60
 gggagcctcc tgttccctgg ctgctgttgt ggccaccgag ccgcagccct ggagccaggc 120
 atccctgtgc ttggggatca gagcgagcag gagcagatcc tctcccttct gggtgcagct 180
 gcagctgccc agccatggct gtggtcccgg aagtctctgt gctcttgga gctgggaggg 240
 ccctctgect cctgcccctt acgcactcca gagtctctc tctgttgaga gctaagcaga 300
 catcaggact accagctgca gagaggagct acccactgtg ggcttcgtct ctgctgagag 360
 ctgaacactc actgggacgc cctgcctatg gaaaccagct gttcactctg ggtctcctct 420
 gagctgttct gtcgctcagt aaaggtcttc ttctgcttac tcgccctcca ttgtctgcc 480
 ttacctcatt catcctggac acaggacaag aacttgggac ttgccggtat ggtggagcta 540
 aaatagctgt aacacaaaca ggattgaaac atgccccttg ctgccacat tgtggatgac 600
 aagagggagg gaagaaagga gagaagatct gcgacccttc ggcaaaccga gacttaggag 660
 atcggagagc caagactgtg acacccttcc tggggctctg tggttcctgg cgtctccaag 720
 cttctgggca cctcggcttt ccccggtgcc agtcgtggaa gctgcttgtg gcctccattt 780
 gctgtttggg aaactctcta cgctatgaat gttagctggc agcaaacact gcctcccact 840
 acaggggcac acagtgttgg tgcctgcttt tccaccctcc acttccaaca ggaagcaagc 900
 acaggacca agcattgcag acagttgtat cagccaatg tgcattcgga gccactgaca 960
 gagtcttgct ttgtcaccca ggctggagta cagtggcgtg atcacagctt actgaaacgt 1020
 ctgcgtctca ggttcaagcg attttctgc ctcagcctct ggtgtagctg gaattacagt 1080

-35-

gtttagcagtc actgatgctc aaacatgaga agactgggac atccatcaga taagaaacgc 1140
 tgcccaaagt gttagactaa taagtgcagc ggttggacaa tgaacccaac cactcaacct 1200
 tccggaaaag tgctggagag gatgtggaga aataggaaca cttttacact gttggtggga 1260
 ctgtaaacta gttcaacat tgtggaagtc agtgtggcga ttcctcagag atgtagaact 1320
 agaaatacca tttgaccag ccatccatt actgggtatg tacccaaagg attataaatc 1380
 atgctgctat aaagacacat acacacgtat gtttattgtg gcactattca caacagcaaa 1440
 gacatggaat caacccaaat gtccaacaac gatagactgg attaagaaaa tgtggcacat 1500
 atacaccatg gaatactatg cagccataaa aaatgatgag ttcattgctt ttgtagggac 1560
 atggatgagg ctaggtgaag caattccttt cctgaggaaa atagaactca ctctgccctg 1620
 gcttgatga ggaggaatag gatataagca gttgaggaag aacgggtccat gagttgccat 1680
 ccttcctct tctgcctgc cagaagaggt agagcccact gaagaaggag cagaataagg 1740
 aatggaaacc ttagttacaa gtccaagaaa ttctaccac tctactattt ttttatgtgt 1800
 aacttgattt atagttttta ctttgaaaga atgtaactat tgtacatgtt tcataaagta 1860
 tcaatagctg aatagacc 1878

<210> 49

<211> 70

<212> PRT

<213> Homo sapiens

<400> 49

Met Thr Arg Gly Arg Glu Glu Arg Arg Glu Asp Leu Arg Pro Phe Gly
 1 5 10 15

Lys Pro Arg Leu Arg Arg Ser Glu Ser Gln Asp Cys Asp Thr Leu Ser
 20 25 30

Gly Ala Leu Trp Phe Leu Ala Ser Pro Ser Phe Trp Ala Pro Arg Leu
 35 40 45

Ser Pro Val Pro Val Val Glu Ala Ala Cys Gly Leu His Leu Leu Phe
 50 55 60

Gly Lys Leu Ser Thr Leu
 65 70

<210> 50

-36-

<211> 103

<212> PRT

<213> Homo sapiens

<400> 50

Met Thr Arg Gly Arg Glu Glu Arg Arg Glu Asp Leu Arg Pro Phe Gly
1 5 10 15

Lys Pro Arg Leu Arg Arg Ser Glu Ser Gln Asp Cys Asp Thr Leu Ser
20 25 30

Gly Ala Leu Trp Phe Leu Ala Ser Pro Ser Phe Trp Ala Pro Arg Leu
35 40 45

Ser Pro Val Pro Val Val Glu Ala Ala Cys Ala Glu Ser Cys Phe Val
50 55 60

Thr Gln Ala Gly Val Gln Trp Arg Asp His Ser Leu Leu Lys Arg Leu
65 70 75 80

Arg Leu Arg Phe Lys Arg Phe Phe Cys Leu Ser Leu Trp Cys Ser Trp
85 90 95

Asn Tyr Ser Val Ser Ser His
100

<210> 51

<211> 778

<212> DNA

<213> Homo sapiens

<400> 51

caggagtggg gtcagcagga ggaactctac agctatggga gaacctgcgt tcacctcttt 60
tccaagcctg cctgttctgg ggaagctcaa aaggaacatg atgccctggg ctttacagaa 120
gaaacgagaa atccacatgg ccaaggccca tcggagacga gctgcgaggt ctgctctccc 180
catgagactc accagctgca tcttccggag gccggtgaca aggatcaggt ctcatcctga 240
caaccaggtc agacgcagaa aaggggacga gcacctggag aagccgcagc aactctgcgc 300
ctaccggaga ctgcaggccc tgcagccctg cagcagccaa ggagaagggt caagtccact 360
gcattgggag agcgtcttaa gtatccttgc accggggacg gccagtgaat ctctggacag 420
ggctggtgct gagcgtgtgc gcagcccgt tgagcccacc cctgggcggt ttccagctgt 480
ggcagggggg ccaaccccag gaatggggtg tcagctccca ccgcccctct ctggccaatt 540

-37-

ggtgactcct gcagatatcc ggagacaggc caggaggggtg aagaaagcca gggagagact 600
 ggccaaggcc ttgcaggcag acaggctggc caggcaggca gaaatgctga catgtagatg 660
 aagcgcagtc ctgggctttc ggtccctttc ttttaatgcc catcctcatt cctactctga 720
 attgtcacac ttttcccttc cccaccagtt ctttaataaa agtatttgaa aggcaaaa 778

<210> 52

<211> 219

<212> PRT

<213> Homo sapiens

<400> 52

Arg Ser Gly Val Ser Arg Arg Asn Ser Thr Ala Met Gly Glu Pro Ala
 1 5 10 15
 Phe Thr Ser Phe Pro Ser Leu Pro Val Leu Gly Lys Leu Lys Arg Asn
 20 25 30
 Met Met Pro Trp Ala Leu Gln Lys Lys Arg Glu Ile His Met Ala Lys
 35 40 45
 Ala His Arg Arg Arg Ala Ala Arg Ser Ala Leu Pro Met Arg Leu Thr
 50 55 60
 Ser Cys Ile Phe Arg Arg Pro Val Thr Arg Ile Arg Ser His Pro Asp
 65 70 75 80
 Asn Gln Val Arg Arg Arg Lys Gly Asp Glu His Leu Glu Lys Pro Gln
 85 90 95
 Gln Leu Cys Ala Tyr Arg Arg Leu Gln Ala Leu Gln Pro Cys Ser Ser
 100 105 110
 Gln Gly Glu Gly Ser Ser Pro Leu His Trp Glu Ser Val Leu Ser Ile
 115 120 125
 Leu Ala Pro Gly Thr Ala Ser Glu Ser Leu Asp Arg Ala Gly Ala Glu
 130 135 140
 Arg Val Arg Ser Pro Leu Glu Pro Thr Pro Gly Arg Phe Pro Ala Val
 145 150 155 160
 Ala Gly Gly Pro Thr Pro Gly Met Gly Cys Gln Leu Pro Pro Pro Leu
 165 170 175
 Ser Gly Gln Leu Val Thr Pro Ala Asp Ile Arg Arg Gln Ala Arg Arg
 180 185 190
 Val Lys Lys Ala Arg Glu Arg Leu Ala Lys Ala Leu Gln Ala Asp Arg

-38-

195	200	205
Leu Ala Arg Gln Ala Glu Met Leu Thr Cys Arg		
210	215	

<210> 53

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide

<400> 53

tgggacatcc atcagataag

20

<210> 54

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide

<400> 54

tttatggctg catagtattc

20

<210> 55

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide

-39-

<400> 55
gctatgggag aacctgcgtt c

21

<210> 56

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide

<400> 56
tccctggctt tcttcaccct c

21

<210> 57

<211> 116

<212> PRT

<213> Homo sapiens

<400> 57

Met Ser Trp Arg Gly Arg Ser Thr Tyr Arg Pro Arg Pro Arg Arg Tyr
1 5 10 15

Val Glu Pro Pro Glu Met Ile Gly Pro Met Arg Pro Glu Gln Phe Ser
20 25 30

Asp Glu Val Glu Pro Ala Thr Pro Glu Glu Gly Glu Pro Ala Thr Gln
35 40 45

Arg Gln Asp Pro Ala Ala Ala Gln Glu Gly Glu Asp Glu Gly Ala Ser
50 55 60

Ala Gly Gln Gly Pro Lys Pro Glu Ala His Ser Gln Glu Gln Gly His
65 70 75 80

Pro Gln Thr Gly Cys Glu Cys Glu Asp Gly Pro Asp Gly Gln Glu Met
85 90 95

Asp Pro Pro Asn Pro Glu Glu Val Lys Thr Pro Glu Glu Gly Glu Lys
100 105 110

Gln Ser Gln Cys
115

~~40~~

<210> 58

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide

<400> 58

accaaggaga agcgtaccac

20

<210> 59

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide

<400> 59

gggaccatct ctgcattcat c

21

SEQUENCE LISTING

<110> LUDWIG INSTITUTE FOR CANCER RESEARCH

OLD, LLOYD

SCANLAN, MATTHEW

CHEN, YAO-TSENG

<120> CANCER-TESTIS ANTIGENS

<130> L0461/7125WO(JRV)

<150> 10/054,683

<151> 2002-01-22

<150> 60/280,718

<151> 2001-03-30

<150> 60/285,154

<151> 2001-04-20

<150> 60/327,432

<151> 2001-10-05

<160> 59

<170> PatentIn version 3.0

<210> 1

<211> 20

-2-

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide

<400> 1

aggaattatg aaaccacttg

20

<210> 2

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide

<400> 2

gacaacagtt gtatcagacc

20

<210> 3

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide

<400> 3

caaggagagg tcgtgtcttc g

21

<210> 4

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide

<400> 4

ggatcttggtt acatgctcac tcatatc

27

<210> 5

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide

<400> 5

ccagattaag aataacgttc

20

<210> 6

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide

<400> 6

agaggaaatg accaagagtc

20

<210> 7

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide

<400> 7
acaagactag cttatgtgtg g

21

<210> 8

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide

<400> 8
ttgagcaaga atcttgactt c

21

<210> 9

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide

<400> 9
gggagtattg acagtggcaa ttt

23

<210> 10

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide

<400> 10
tggttctcaat gtagcgcctt tc

22

-5-

<210> 11

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide

<400> 11

ccacctgtag ctataccagc cagactccc

29

<210> 12

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide

<400> 12

gcagagtccc ctccctgac

19

<210> 13

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide

<400> 13

acaggaactg gctctgctta aga

23

<210> 14

<211> 26

-6-

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide

<400> 14

tcaggacat ctccaggtgc atcctc

26

<210> 15

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide

<400> 15

ccagagtctc atgttaaaat cacttaca

28

<210> 16

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide

<400> 16

gaaacacttc ctctctttct ttaagtacaa

30

<210> 17

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide

<400> 17

accagaaag accaccactt tgcaggta

28

<210> 18

<211> 2640

<212> DNA

<213> Homo Sapiens

<400> 18

catctcgcac ttccaactgc cctgtaacca ccaactgccc ttattccggc tgggacccag	60
gacttcaagc catgtgggtc ttgtttctgc tcagcgggct cggcgggctg cggatggaca	120
gtaattttga tagtttacct gtgcaaatta cagttccgga gaaaatacgg tcaataataa	180
aggaaggaat tgaatcgcag gcacccctaca aaattgtaat tgaagggaaa ccatatactg	240
tgaatttqat gcaaaaaaac tttttacccc ataattttag agtttacagt tatagtggca	300
caggaattat gaaaccactt gaccaagatt ttcagaattt ctgccactac caagggtata	360
ttgaagggtta tccaaaatct gtggtgatgg ttagcacatg tactggactc aggggcgtac	420
tacagtttga aaatgttagt tatggaatag aacccttgga gtcttcagtt ggctttgaac	480
atgtaattta ccaagtaaaa cataagaaag cagatgtttc cttatataat gagaaggata	540
ttgaatcaag agatctgtcc tttaaattac aaagcgcaga gccacagcaa gattttgcaa	600
agtatataga aatgcatggt atagttgaaa aacaattgta taatcatatg gggctctgata	660
caactgttgt cgctcaaaaa gttttccagt tgattggatt gacgaatgct atttttgttt	720
catttaatat tacaattatt ctgtcttcat tggagctttg gatagatgaa aataaaattg	780
caaccactgg agaagctaag gagttattac acacattttt aagatggaaa acatcttatc	840
ttgttttacg tctcatgat gtggcatttt tacttgttta cagagaaaag tcaaattatg	900
ttggtgcaac ctttcaaggg aagatgtgtg atgcaaacta tgcaggaggt gttgttctgc	960
acccagaaac cataagtctg gaatcacttg cagttatttt agctcaatta ttgagcctta	1020
gtatggggat cacttatgat gacattaaca aatgccagtg ctcaggagct gtctgcatta	1080
tgaatccaga agcaattcat ttcagtgggtg tgaagatctt tagtaactgc agcttcgaag	1140

actttgcaca ttttatttca aagcagaagt cccagtgtct tcacaatcag cctcgcttag 1200
atcctttttt caaacagcaa gcagtgtgtg gtaatgcaaa gctggaagca ggagaggagt 1260
gtgactgtgg gactgaacag gattgtgccc ttattggaga aacatgctgt gatattgcca 1320
catgtagatt taaagccggt tcaaactgtg ctgaaggacc atgctgcgaa aactgtctat 1380
ttatgtcaaa agaaagaatg tgtaggcctt cctttgaaga atgcgacctc cctgaatatt 1440
gcaatggatc atctgcatca tgcccagaaa accactatgt tcagactggg catccgtgtg 1500
gactgaatca atggatctgt atagatggag tttgtatgag tggggataaa caatgtacag 1560
acacatttgg caaagaagta gagtttggcc cttcagaatg ttattctcac ctttaattcaa 1620
agactgatgt atctggaaac tgtggtataa gtgattcagg atacacacag tgtgaagctg 1680
acaatctgca gtgcggaaaa ttaatatgta aatatgtagg taaattttta ttacaaattc 1740
caagagccac tattatttat gccaacataa gtggacatct ctgcattgct gtggaatttg 1800
ccagtgatca tgcagacagc caaaagatgt ggataaaaga tggaacttct tgtggttcaa 1860
ataaggtttg caggaatcaa agatgtgtga gttcttcata cttgggttat gattgtacta 1920
ctgacaaatg caatgataga ggtgtatgca ataacaaaaa gcactgtcac tgtagtgctt 1980
catatttacc tccagattgc tcagttcaat cagatctatg gcctgggtggg agtattgaca 2040
gtggcaattt tccacctgta gctataccag ccagactccc tgaaaggcgc tacattgaga 2100
acatttacca ttccaaacca atgagatggc catttttctt attcattcct ttctttatta 2160
ttttctgtgt actgattgct ataatgggtga aagttaattt ccaaaggaaa aaatggagaa 2220
ctgaggacta ttcaagcgat gagcaacctg aaagtgagag tgaacctaaa gggtagtctg 2280
gacaacagag atgccatgat atcacttctt ctagagtaat tatctgtgat ggatggacac 2340
aaaaaaatgg aaagaaaaga atgtacatta cctgggttcc tgggattcaa acctgcatat 2400
tgtgatttta atttgaccag aaaatatgat atatatgtat aatttcacag ataatttact 2460
tatttaaaaa tgcattgataa tgagttttac attacaaatt tctgtttttt taaagttatc 2520
ttacgctatt tctgttggtt agtagacact aattctgtca gtaggggcat ggtataagga 2580
aatatcataa tgtaatgagg tggtagtatg attaaaagcc actgttacat ttcaaaaaaa 2640

<210> 19

<211> 734

<212> PRT

<213> Homo Sapiens

<400> 19

Met Trp Val Leu Phe Leu Leu Ser Gly Leu Gly Gly Leu Arg Met Asp
1 5 10 15

Ser Asn Phe Asp Ser Leu Pro Val Gln Ile Thr Val Pro Glu Lys Ile
20 25 30

Arg Ser Ile Ile Lys Glu Gly Ile Glu Ser Gln Ala Ser Tyr Lys Ile
35 40 45

Val Ile Glu Gly Lys Pro Tyr Thr Val Asn Leu Met Gln Lys Asn Phe
50 55 60

Leu Pro His Asn Phe Arg Val Tyr Ser Tyr Ser Gly Thr Gly Ile Met
65 70 75 80

Lys Pro Leu Asp Gln Asp Phe Gln Asn Phe Cys His Tyr Gln Gly Tyr
85 90 95

Ile Glu Gly Tyr Pro Lys Ser Val Val Met Val Ser Thr Cys Thr Gly
100 105 110

Leu Arg Gly Val Leu Gln Phe Glu Asn Val Ser Tyr Gly Ile Glu Pro
115 120 125

Leu Glu Ser Ser Val Gly Phe Glu His Val Ile Tyr Gln Val Lys His
130 135 140

Lys Lys Ala Asp Val Ser Leu Tyr Asn Glu Lys Asp Ile Glu Ser Arg
145 150 155 160

Asp Leu Ser Phe Lys Leu Gln Ser Ala Glu Pro Gln Gln Asp Phe Ala
165 170 175

Lys Tyr Ile Glu Met His Val Ile Val Glu Lys Gln Leu Tyr Asn His
180 185 190

Met Gly Ser Asp Thr Thr Val Val Ala Gln Lys Val Phe Gln Leu Ile
195 200 205

Gly Leu Thr Asn Ala Ile Phe Val Ser Phe Asn Ile Thr Ile Ile Leu
210 215 220

Ser Ser Leu Glu Leu Trp Ile Asp Glu Asn Lys Ile Ala Thr Thr Gly
225 230 235 240

Glu Ala Asn Glu Leu Leu His Thr Phe Leu Arg Trp Lys Thr Ser Tyr
245 250 255

Leu Val Leu Arg Pro His Asp Val Ala Phe Leu Leu Val Tyr Arg Glu
260 265 270

Lys Ser Asn Tyr Val Gly Ala Thr Phe Gln Gly Lys Met Cys Asp Ala
275 280 285

Asn Tyr Ala Gly Gly Val Val Leu His Pro Arg Thr Ile Ser Leu Glu

-10-

290	295	300
Ser Leu Ala Val Ile Leu Ala Gln Leu Leu Ser Leu Ser Met Gly Ile 305 310 315 320		
Thr Tyr Asp Asp Ile Asn Lys Cys Gln Cys Ser Gly Ala Val Cys Ile 325 330 335		
Met Asn Pro Glu Ala Ile His Phe Ser Gly Val Lys Ile Phe Ser Asn 340 345 350		
Cys Ser Phe Glu Asp Phe Ala His Phe Ile Ser Lys Gln Lys Ser Gln 355 360 365		
Cys Leu His Asn Gln Pro Arg Leu Asp Pro Phe Phe Lys Gln Gln Ala 370 375 380		
Val Cys Gly Asn Ala Lys Leu Glu Ala Gly Glu Glu Cys Asp Cys Gly 385 390 395 400		
Thr Glu Gln Asp Cys Ala Leu Ile Gly Glu Thr Cys Cys Asp Ile Ala 405 410 415		
Thr Cys Arg Phe Lys Ala Gly Ser Asn Cys Ala Glu Gly Pro Cys Cys 420 425 430		
Glu Asn Cys Leu Phe Met Ser Lys Glu Arg Met Cys Arg Pro Ser Phe 435 440 445		
Glu Glu Cys Asp Leu Pro Glu Tyr Cys Asn Gly Ser Ser Ala Ser Cys 450 455 460		
Pro Glu Asn His Tyr Val Gln Thr Gly His Pro Cys Gly Leu Asn Gln 465 470 475 480		
Trp Ile Cys Ile Asp Gly Val Cys Met Ser Gly Asp Lys Gln Cys Thr 485 490 495		
Asp Thr Phe Gly Lys Glu Val Glu Phe Gly Pro Ser Glu Cys Tyr Ser 500 505 510		
His Leu Asn Ser Lys Thr Asp Val Ser Gly Asn Cys Gly Ile Ser Asp 515 520 525		
Ser Gly Tyr Thr Gln Cys Glu Ala Asp Asn Leu Gln Cys Gly Lys Leu 530 535 540		
Ile Cys Lys Tyr Val Gly Lys Phe Leu Leu Gln Ile Pro Arg Ala Thr 545 550 555 560		
Ile Ile Tyr Ala Asn Ile Ser Gly His Leu Cys Ile Ala Val Glu Phe 565 570 575		
Ala Ser Asp His Ala Asp Ser Gln Lys Met Trp Ile Lys Asp Gly Thr 580 585 590		
Ser Cys Gly Ser Asn Lys Val Cys Arg Asn Gln Arg Cys Val Ser Ser 595 600 605		

-11-

Ser Tyr Leu Gly Tyr Asp Cys Thr Thr Asp Lys Cys Asn Asp Arg Gly
610 615 620

Val Cys Asn Asn Lys Lys His Cys His Cys Ser Ala Ser Tyr Leu Pro
625 630 635 640

Pro Asp Cys Ser Val Gln Ser Asp Leu Trp Pro Gly Gly Ser Ile Asp
645 650 655

Ser Gly Asn Phe Pro Pro Val Ala Ile Pro Ala Arg Leu Pro Glu Arg
660 665 670

Arg Tyr Ile Glu Asn Ile Tyr His Ser Lys Pro Met Arg Trp Pro Phe
675 680 685

Phe Leu Phe Ile Pro Phe Phe Ile Ile Phe Cys Val Leu Ile Ala Ile
690 695 700

Met Val Lys Val Asn Phe Gln Arg Lys Lys Trp Arg Thr Glu Asp Tyr
705 710 715 720

Ser Ser Asp Glu Gln Pro Glu Ser Glu Ser Glu Pro Lys Gly
725 730

<210> 20

<211> 528

<212> DNA

<213> Homo Sapiens

<400> 20

```

ggcacgagggc ttcgttcttt ccgccatctt cgttctttcc aacatcttcg ttctttctca      60
ctgaccgaga ctcagccgtg agagatatga gtgagcatgt aacaagatcc caatcctcag      120
aaagaggaaa tgaccaagag tcttcccagc cagttggacc tgtgattgtc cagcagccca      180
ctgaggaaaa acgtcaagaa gaggaaccac caactgataa tcagggtatt gcacctagtg      240
gggagatcaa aaatgaagga gcacctgctg ttcaagggac tgatgtggaa gcttttcaac      300
aggaactggc tctgcttaag atagaggatg cacctggaga tggtcctgat gtcagggagg      360
ggactctgcc cacttttgat ccactaaag tgctggaagc aggtgaaggg caactatagg      420
tttaaaccaa gacaaatgaa gactgaaacc aagaatattg ttcttatgct ggaaatttga      480
ctgctaacat tctcttaata aagttttaca gttttctgca aaaaaaaaaa      528

```

<210> 21

<211> 110

-12-

<212> PRT

<213> Homo Sapiens

<400> 21

Met Ser Glu His Val Thr Arg Ser Gln Ser Ser Glu Arg Gly Asn Asp
1 5 10 15

Gln Glu Ser Ser Gln Pro Val Gly Pro Val Ile Val Gln Gln Pro Thr
20 25 30

Glu Glu Lys Arg Gln Glu Glu Glu Pro Pro Thr Asp Asn Gln Gly Ile
35 40 45

Ala Pro Ser Gly Glu Ile Lys Asn Glu Gly Ala Pro Ala Val Gln Gly
50 55 60

Thr Asp Val Glu Ala Phe Gln Gln Glu Leu Ala Leu Leu Lys Ile Glu
65 70 75 80

Asp Ala Pro Gly Asp Gly Pro Asp Val Arg Glu Gly Thr Leu Pro Thr
85 90 95

Phe Asp Pro Thr Lys Val Leu Glu Ala Gly Glu Gly Gln Leu
100 105 110

<210> 22

<211> 877

<212> DNA

<213> Homo Sapiens

<400> 22

ggcacgagggc ttgttcatgg catctttaga aacaaactgc aattttattt catttccttg 60
tcgttcatac aaagattaca agactagctt atgtgtggac tgtgactgtt ttaaggaaaa 120
atcatgtcct cggctggggt atcaagccaa gctatttaaa ggtgttttaa aagaaaggat 180
ggaaggaaga cctcttagga ccactgtgtt tttggatata agtggtacat atccattctg 240
tacctattat tttgttctca gtataattgt tccagataaa actatgatgg atggctcgtt 300
ttcatttaaa ttattaaatc agcttgaaat gattgaagag ccaaggcttt atgaaaagaa 360
caaaccattt tataaacttc aagaagtcaa gattcttgct caattttata atgactttgt 420
aatattttca agcattgggt tgacatattt ccagagctca aatctgcagt gttccacatg 480
cacatacaag atccagagtc tcatgttaaa atcacttaca taccagaaa gaccaccact 540
ttgcaggtat aatattgtac ttaaagaaag agaggaagtg tttcttaatc caaacacatg 600

-13-

tacaccaaag aacacataag atgccttctt ccatcaaag cacttgcttg tgaattaatg 660
gacttgtaaa tgaacaatg caatcagtct ttataatac actgttcaat ttgagattca 720
agtatttcta tttcttgga aaaattttta gaatcaaaaa taaagaaaat aaaaagtgca 780
tacagttaaa cattcaaaa aaaaaaaaaa aaaaaaaaaa aaaattggcg gccgcaagct 840
tattcccttt agtgagggtt aattttagct tggcact 877

<210> 23

<211> 205

<212> PRT

<213> Homo Sapiens

<400> 23

Ala Arg Gly Leu Phe Met Ala Ser Leu Glu Thr Asn Cys Asn Phe Ile
1 5 10 15
Ser Phe Pro Cys Arg Ser Tyr Lys Asp Tyr Lys Thr Ser Leu Cys Val
20 25 30
Asp Cys Asp Cys Phe Lys Glu Lys Ser Cys Pro Arg Leu Gly Tyr Gln
35 40 45
Ala Lys Leu Phe Lys Gly Val Leu Lys Glu Arg Met Glu Gly Arg Pro
50 55 60
Leu Arg Thr Thr Val Phe Leu Asp Thr Ser Gly Thr Tyr Pro Phe Cys
65 70 75 80
Thr Tyr Tyr Phe Val Leu Ser Ile Ile Val Pro Asp Lys Thr Met Met
85 90 95
Asp Gly Ser Phe Ser Phe Lys Leu Leu Asn Gln Leu Glu Met Ile Glu
100 105 110
Glu Pro Arg Leu Tyr Glu Lys Asn Lys Pro Phe Tyr Lys Leu Gln Glu
115 120 125
Val Lys Ile Leu Ala Gln Phe Tyr Asn Asp Phe Val Asn Ile Ser Ser
130 135 140
Ile Gly Leu Thr Tyr Phe Gln Ser Ser Asn Leu Gln Cys Ser Thr Cys
145 150 155 160
Thr Tyr Lys Ile Gln Ser Leu Met Leu Lys Ser Leu Thr Tyr Pro Glu
165 170 175
Arg Pro Pro Leu Cys Arg Tyr Asn Ile Val Leu Lys Glu Arg Glu Glu
180 185 190

Val Phe Leu Asn Pro Asn Thr Cys Thr Pro Lys Asn Thr
 195 200 205

<210> 24

<211> 2270

<212> DNA

<213> Homo Sapiens

<400> 24

```

gggcacattg cagattgttc gggtaaattt aaaatgctag agcatgccct acgtgatgcc      60
aagatggcgg agacttgtat tgtgaaagaa aagcaagatt ataagcagaa attgaaggca      120
cttaagattg aagtcaacaa actaaaagag gacctcaatg aaaagacgac agaaaataat      180
gagcaacgag aagagatcat tcgcctcaag caagagaaaa gttgcctgca cgatgaattg      240
ctttttactg tagagagaga aaagaggaaa gatgaattgc ttaatatgtc gaagtcaaag      300
caagaacgca caaattcaga actgcacaat ctgagacaga tttatgtaaa acaacagagt      360
gatctgcagt ttcttaattt caatgtggaa aattctcagg aattaatata gatgtatgac      420
tcaaagatgg aggaatcaaa ggctctggac tccagcagag acatgtgttt atcagacctt      480
gaaaataacc acccaaaagt cgatattaag agggaaaaaa atcagaagtc actgtttaag      540
gaccagaaat ttgaagccat gttggttcag caaaataggt cagacaagag ctcttgcgat      600
gaatgcaaag agaagaaaca acagatcgat actgtgtttg gggagaaaag tgtaattacg      660
ctgtcatcca tattcaccaa agacttagta gagaaacaca acctcccttg gtctctggga      720
ggaaaaaccc agattgaacc cgaaaacaaa attacattgt gcaagatcca cacaaaatca      780
ccaaaatgtc atggcactgg gggtcagaac gaaggaaaac aaccctcaga aacacccact      840
ttatctgatg agaagcagtg gcatgatgtc agtgtttacc tgggcctgac caactgtcca      900
agttcaaaac atccagaaaa gctggatgta gaatgtcaag atcagatgga aaggtccgaa      960
atctcatgct gccagaaaaa tgaagcctgt ctgggcgaaa gtggcatgtg tgactccaag     1020
tgctgccacc cgagtaactt cataattgaa gccccaggcc acatgtctga cgtggagtgg     1080
atgagtattt tcaagccttc caaaatgcag agaattgtcc gcctcaaata tgggtgcacc     1140
tggtcagaaa gcatctgtgg cacacaacat gactccccgg caagtgagct aattgccatc     1200
caagattccc actctttggg ttcttcaaaa tctgccttga gagaagatga gacggagtcc     1260
tcttccaata aaaagaactc acctacgagt ttgttaatct acaaagatgc accagcattc     1320

```


-15-

```

aatgaaaagg cttcaattgt gttaccctcc caggatgatt tctcgccac gagcaagctc 1380
cagcgtttgc tggcggaatc tcgtcagatg gtgacggacc tggagctgaa cacactgctg 1440
cccatcagcc atgagaatct cactggcagt gccacaaata tttctcatct atgtggaagg 1500
cagaaagcag acaccaatac tgaatgaata cttaaccgta aaactgaaag aggattctag 1560
ttcttcataa acggcactta attccagctg ggagcagaac tagaaagtta atttttaaac 1620
atctacactt cattttcaag ttaaccattt ttgtgctgaa gaaatatttt catgtgtaag 1680
aaagtagacc ttattgtaca tatagaaagt tggaattatg ctaagaatga aaaagacttc 1740
tctgtaaaga tacagactac agttaaatgc tagagaagct ctttaaaaat gtgaatgtca 1800
aatagagaaa gaaccctgc atagaaagtg ctgttttaac tatctgattt ttaaaaaatc 1860
tgtgcataca tttaaattct aaacaatagc ttatcagagt cagctcaaaa tatatgagaa 1920
acagtattct ctcattggtt tagcttttga ctttgctgtg taaatagaca taagggtgctt 1980
tgatataaaa tataaagtgt aactggaaaa tagctcgagg tccttctgtc ccaagctgag 2040
cagagcccca tctttctggg tctatattag tcccacctac tgacacaaac aaaagcttgc 2100
tggaagatcg agttttagac gcatttttaa aaatcttaaa gactaaaaca cttccatttt 2160
aacttgtaaa gtaatttaat tttttaaaga ttatactata tgcctctgtg tcttctctaa 2220
aagaatagat caacttcagt ccataaaaga tattttttaat attaaagaaa 2270

```

<210> 25

<211> 497

<212> PRT

<213> Homo Sapiens

<400> 25

```

Met Leu Glu His Ala Leu Arg Asp Ala Lys Met Ala Glu Thr Cys Ile
1           5           10           15
Val Lys Glu Lys Gln Asp Tyr Lys Gln Lys Leu Lys Ala Leu Lys Ile
20           25           30
Glu Val Asn Lys Leu Lys Glu Asp Leu Asn Glu Lys Thr Thr Glu Asn
35           40           45
Asn Glu Gln Arg Glu Glu Ile Ile Arg Leu Lys Gln Glu Lys Ser Cys
50           55           60
Leu His Asp Glu Leu Leu Phe Thr Val Glu Arg Glu Lys Arg Lys Asp
65           70           75           80

```


-16-

Glu Leu Leu Asn Ile Ala Lys Ser Lys Gln Glu Arg Thr Asn Ser Glu
 85 90 95
 Leu His Asn Leu Arg Gln Ile Tyr Val Lys Gln Gln Ser Asp Leu Gln
 100 105 110
 Phe Leu Asn Phe Asn Val Glu Asn Ser Gln Glu Leu Ile Gln Met Tyr
 115 120 125
 Asp Ser Lys Met Glu Glu Ser Lys Ala Leu Asp Ser Ser Arg Asp Met
 130 135 140
 Cys Leu Ser Asp Leu Glu Asn Asn His Pro Lys Val Asp Ile Lys Arg
 145 150 155 160
 Glu Lys Asn Gln Lys Ser Leu Phe Lys Asp Gln Lys Phe Glu Ala Met
 165 170 175
 Leu Val Gln Gln Asn Arg Ser Asp Lys Ser Ser Cys Asp Glu Cys Lys
 180 185 190
 Glu Lys Lys Gln Gln Ile Asp Thr Val Phe Gly Glu Lys Ser Val Ile
 195 200 205
 Thr Leu Ser Ser Ile Phe Thr Lys Asp Leu Val Glu Lys His Asn Leu
 210 215 220
 Pro Trp Ser Leu Gly Gly Lys Thr Gln Ile Glu Pro Glu Asn Lys Ile
 225 230 235 240
 Thr Leu Cys Lys Ile His Thr Lys Ser Pro Lys Cys His Gly Thr Gly
 245 250 255
 Val Gln Asn Glu Gly Lys Gln Pro Ser Glu Thr Pro Thr Leu Ser Asp
 260 265 270
 Glu Lys Gln Trp His Asp Val Ser Val Tyr Leu Gly Leu Thr Asn Cys
 275 280 285
 Pro Ser Ser Lys His Pro Glu Lys Leu Asp Val Glu Cys Gln Asp Gln
 290 295 300
 Met Glu Arg Ser Glu Ile Ser Cys Cys Gln Lys Asn Glu Ala Cys Leu
 305 310 315 320
 Gly Glu Ser Gly Met Cys Asp Ser Lys Cys Cys His Pro Ser Asn Phe
 325 330 335
 Ile Ile Glu Ala Pro Gly His Met Ser Asp Val Glu Trp Met Ser Ile
 340 345 350
 Phe Lys Pro Ser Lys Met Gln Arg Ile Val Arg Leu Lys Ser Gly Cys
 355 360 365
 Thr Cys Ser Glu Ser Ile Cys Gly Thr Gln His Asp Ser Pro Ala Ser
 370 375 380
 Glu Leu Ile Ala Ile Gln Asp Ser His Ser Leu Gly Ser Ser Lys Ser

-17-

385		390		395		400									
Ala	Leu	Arg	Glu	Asp	Glu	Thr	Glu	Ser	Ser	Ser	Asn	Lys	Lys	Asn	Ser
			405						410					415	
Pro	Thr	Ser	Leu	Leu	Ile	Tyr	Lys	Asp	Ala	Pro	Ala	Phe	Asn	Glu	Lys
			420					425					430		
Ala	Ser	Ile	Val	Leu	Pro	Ser	Gln	Asp	Asp	Phe	Ser	Pro	Thr	Ser	Lys
		435					440					445			
Leu	Gln	Arg	Leu	Leu	Ala	Glu	Ser	Arg	Gln	Met	Val	Thr	Asp	Leu	Glu
	450					455					460				
Leu	Asn	Thr	Leu	Leu	Pro	Ile	Ser	His	Glu	Asn	Leu	Thr	Gly	Ser	Ala
465					470					475					480
Thr	Asn	Ile	Ser	His	Leu	Cys	Gly	Arg	Gln	Lys	Ala	Asp	Thr	Asn	Thr
				485					490					495	

Glu

<210> 26

<211> 996

<212> DNA

<213> Homo Sapiens

<400> 26

gtatgttcct ggcagaaaag ttgcataact tggggggttaa agacaggaat atggcacaat	60
gcccattgtg ggcagtgtcc agacagaaga agagactcat atcacctaaa tgacaaaccc	120
agaatatgtc acaatgtatc ctgttgaaag gaccagaaac gaggatgaat tgccacatca	180
tctggttctg agttctgaga tattcacaag tccccttaga aaacaactca ggcaagagag	240
ttacatcacc taggagcccg ttccaccctt atgtcacagt gcttcatgtg tacaggacta	300
agaagaaagt cacatcacct agatgataga cccagagaca cgtcacaaag ccttcctgaa	360
agcatggccc tggcaaaata gtacaatcac ctttgtacct ggtctagcaa tatgtcatta	420
ttcaagtgtg caggtaccaa ggagaggagc catactacct atgttatatg ccctgtgcta	480
tgtcaaaatg ccttcttttc agcatggccc tggaagaatg tatcatctca catgtgactg	540
gcctaggaag atgtcactat cctgccatgt gtgcagggcc cattttagag attagagtta	600
tgtcttcttc taagtcatgg acccagtgat atatcactat gatgtctgtg agaatgggca	660
ggcaggaatg taatgtcact tgcattctag atccagtgat gtcacaattc ttactgaggg	720
cagagcccag tcagaagagt catatctttt acagggtggc ccaagtagat gtcaaaaacc	780

-18-

cctatggatt agatttacia taccacacat ctcttgtttt catgtaggag agttgcctgc 840
 attcatctgt gatgatgaaa gtccttactg tcagccaagt gtgcatatga gactcacaat 900
 ttcctctgtt tgctaaccac tattatgaca ctctctattc aaccaacgg ttttataaaa 960
 catttgtcat tgttataaaa aaaaaaaaaa aaaaaa 996

<210> 27

<211> 90

<212> PRT

<213> Homo Sapiens

<400> 27

Met Ile Asp Pro Glu Thr Arg His Lys Ala Phe Leu Lys Ala Trp Pro
 1 5 10 15
 Trp Gln Asn Ser Thr Ile Thr Phe Val Pro Gly Leu Ala Ile Cys His
 20 25 30
 Tyr Ser Ser Val Gln Val Pro Arg Arg Gly Ala Ile Leu Pro Met Leu
 35 40 45
 Tyr Ala Leu Cys Tyr Val Lys Met Pro Ser Phe Gln His Gly Pro Gly
 50 55 60
 Arg Met Tyr His Leu Thr Cys Asp Trp Pro Arg Lys Met Ser Leu Ser
 65 70 75 80
 Cys His Val Cys Arg Ala His Phe Arg Asp
 85 90

<210> 28

<211> 2347

<212> DNA

<213> Homo Sapiens

<400> 28

gggaggtttg gagccctgca taaagagaag gacgggacca cagctgactg ctgtgtcccc 60
 acagatctgg gcctcctgct gccaccatgg ccaaaggtgg agaagccctg ccacagggca 120
 gccagcacc agtccaggat cccacactca tcaaggtgac agtgaagacg cccaagaca 180
 aggaggattt ctcatgtaca gacacatgca ctatccagca gctgaaggaa gagatatctc 240

agcgctttaa ggcccacccc gatcagcttg ttctaattctt tgctggcaaa atcctcaagg 300
atcctgactc actggcacag tgtggagtgc gagatggcct cactgtccac ctggatcatca 360
agaggcagca ccgtgccatg ggcaatgagt gccagctgc ctctgtccct acccagggcc 420
caagtcctgg atcactccct cagccaagct ccatttacct agcagatggg cccctgcct 480
ttagcttagg tctcctcaca ggctcagta ggctgggctt ggcttatcgt ggcttccctg 540
accagccaag ctccctgatg cggcagcatg tgtctgtgcc tgagtttgtg actcagctca 600
ttgatgacct cttcatcccg ggtctgctgt ccaacacagg cctagtacgc cagctgggtc 660
ttgacaacct ccatatgcag cagctgatcc agcacaacct tgagattggg catattctta 720
acaaccgga aattatgcgg cagacactgg agtttttacg taaccctgcc atgatgcagg 780
agatgatacg tagccaggac cgggtgctca gtaacttga gagcattcct ggtggctaca 840
atgtgctttg cactatgtac acagatatta tggaccaat gcttaacgca gtccaggagc 900
agtttggcgg caatcccttt gccactgcca ctactgataa tgccaccacc accaccagcc 960
aaccttcaag gatggagaat tgtgacctc tccccaacct ctggacttcc acacatggag 1020
gctcaggtag caggcaagga aggcaggatg gggatcagga tgcacctgac attagaaata 1080
ggtttccaaa ctttctgggt attataaggc tctatgacta tctccagcaa ttacacgaga 1140
acccccagtc cctaggaact tatctacagg ggactgcac tgccctcagc caaagccagg 1200
aaccaccacc atcagtaaac agagttcccc catcgtcacc ctcatctcag gagcctgggt 1260
caggccagcc tctccccgag gagtcagtag caatcaaggg aaggtccctc tgcccagctt 1320
tcctgagata cccacagag aacagtactg gacaagggtg agaccaagat ggtgcaggga 1380
aaagctctac tggacatagc acaaacttgc ctgatcttgt ctgggggctg ggagattctg 1440
ccaacagggt tccatttgct cccttatctt tttccccac ggcagccatt cctggaatcc 1500
ctgagcctcc ctggctgcca tccccggctt atccaagatc tctgaggcca gatggcatga 1560
atccagctcc acagttacag gatgagatac aaccacagct gccactgctg atgcacctc 1620
aggcagccat ggcaaacccc cgtgccctgc aagccctgcg gcagattgag cagggtctac 1680
aggtcctagc tactgaagca cctcgcctcc tactctgggt catgccttgc ctagcaggga 1740
cgggtagtgt ggcaggaggt atagagtcta gagaagatcc ccttatgtct gaggatcctc 1800
tcccaaatcc acctcctgag gtgttcccag cactggactc tgcagagctg ggcttccctt 1860
cccctccctt tctccatatg ctgcaagatt tagtttagtac aaatccccag cagctgcagc 1920
ctgaggctca ctttcagggt cagctggagc aactgcggtc catgggcttt ctgaatcgtg 1980
aagccaatct tcaggccctc attgctacgg ggggcgacgt ggatgctgct gtggagaagc 2040

-20-

tgagacagtc gtaggagcct tattcattca aaccatacgt tttcctctgt gcctttttcc 2100
 catatcctag ttccctagct ctcccatttt tgaatacagc tgcattataa accaaattta 2160
 ctatgaagtc ctttgctgtg gaggcaatgt tgttccagag tcaacgagga agactaatgg 2220
 ccaaaacata gtggaggtgc tgtgtgtgag tcaaccactt gtaccactat accactgggg 2280
 ggccccagtc taagctctgc ttatgcctat cttgagatgc aattacaccc aatttccaat 2340
 gtgaaaa 2347

<210> 29

<211> 655

<212> PRT

<213> Homo Sapiens

<400> 29

Met	Ala	Lys	Gly	Gly	Glu	Ala	Leu	Pro	Gln	Gly	Ser	Pro	Ala	Pro	Val	1	5	10	15
Gln	Asp	Pro	His	Leu	Ile	Lys	Val	Thr	Val	Lys	Thr	Pro	Lys	Asp	Lys	20	25	30	
Glu	Asp	Phe	Ser	Val	Thr	Asp	Thr	Cys	Thr	Ile	Gln	Gln	Leu	Lys	Glu	35	40	45	
Glu	Ile	Ser	Gln	Arg	Phe	Lys	Ala	His	Pro	Asp	Gln	Leu	Val	Leu	Ile	50	55	60	
Phe	Ala	Gly	Lys	Ile	Leu	Lys	Asp	Pro	Asp	Ser	Leu	Ala	Gln	Cys	Gly	65	70	75	80
Val	Arg	Asp	Gly	Leu	Thr	Val	His	Leu	Val	Ile	Lys	Arg	Gln	His	Arg	85	90	95	
Ala	Met	Gly	Asn	Glu	Cys	Pro	Ala	Ala	Ser	Val	Pro	Thr	Gln	Gly	Pro	100	105	110	
Ser	Pro	Gly	Ser	Leu	Pro	Gln	Pro	Ser	Ser	Ile	Tyr	Pro	Ala	Asp	Gly	115	120	125	
Pro	Pro	Ala	Phe	Ser	Leu	Gly	Leu	Leu	Thr	Gly	Leu	Ser	Arg	Leu	Gly	130	135	140	
Leu	Ala	Tyr	Arg	Gly	Phe	Pro	Asp	Gln	Pro	Ser	Ser	Leu	Met	Arg	Gln	145	150	155	160
His	Val	Ser	Val	Pro	Glu	Phe	Val	Thr	Gln	Leu	Ile	Asp	Asp	Pro	Phe	165	170	175	

-21-

Ile Pro Gly Leu Leu Ser Asn Thr Gly Leu Val Arg Gln Leu Val Leu
 180 185 190
 Asp Asn Pro His Met Gln Gln Leu Ile Gln His Asn Pro Glu Ile Gly
 195 200 205
 His Ile Leu Asn Asn Pro Glu Ile Met Arg Gln Thr Leu Glu Phe Leu
 210 215 220
 Arg Asn Pro Ala Met Met Gln Glu Met Ile Arg Ser Gln Asp Arg Val
 225 230 235 240
 Leu Ser Asn Leu Glu Ser Ile Pro Gly Gly Tyr Asn Val Leu Cys Thr
 245 250 255
 Met Tyr Thr Asp Ile Met Asp Pro Met Leu Asn Ala Val Gln Glu Gln
 260 265 270
 Phe Gly Gly Asn Pro Phe Ala Thr Ala Thr Thr Asp Asn Ala Thr Thr
 275 280 285
 Thr Thr Ser Gln Pro Ser Arg Met Glu Asn Cys Asp Pro Leu Pro Asn
 290 295 300
 Pro Trp Thr Ser Thr His Gly Gly Ser Gly Ser Arg Gln Gly Arg Gln
 305 310 315 320
 Asp Gly Asp Gln Asp Ala Pro Asp Ile Arg Asn Arg Phe Pro Asn Phe
 325 330 335
 Leu Gly Ile Ile Arg Leu Tyr Asp Tyr Leu Gln Gln Leu His Glu Asn
 340 345 350
 Pro Gln Ser Leu Gly Thr Tyr Leu Gln Gly Thr Ala Ser Ala Leu Ser
 355 360 365
 Gln Ser Gln Glu Pro Pro Pro Ser Val Asn Arg Val Pro Pro Ser Ser
 370 375 380
 Pro Ser Ser Gln Glu Pro Gly Ser Gly Gln Pro Leu Pro Glu Glu Ser
 385 390 395 400
 Val Ala Ile Lys Gly Arg Ser Ser Cys Pro Ala Phe Leu Arg Tyr Pro
 405 410 415
 Thr Glu Asn Ser Thr Gly Gln Gly Gly Asp Gln Asp Gly Ala Gly Lys
 420 425 430
 Ser Ser Thr Gly His Ser Thr Asn Leu Pro Asp Leu Val Ser Gly Leu
 435 440 445
 Gly Asp Ser Ala Asn Arg Val Pro Phe Ala Pro Leu Ser Phe Ser Pro
 450 455 460
 Thr Ala Ala Ile Pro Gly Ile Pro Glu Pro Pro Trp Leu Pro Ser Pro
 465 470 475 480
 Ala Tyr Pro Arg Ser Leu Arg Pro Asp Gly Met Asn Pro Ala Pro Gln
 485 490 495

-22-

Leu Gln Asp Glu Ile Gln Pro Gln Leu Pro Leu Leu Met His Leu Gln
 500 505 510
 Ala Ala Met Ala Asn Pro Arg Ala Leu Gln Ala Leu Arg Gln Ile Glu
 515 520 525
 Gln Gly Leu Gln Val Leu Ala Thr Glu Ala Pro Arg Leu Leu Leu Trp
 530 535 540
 Phe Met Pro Cys Leu Ala Gly Thr Gly Ser Val Ala Gly Gly Ile Glu
 545 550 555 560
 Ser Arg Glu Asp Pro Leu Met Ser Glu Asp Pro Leu Pro Asn Pro Pro
 565 570 575
 Pro Glu Val Phe Pro Ala Leu Asp Ser Ala Glu Leu Gly Phe Leu Ser
 580 585 590
 Pro Pro Phe Leu His Met Leu Gln Asp Leu Val Ser Thr Asn Pro Gln
 595 600 605
 Gln Leu Gln Pro Glu Ala His Phe Gln Val Gln Leu Glu Gln Leu Arg
 610 615 620
 Ser Met Gly Phe Leu Asn Arg Glu Ala Asn Leu Gln Ala Leu Ile Ala
 625 630 635 640
 Thr Gly Gly Asp Val Asp Ala Ala Val Glu Lys Leu Arg Gln Ser
 645 650 655

<210> 30

<211> 899

<212> DNA

<213> Homo Sapiens

<400> 30

ctagagagta tagggcagaa ggatggcaga tgagtgactc cacatccaga gctgcctccc 60
 tttaatccag gatcctgtcc ttcctgtcct gtaggagtgc ctgttgccag tgtgggggtga 120
 gacaagtttg tcccacaggg ctgtctgagc agataagatt aagggctggg tctgtgctca 180
 attaactcct gtgggcacgg gggctgggaa gagcaaagtc agcgggtgcct acagtcagca 240
 ccatgctggg cctgccgtgg aaggagggtc tgcctgggc gctgctgctg cttctcttag 300
 gctcccagat cctgctgata tatgcctggc attccacga gcaaaggac tgtgatgaac 360
 acaatgtcat ggctcgttac ctccctgcca cagtggagtt tgctgtccac acattcaacc 420
 aacagagcaa ggactactat gcctacagac tggggcacat cttgaattcc tggaaggagc 480
 aggtggagtc caagactgta ttctcaatgg agctactgct ggggagaact aggtgtggga 540

-23-

aatttgaaga cgacattgac aactgccatt tccaagaaag cacagagctg aacaatactt 600
tcacctgctt cttcaccatc agcaccaggc cctggatgac tcagttcagc ctctgaaca 660
agacctgctt ggagggattc cactgagtga aaccactca caggcttgtc catgtgctgc 720
tcccacattc cgtggacatc agcactactc tcctgaggac tcttcagtgg ctgagcagct 780
ttggacttgt ttgttatcct attttgcattg tgtttgagat ctcagatcag tgtttttagaa 840
aatccacaca tcttgagcct aatcatgtag tgtagatcat taaacatcag cattttaag 899

<210> 31

<211> 147

<212> PRT

<213> Homo Sapiens

<400> 31

Met Leu Gly Leu Pro Trp Lys Gly Gly Leu Ser Trp Ala Leu Leu Leu
1 5 10 15
Leu Leu Leu Gly Ser Gln Ile Leu Leu Ile Tyr Ala Trp His Phe His
20 25 30
Glu Gln Arg Asp Cys Asp Glu His Asn Val Met Ala Arg Tyr Leu Pro
35 40 45
Ala Thr Val Glu Phe Ala Val His Thr Phe Asn Gln Gln Ser Lys Asp
50 55 60
Tyr Tyr Ala Tyr Arg Leu Gly His Ile Leu Asn Ser Trp Lys Glu Gln
65 70 75 80
Val Glu Ser Lys Thr Val Phe Ser Met Glu Leu Leu Leu Gly Arg Thr
85 90 95
Arg Cys Gly Lys Phe Glu Asp Asp Ile Asp Asn Cys His Phe Gln Glu
100 105 110
Ser Thr Glu Leu Asn Asn Thr Phe Thr Cys Phe Phe Thr Ile Ser Thr
115 120 125
Arg Pro Trp Met Thr Gln Phe Ser Leu Leu Asn Lys Thr Cys Leu Glu
130 135 140
Gly Phe His
145

<210> 32

<211> 2186

<212> DNA

<213> Homo Sapiens

<400> 32

tggagaggcc acagctgctg gcttcctggg cttctccaaa ctctgtgtg tcgccactgc	60
caccggcagg gagccaggag agagacagaa aggggctgag acagaatgat caaaaggaga	120
gccaccctg gtgcgggagg cgacaggacc aggcctcgac ggcgccgttc cactgagagc	180
tggattgaaa gatgtctcaa cgaaagtga aacaaacgtt attccagcca cacatctctg	240
gggaatgttt ctaatgatga aaatgaggaa aaagaaaata atagagcatc caagccccac	300
tccactcctg ctactctgca atggctggag gagaactatg agattgcaga gggggtctgc	360
atccctcgca gtgccctcta tatgcattac ctggatttct gcgagaagaa tgatacccaa	420
cctgtcaatg ctgccagctt tggaaagatc ataaggcagc agtttcctca gttaaccacc	480
agaagactcg ggacccgagg acagtcaaag taccattact atggcattgc agtgaaagaa	540
agctcccaat attatgatgt gatgtattcc aagaaaggag ctgcctgggt gagtgagacg	600
ggcaagaaag aagtgagcaa acagacagtg gcatattcac cccggtccaa actcggaaca	660
ctgctgccag aatttcccaa tgtcaaagat ctaaactctgc cagccagcct gcctgaggag	720
aaggtttcta cttttattat gatgtacaga acacactgtc agagaatact ggacactgta	780
ataagagcca actttgatga ggttcaaagt ttccttctgc acttttggca aggaatgccg	840
ccccacatgc tgccctgtgct gggctcctcc acggtgggtga acattgtcgg cgtgtgtgac	900
tccatcctct acaaagctat ctccggggtg ctgatgccca ctgtgctgca ggcattacct	960
gacagcttaa ctgaggtgat tcgaaagttt gccaaagcaac tggatgagtg gctaaaagtg	1020
gctctccacg acctcccaga aaacttgcca aacatcaagt tcgaattgtc gagaagggttc	1080
tcccaaattc tgagacggca aacatcacta aatcatctct gccaggcatc tcgaacagtg	1140
atccacagtg cagacatcac gttccaaatg ctggaagact ggaggaacgt ggacctgaac	1200
agcatcacca agcaaaccct ttacaccatg gaagactctc gcgatgagca ccggaaactc	1260
atcacccaat tatatcagga gtttgaccat ctcttgagg agcagtctcc catcgagtcc	1320
tacattgagt ggctggatac catggttgac cgctgtgttg tgaagggtggc tgccaagaga	1380
caagggtcct tgaagaaagt ggcccagcag ttctcttga tgtggtcctg tttcggcaca	1440
agggtgatcc gggacatgac cttgcacagc gccccagct tcgggtcttt tcacctaat	1500

-25-

cacttaatgt ttgatgacta cgtgctctac ctggttagaat ctctgcactg tcaggagcgg 1560
 gccaatgagc tcatgcgagc catgaaggga gaaggaagca ctgcagaagt ccgagaagag 1620
 atcatcttga cagaggctgc cgcaccaacc ccttcaccag tgccatcggt ttctccagca 1680
 aaatctgcca catctgtgga agtgccacct ccctcttccc ctggttagcaa tccttcccct 1740
 gagtacactg gcctcagcac tacaggtaat ggaaagtcct tcaaaaactt tgggtagtta 1800
 atgtttgaag aaagggtttt ctgccagcct gggcaacata gtgagacttc atttccacac 1860
 acacaaaaag ccagacatct tggctcacac ctgtagtccc agctacttgg gaggctgagg 1920
 tgggagaatt gcttgagccc aggagctacg atcgaccac tgcattctag ccttagtgat 1980
 acagtgagac cttgtctcaa aaaaggaaaa acagggtttt ctggaaaaac attcttctcc 2040
 cacaatctcc aaaagataat gccaaaacct gggatatctt ctggatttgt gaatgacgta 2100
 caggtattca tttattcatt ggtacacatt ctgtatgctg ctgttttcaa gttggcaa 2160
 taagcatatg ataaaatccc aaaact 2186

<210> 33

<211> 563

<212> PRT

<213> Homo Sapiens

<400> 33

Met Ile Lys Arg Arg Ala His Pro Gly Ala Gly Gly Asp Arg Thr Arg
 1 5 10 15
 Pro Arg Arg Arg Arg Ser Thr Glu Ser Trp Ile Glu Arg Cys Leu Asn
 20 25 30
 Glu Ser Glu Asn Lys Arg Tyr Ser Ser His Thr Ser Leu Gly Asn Val
 35 40 45
 Ser Asn Asp Glu Asn Glu Glu Lys Glu Asn Asn Arg Ala Ser Lys Pro
 50 55 60
 His Ser Thr Pro Ala Thr Leu Gln Trp Leu Glu Glu Asn Tyr Glu Ile
 65 70 75 80
 Ala Glu Gly Val Cys Ile Pro Arg Ser Ala Leu Tyr Met His Tyr Leu
 85 90 95
 Asp Phe Cys Glu Lys Asn Asp Thr Gln Pro Val Asn Ala Ala Ser Phe
 100 105 110
 Gly Lys Ile Ile Arg Gln Gln Phe Pro Gln Leu Thr Thr Arg Arg Leu

-26-

115					120					125					
Gly	Thr	Arg	Gly	Gln	Ser	Lys	Tyr	His	Tyr	Tyr	Gly	Ile	Ala	Val	Lys
130						135					140				
Glu	Ser	Ser	Gln	Tyr	Tyr	Asp	Val	Met	Tyr	Ser	Lys	Lys	Gly	Ala	Ala
145					150					155					160
Trp	Val	Ser	Glu	Thr	Gly	Lys	Lys	Glu	Val	Ser	Lys	Gln	Thr	Val	Ala
				165					170					175	
Tyr	Ser	Pro	Arg	Ser	Lys	Leu	Gly	Thr	Leu	Leu	Pro	Glu	Phe	Pro	Asn
			180					185					190		
Val	Lys	Asp	Leu	Asn	Leu	Pro	Ala	Ser	Leu	Pro	Glu	Glu	Lys	Val	Ser
		195					200					205			
Thr	Phe	Ile	Met	Met	Tyr	Arg	Thr	His	Cys	Gln	Arg	Ile	Leu	Asp	Thr
	210					215					220				
Val	Ile	Arg	Ala	Asn	Phe	Asp	Glu	Val	Gln	Ser	Phe	Leu	Leu	His	Phe
225					230					235					240
Trp	Gln	Gly	Met	Pro	Pro	His	Met	Leu	Pro	Val	Leu	Gly	Ser	Ser	Thr
				245					250					255	
Val	Val	Asn	Ile	Val	Gly	Val	Cys	Asp	Ser	Ile	Leu	Tyr	Lys	Ala	Ile
			260					265					270		
Ser	Gly	Val	Leu	Met	Pro	Thr	Val	Leu	Gln	Ala	Leu	Pro	Asp	Ser	Leu
		275					280					285			
Thr	Gln	Val	Ile	Arg	Lys	Phe	Ala	Lys	Gln	Leu	Asp	Glu	Trp	Leu	Lys
	290					295					300				
Val	Ala	Leu	His	Asp	Leu	Pro	Glu	Asn	Leu	Arg	Asn	Ile	Lys	Phe	Glu
305					310					315					320
Leu	Ser	Arg	Arg	Phe	Ser	Gln	Ile	Leu	Arg	Arg	Gln	Thr	Ser	Leu	Asn
				325					330					335	
His	Leu	Cys	Gln	Ala	Ser	Arg	Thr	Val	Ile	His	Ser	Ala	Asp	Ile	Thr
			340					345					350		
Phe	Gln	Met	Leu	Glu	Asp	Trp	Arg	Asn	Val	Asp	Leu	Asn	Ser	Ile	Thr
		355					360					365			
Lys	Gln	Thr	Leu	Tyr	Thr	Met	Glu	Asp	Ser	Arg	Asp	Glu	His	Arg	Lys
	370					375					380				
Leu	Ile	Thr	Gln	Leu	Tyr	Gln	Glu	Phe	Asp	His	Leu	Leu	Glu	Glu	Gln
385					390					395					400
Ser	Pro	Ile	Glu	Ser	Tyr	Ile	Glu	Trp	Leu	Asp	Thr	Met	Val	Asp	Arg
				405					410					415	
Cys	Val	Val	Lys	Val	Ala	Ala	Lys	Arg	Gln	Gly	Ser	Leu	Lys	Lys	Val
			420				425						430		

-27-

Ala Gln Gln Phe Leu Leu Met Trp Ser Cys Phe Gly Thr Arg Val Ile
435 440 445

Arg Asp Met Thr Leu His Ser Ala Pro Ser Phe Gly Ser Phe His Leu
450 455 460

Ile His Leu Met Phe Asp Asp Tyr Val Leu Tyr Leu Leu Glu Ser Leu
465 470 475 480

His Cys Gln Glu Arg Ala Asn Glu Leu Met Arg Ala Met Lys Gly Glu
485 490 495

Gly Ser Thr Ala Glu Val Arg Glu Glu Ile Ile Leu Thr Glu Ala Ala
500 505 510

Ala Pro Thr Pro Ser Pro Val Pro Ser Phe Ser Pro Ala Lys Ser Ala
515 520 525

Thr Ser Val Glu Val Pro Pro Pro Ser Ser Pro Val Ser Asn Pro Ser
530 535 540

Pro Glu Tyr Thr Gly Leu Ser Thr Thr Gly Asn Gly Lys Ser Phe Lys
545 550 555 560

Asn Phe Gly

<210> 34

<211> 558

<212> DNA

<213> Homo Sapiens

<400> 34

acagacaaat ggtttatcta ctattggagc catgggtcct gggaatattg gaccacccca 60
aatagaagag ctcaaagtca tccctgaaac cagcgaggaa aataatgagg acatctggaa 120
ttcagaagag attccagaag gagcagaata tgatgatatg tgggatgtta gagaaatccc 180
agagtatgag attatattca gacagcaggt gggaactgaa gatataattt tagggttgtc 240
aaaaaaggac tcctcaacag gttgttgcag tgaactagt gctaaaatta aattgccaaa 300
tacaaaccct tctgatattc aaattgatat ccaggaaaca atccttgacc ttcgtactcc 360
tcagaagaag ctgttgataa ctcttcctga gctggtggaa tgtaccagt ccaaagcatt 420
ctatatccca gagactgaaa ctcttgaaat ccctatgact atgaaaagag agttagatat 480
tgctaatttc ttctgaaact gcatgaaaaa gataaaaagt agtaaaatgg cattggtaac 540
aataaaaaaa ctttgaaa 558

-28-

<210> 35

<211> 164

<212> PRT

<213> Homo Sapiens

<400> 35

Gln Thr Asn Gly Leu Ser Thr Ile Gly Ala Met Gly Pro Gly Asn Ile
1 5 10 15

Gly Pro Pro Gln Ile Glu Glu Leu Lys Val Ile Pro Glu Thr Ser Glu
20 25 30

Glu Asn Asn Glu Asp Ile Trp Asn Ser Glu Glu Ile Pro Glu Gly Ala
35 40 45

Glu Tyr Asp Asp Met Trp Asp Val Arg Glu Ile Pro Glu Tyr Glu Ile
50 55 60

Ile Phe Arg Gln Gln Val Gly Thr Glu Asp Ile Phe Leu Gly Leu Ser
65 70 75 80

Lys Lys Asp Ser Ser Thr Gly Cys Cys Ser Glu Leu Val Ala Lys Ile
85 90 95

Lys Leu Pro Asn Thr Asn Pro Ser Asp Ile Gln Ile Asp Ile Gln Glu
100 105 110

Thr Ile Leu Asp Leu Arg Thr Pro Gln Lys Lys Leu Leu Ile Thr Leu
115 120 125

Pro Glu Leu Val Glu Cys Thr Ser Ala Lys Ala Phe Tyr Ile Pro Glu
130 135 140

Thr Glu Thr Leu Glu Ile Pro Met Thr Met Lys Arg Glu Leu Asp Ile
145 150 155 160

Ala Asn Phe Phe

<210> 36

<211> 538

<212> DNA

<213> Homo Sapiens

<400> 36

ggcagcaggt cgaaaactcc tggaaccctc tgagagagga cagtttccag actcctcggt 60

agggacgcgg gaagagacca tgtgtgggaa atatgagtga gcatgtgaga acaagatccc 120

-29-

aatcctcaga aagaggaaat gaccaagagt cttcccagcc agttggatct gtgattgtcc 180
 aggagcccac tgaggaaaaa cgtcaagaag aggaaccacc aactgataat cagggtattg 240
 cacctagtgg ggagatcgaa aatgaaggag cacctgccgt tcaagggcct gacatggaag 300
 cttttcaaca ggaactggct ctgcttaaga tagaggatga gcctggagat ggtcctgatg 360
 tcagggaggg gattatgccc acttttgatc tcactaaagt gctggaagca ggtgatgcgc 420
 aaccataggt ttcaagcaag acaaatgaag actgaaacca agaacgttat tcttaatctg 480
 gaaatttgac tgataatatt ctcttaataa agttttaagt tttctgcaaa gaaaaaaaa 538

<210> 37

<211> 111

<212> PRT

<213> Homo Sapiens

<400> 37

Met Ser Glu His Val Arg Thr Arg Ser Gln Ser Ser Glu Arg Gly Asn
 1 5 10 15
 Asp Gln Glu Ser Ser Gln Pro Val Gly Ser Val Ile Val Gln Glu Pro
 20 25 30
 Thr Glu Glu Lys Arg Gln Glu Glu Glu Pro Pro Thr Asp Asn Gln Gly
 35 40 45
 Ile Ala Pro Ser Gly Glu Ile Glu Asn Glu Gly Ala Pro Ala Val Gln
 50 55 60
 Gly Pro Asp Met Glu Ala Phe Gln Gln Glu Leu Ala Leu Leu Lys Ile
 65 70 75 80
 Glu Asp Glu Pro Gly Asp Gly Pro Asp Val Arg Glu Gly Ile Met Pro
 85 90 95
 Thr Phe Asp Leu Thr Lys Val Leu Glu Ala Gly Asp Ala Gln Pro
 100 105 110

<210> 38

<211> 520

<212> DNA

<213> Homo sapiens

-30-

<400> 38
gagttgtgag ggtgtgaggg tcgcgttcct gctgtctgga ctttttctgt cccactgaga 60
cgcagctgtg tgaaatatga tttggcgagg aagatcaaca tataggccta ggccgaggag 120
aagtgtacca cctcctgagc tgattggggc tatgctggag cccggtgatg aggagcctca 180
gcaagaggaa ccaccaactg aaagtcggga tcctgcacct ggtcaggaga gagaagaaga 240
tcagggtgca gctgagactc aagtgcctga cctggaagct gatctccagg agctgtctca 300
gtcaaagact ggggggtgaat gtggaaatgg tcctgatgac caggggaaga ttctgccaaa 360
atcagaacaa tttaaaatgc cagaaggagg tgacaggcaa ccacaggttt aaatgaagac 420
aagctgaaac aacccaaaac tgtttttatt taagatattt gacttaaaaa tatcgaaata 480
aacttttgca gcttttctcca aaaaaaaaaa aaaaaaaaaa 520

<210> 39

<211> 111

<212> PRT

<213> Homo sapiens

<400> 39

Met Ile Trp Arg Gly Arg Ser Thr Tyr Arg Pro Arg Pro Arg Arg Ser
1 5 10 15
Val Pro Pro Pro Glu Leu Ile Gly Pro Met Leu Glu Pro Gly Asp Glu
20 25 30
Glu Pro Gln Gln Glu Glu Pro Pro Thr Glu Ser Arg Asp Pro Ala Pro
35 40 45
Gly Gln Glu Arg Glu Glu Asp Gln Gly Ala Ala Glu Thr Gln Val Pro
50 55 60
Asp Leu Glu Ala Asp Leu Gln Glu Leu Ser Gln Ser Lys Thr Gly Gly
65 70 75 80
Glu Cys Gly Asn Gly Pro Asp Asp Gln Gly Lys Ile Leu Pro Lys Ser
85 90 95
Glu Gln Phe Lys Met Pro Glu Gly Gly Asp Arg Gln Pro Gln Val
100 105 110

<210> 40

<211> 756

<212> DNA

-31-

<213> Homo sapiens

<400> 40

```

aggctagtag aggctggggg tgtgaatcgg cagaggggttc tggacacctg cctcagtgtg      60
catgttcact gggcatcttc ccttcgaccc ctttgcccac gtggtgaccg ctggggagct      120
gtgagagtgt gaggggcacg ttccagccgt ctggactctt tctctcctac tgagacgcag      180
cctatagggtc cgcaggccag tcctcccagg aactgaaata gtgaaatatg agttggcgag      240
gaagatcaac atataggcct aggccaagaa gaagtttaca gcctcctgag ctgattgggg      300
ctatgcttga acccactgat gaagagccta aagaagagaa accaccact aaaagtcgga      360
atcctacacc tgatcagaag agagaagatg atcaggggtgc agctgagatt caagtgcctg      420
acctggaagc cgatctccag gagctatgtc agacaaagac tggggatgga tgtgaagggtg      480
gtactgatgt caaggggaag attctaccaa aagcagagca ttttaaaatg ccagaagcag      540
gtgaagggaa atcacagggt taaaggaaga taagctgaaa caacacaaac tgtttttata      600
ttagatatatt tactttaaaa tatcttaata aagttttaag cttttctcca aaaaaaaaaa      660
aaaaaaaaaa aacttggggg ctctatgggg ggggggaaaa ggggggttga aggggccggg      720
gccatggggg ttcccggacc cagttttttg gtccag                                756

```

<210> 41

<211> 111

<212> PRT

<213> Homo sapiens

<400> 41

```

Met Ser Trp Arg Gly Arg Ser Thr Tyr Arg Pro Arg Pro Arg Arg Ser
1          5          10          15
Leu Gln Pro Pro Glu Leu Ile Gly Ala Met Leu Glu Pro Thr Asp Glu
20          25          30
Glu Pro Lys Glu Glu Lys Pro Pro Thr Lys Ser Arg Asn Pro Thr Pro
35          40          45
Asp Gln Lys Arg Glu Asp Asp Gln Gly Ala Ala Glu Ile Gln Val Pro
50          55          60
Asp Leu Glu Ala Asp Leu Gln Glu Leu Cys Gln Thr Lys Thr Gly Asp
65          70          75          80

```


-32-

Gly Cys Glu Gly Gly Thr Asp Val Lys Gly Lys Ile Leu Pro Lys Ala
85 90 95

Glu His Phe Lys Met Pro Glu Ala Gly Glu Gly Lys Ser Gln Val
100 105 110

<210> 42

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide

<400> 42

aggccgagga gaagtgtacc

20

<210> 43

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide

<400> 43

aacctgtggt tgcctgtcac

20

<210> 44

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide

<400> 44

agccgtctgg actctttctc

20

-33-

<210> 45

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide

<400> 45

tgatttcctt tcacctgctt c

21

<210> 46

<211> 334

<212> DNA

<213> Homo sapiens

<400> 46

tgaggatcgc gttcctgctg tcgggacttt ttctgtcctg ctgagacgca gcgtgtgaaa 60

tatgatttgg agagtaagat caacatatag gcctagacca aggagaagcg taccacctcc 120

tgagctgatt gggcctatgc tggagcccag tgatgaggaa cctcagcaag aggaaccacc 180

aactgaaagt cgggatccta cacctgtacc tgacctggaa actgatctcc aggagctgtc 240

tcagtcaaag actggggatg aatgcagaga tgggtcccgat gacaagggga agattctgcc 300

aaaatcagag caatttaaaa tgccagaagg aggt 334

<210> 47

<211> 91

<212> PRT

<213> Homo sapiens

<400> 47

Met Ile Trp Arg Val Arg Ser Thr Tyr Arg Pro Arg Pro Arg Arg Ser
1 5 10 15

Val Pro Pro Pro Glu Leu Ile Gly Pro Met Leu Glu Pro Ser Asp Glu
20 25 30

-34-

Glu Pro Gln Gln Glu Glu Pro Pro Thr Glu Ser Arg Asp Pro Thr Pro
 35 40 45
 Val Pro Asp Leu Glu Thr Asp Leu Gln Glu Leu Ser Gln Ser Lys Thr
 50 55 60
 Gly Asp Glu Cys Arg Asp Gly Pro Asp Asp Lys Gly Lys Ile Leu Pro
 65 70 75 80
 Lys Ser Glu Gln Phe Lys Met Pro Glu Gly Gly
 85 90

<210> 48

<211> 1878

<212> DNA

<213> Homo sapiens

<400> 48

acagagctgg tgggagctgg gaataggtga aaaccctgcc tccttgtgag ttggcaggac 60
 gggagcctcc tgttccttgg ctgctgttgt ggccaccgag ccgcagccct ggagccaggc 120
 atccctgtgc ttggggatca gagegagcag gagcagatcc tctcccttct ggggtgcagct 180
 gcagctgccc agccatggct gtgggtcccg aagtctctgt gctcttggga gctgggaggg 240
 ccctctgcct cctgcccctt acgcactcca gagtctcttc tctgttgaga gctaagcaga 300
 catcaggact accagctgca gagaggagct acccactgtg ggcttcgtct ctgctgagag 360
 ctgaacactc actgggacgc cctgcctatg gaaaccagct gttcactctg ggtctcctct 420
 gagctgttct gtcgctcagt aaaggtcttc ttctgcttac tcgccctcca tttgtctgcc 480
 ttacctcatt catcctggac acaggacaag aacttgggac ttgccggtat ggtggagcta 540
 aaatagctgt aacacaaaca ggattgaaac atgccccttg ctgcacacat tgtggatgac 600
 aagagggagg gaagaaagga gagaagatct gcgacccttc ggcaaaccce gacttaggag 660
 atcggagagc caagactgtg acacccttcc tggggctctg tggttcctgg cgtctccaag 720
 cttctgggca cctcggcttt ccccggtgcc agtcgtggaa gctgcttgtg gcctccattt 780
 gctgtttggg aaactctcta cgctatgaat gttagctggc agcaaacact gcctcccact 840
 acaggggcac acagtgttgg tgcctgcttt tccaccctcc acttccaaca ggaagcaagc 900
 acaggacca agcattgcag acagttgtat cagccaatg tgcattcgga gccactgaca 960
 gagtcttgct ttgtcaccca ggctggagta cagtggcgtg atcacagctt actgaaacgt 1020
 ctgcgtctca ggttcaagcg atttttctgc ctcagcctct ggtgtagctg gaattacagt 1080

-35-

gtttagcagtc actgatgctc aaacatgaga agactgggac atccatcaga taagaaacgc 1140
 tgcccaaagt gttagactaa taagtgcagc ggttggacaa tgaacccaac cactcaacct 1200
 tccggaaaag tgctggagag gatgtggaga aataggaaca cttttacact gttggtggga 1260
 ctgtaaacta gttcaaccat tgtggaagtc agtgtggcga ttcctcagag atgtagaact 1320
 agaaatacca tttgaccagc ccatccatt actgggtatg tacccaaagg attataaatc 1380
 atgctgctat aaagacacat acacacgtat gtttattgtg gcactattca caacagcaaa 1440
 gacatggaat caacccaaat gtccaacaac gatagactgg attaagaaaa tgtggcacat 1500
 atacaccatg gaatactatg cagccataaa aaatgatgag ttcatgtcct ttgtagggac 1560
 atggatgagg ctaggtgaag caattccttt cctgaggaaa atagaactca ctctgcctg 1620
 gcttgatga ggaggaatag gatataagca gttgaggaag aacggtccat gagttgcat 1680
 ccttcctct tctgcctgc cagaagaggt agagcccact gaagaaggag cagaataagg 1740
 aatggaaacc ttagttacaa gtccaagaaa ttctaccac tctactattt ttttatgtgt 1800
 aacttgattt atagttttta ctttgaaaga atgtaactat tgtacatgtt tcataaagta 1860
 tcaatagctg aatagacc 1878

<210> 49

<211> 70

<212> PRT

<213> Homo sapiens

<400> 49

Met	Thr	Arg	Gly	Arg	Glu	Glu	Arg	Arg	Glu	Asp	Leu	Arg	Pro	Phe	Gly
1				5					10					15	
Lys	Pro	Arg	Leu	Arg	Arg	Ser	Glu	Ser	Gln	Asp	Cys	Asp	Thr	Leu	Ser
			20					25					30		
Gly	Ala	Leu	Trp	Phe	Leu	Ala	Ser	Pro	Ser	Phe	Trp	Ala	Pro	Arg	Leu
		35					40					45			
Ser	Pro	Val	Pro	Val	Val	Glu	Ala	Ala	Cys	Gly	Leu	His	Leu	Leu	Phe
		50				55					60				
Gly	Lys	Leu	Ser	Thr	Leu										
65					70										

<210> 50

-36-

<211> 103

<212> PRT

<213> Homo sapiens

<400> 50

Met	Thr	Arg	Gly	Arg	Glu	Glu	Arg	Arg	Glu	Asp	Leu	Arg	Pro	Phe	Gly
1				5					10					15	

Lys	Pro	Arg	Leu	Arg	Arg	Ser	Glu	Ser	Gln	Asp	Cys	Asp	Thr	Leu	Ser
			20					25					30		

Gly	Ala	Leu	Trp	Phe	Leu	Ala	Ser	Pro	Ser	Phe	Trp	Ala	Pro	Arg	Leu
		35					40					45			

Ser	Pro	Val	Pro	Val	Val	Glu	Ala	Ala	Cys	Ala	Glu	Ser	Cys	Phe	Val
	50					55					60				

Thr	Gln	Ala	Gly	Val	Gln	Trp	Arg	Asp	His	Ser	Leu	Leu	Lys	Arg	Leu
65					70					75					80

Arg	Leu	Arg	Phe	Lys	Arg	Phe	Phe	Cys	Leu	Ser	Leu	Trp	Cys	Ser	Trp
				85					90					95	

Asn	Tyr	Ser	Val	Ser	Ser	His
			100			

<210> 51

<211> 778

<212> DNA

<213> Homo sapiens

<400> 51

caggagtggg gtcagcagga ggaactctac agctatggga gaacctgcgt tcacctcttt	60
tccaagcctg cctgttctgg ggaagctcaa aaggaacatg atgccctggg ctttacagaa	120
gaaacgagaa atccacatgg ccaaggccca tcggagacga gctgcgaggt ctgctctccc	180
catgagactc accagctgca tcttccggag gccggtgaca aggatcaggt ctcatcctga	240
caaccaggtc agacgcagaa aaggggacga gcacctggag aagccgcagc aactctgcgc	300
ctaccggaga ctgcaggccc tgcagccctg cagcagccaa ggagaagggt caagtccact	360
gcattgggag agcgtcttaa gtatccttgc accggggacg gccagtgaat ctctggacag	420
ggctggtgct gagcgtgtgc gcagcccgt tgagcccacc cctgggcggt ttccagctgt	480
ggcagggggg ccaaccccag gaatgggttg tcagctccca ccgcccctct ctggccaatt	540

ggtgactcct gcagatatcc ggagacaggc caggagggtg aagaaagcca gggagagact 600
 ggccaaggcc ttgcaggcag acaggctggc caggcaggca gaaatgctga catgtagatg 660
 aagcgcagtc ctgggctttc ggccctttc ttttaatgcc catcctcatt cctactctga 720
 attgtcacac ttttccttc cccaccagtt ctttaataaa agtatttgaa aggcaaaa 778

<210> 52

<211> 219

<212> PRT

<213> Homo sapiens

<400> 52

Arg	Ser	Gly	Val	Ser	Arg	Arg	Asn	Ser	Thr	Ala	Met	Gly	Glu	Pro	Ala	1	5	10	15
Phe	Thr	Ser	Phe	Pro	Ser	Leu	Pro	Val	Leu	Gly	Lys	Leu	Lys	Arg	Asn	20	25	30	
Met	Met	Pro	Trp	Ala	Leu	Gln	Lys	Lys	Arg	Glu	Ile	His	Met	Ala	Lys	35	40	45	
Ala	His	Arg	Arg	Arg	Ala	Ala	Arg	Ser	Ala	Leu	Pro	Met	Arg	Leu	Thr	50	55	60	
Ser	Cys	Ile	Phe	Arg	Arg	Pro	Val	Thr	Arg	Ile	Arg	Ser	His	Pro	Asp	65	70	75	80
Asn	Gln	Val	Arg	Arg	Arg	Lys	Gly	Asp	Glu	His	Leu	Glu	Lys	Pro	Gln	85	90	95	
Gln	Leu	Cys	Ala	Tyr	Arg	Arg	Leu	Gln	Ala	Leu	Gln	Pro	Cys	Ser	Ser	100	105	110	
Gln	Gly	Glu	Gly	Ser	Ser	Pro	Leu	His	Trp	Glu	Ser	Val	Leu	Ser	Ile	115	120	125	
Leu	Ala	Pro	Gly	Thr	Ala	Ser	Glu	Ser	Leu	Asp	Arg	Ala	Gly	Ala	Glu	130	135	140	
Arg	Val	Arg	Ser	Pro	Leu	Glu	Pro	Thr	Pro	Gly	Arg	Phe	Pro	Ala	Val	145	150	155	160
Ala	Gly	Gly	Pro	Thr	Pro	Gly	Met	Gly	Cys	Gln	Leu	Pro	Pro	Pro	Leu	165	170	175	
Ser	Gly	Gln	Leu	Val	Thr	Pro	Ala	Asp	Ile	Arg	Arg	Gln	Ala	Arg	Arg	180	185	190	
Val	Lys	Lys	Ala	Arg	Glu	Arg	Leu	Ala	Lys	Ala	Leu	Gln	Ala	Asp	Arg				

-38-

195	200	205
Leu Ala Arg Gln Ala Glu Met Leu Thr Cys Arg		
210	215	

<210> 53

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide

<400> 53

tgggacatcc atcagataag

20

<210> 54

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide

<400> 54

tttatggctg catagtattc

20

<210> 55

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide

-39-

<400> 55
gctatgggag aacctgcggt c

21

<210> 56

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide

<400> 56
tccctggctt tcttcaccct c

21

<210> 57

<211> 116

<212> PRT

<213> Homo sapiens

<400> 57

Met Ser Trp Arg Gly Arg Ser Thr Tyr Arg Pro Arg Pro Arg Arg Tyr
1 5 10 15

Val Glu Pro Pro Glu Met Ile Gly Pro Met Arg Pro Glu Gln Phe Ser
20 25 30

Asp Glu Val Glu Pro Ala Thr Pro Glu Glu Gly Glu Pro Ala Thr Gln
35 40 45

Arg Gln Asp Pro Ala Ala Ala Gln Glu Gly Glu Asp Glu Gly Ala Ser
50 55 60

Ala Gly Gln Gly Pro Lys Pro Glu Ala His Ser Gln Glu Gln Gly His
65 70 75 80

Pro Gln Thr Gly Cys Glu Cys Glu Asp Gly Pro Asp Gly Gln Glu Met
85 90 95

Asp Pro Pro Asn Pro Glu Glu Val Lys Thr Pro Glu Glu Gly Glu Lys
100 105 110

Gln Ser Gln Cys
115

<210> 58

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide

<400> 58

accaaggaga agcgtaccac

20

<210> 59

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Oligonucleotide

<400> 59

gggaccatct ctgcattcat c

21

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.